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ABSTRACT
Endothelin-1 (ET-1) is a powerful vasoactive peptide. First isolated in 1988, ET-1 is
both a vasoconstrictor, acting directly on vascular smooth muscle cells, and
potentially a vasodilator acting on endothelial cells to cause the synthesis and release
of endothelium derived mediators. The cellular responses to ET-1 are mediated by at
least two receptors, the ETa and the ETb receptor. Early findings on the actions of
ET-1 on blood platelets were inconclusive. It was, therefore the aim of the work
presented in this thesis to investigate and characterise the effects of ET-1 on human
platelets and to examine whether these effect were altered in subjects with essential
hypertension.
To investigate the direct actions of ET-1 on human platelets, aggregation studies
were performed in platelet rich plasma. Light transmittance platelet aggregometry
was used to examine the effect of ET-1 alone and the effect of pre-incubation with
ET-1 on adrenaline- and ADP -induced primary and secondary aggregation. ET-1
(l|iM) alone caused slight but significant platelet aggregation (p=0.04, n=14). In
addition ET-1 (InM) significantly potentiated adrenaline induced-primary
aggregation (p=0.04, n=14) and inhibited adrenaline-induced secondary aggregation
(p=0.04, n=14). ET-1 did not significantly alter ADP-induced primary or secondary
aggregation. It was concluded from these studies that ET-1 at high concentrations
had a slight aggregatory effect and at lower concentrations modulated primary and
secondary aggregation to adrenaline in a bi-directional manner.
The ET receptor subtype which mediated the potentiation of the pro-aggregatory
actions of ET-1 on adrenaline-induced primary aggregation was investigated. Both
the selective ETa/ETb agonist ET-1 and the ETb selective agonist SRTX S6c were
employed as well as the ETa and the ETb selective antagonists BQ 123 and BQ 788
respectively. ET-1 and SRTX S6c dose dependently potentiated adrenaline induced
primary aggregation (p=0.03 & p=0.05 respectively n=12 for both). Furthermore the
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potentiation of aggregation was attenuated by BQ 788 (p=0.04, n=6) but unaltered
by BQ 123. Hence, it was concluded that potentiation of adrenaline induced
aggregation by ET-1 is dose dependent and is largely mediated by the ETb receptor.
To investigate possible second messengers involved in ET receptor mediated effects
platelets cyclic AMP and cyclic GMP levels were measured after incubation with
ET-1 and SRTX S6c. Both ET-1 and SRTX S6c caused an increase in platelet cyclic
GMP levels (p=0.03 & p=0.01 respectively, n=6 for both). However neither agonists
altered platelet cyclic AMP levels. From this it would appear that the platelet ETb
receptor is associated with an accumulation of cyclic GMP but not cyclic AMP.
Additional evidence for the existence of specific binding sites for ET-1 on platelets
was investigated by radio ligand binding studies and RT-PCR. RT-PCR was
performed on RNA extracted from platelets isolated by centrifugation and on
platelets isolated by centrifugation on discontinuous gradients of percoll. Mean
binding of 125I-ET-1 to platelet membranes was not significantly altered by
increasing concentrations of cold ligand (p=0.18; n=6). However, in platelet
preparations from two subjects, binding of cold ET-1 was dose dependency reduced
providing Kqs of 1.1 and 0.4 nM. RT-PCR on RNA extracted from platelet isolated
by centrifugation alone was positive for ETb mRNA for all subjects tested, but there
was an indication that this preparation may have been contaminated by other blood
cells. There was no evidence for contamination in the platelets prepared by
centrifugation through percoll. In this preparation 4 of the 6 samples were positive
for ETb mRNA. Although neither study produced evidence for ET receptors on
platelet from all subjects tested, the results of both studies did indicate that ET
receptors exist on platelet from some subjects.
6
To examine the role of ET-l-mediated release of endothelium derived platelet
modulators on the action of ET-1 on platelets, an ex vivo study was performed. ET-1
was infused into the brachial artery, at the end of the infusion venous blood was
sampled and in vitro aggregation studies were carried out. In an attempt to establish
the role of ET derived prostacyclin ex vivo studies were carried out in the presence
and absence of aspirin. Forearm blood flow was measured during all ex vivo studies.
In vitro studies were also carried out on the same subjects. In the ex vivo studies ET-
1 infusion caused a significant reduction in blood flow (32.8% at 60 min). This
effect was significantly increased after intravenous aspirin infusion (50.3% at 60
min). ET-1 infusion did not significantly alter ex vivo primary platelet aggregation to
adrenaline or ADP, nor did it alter ADP-induced secondary aggregation. However,
adrenaline induced secondary aggregation was significantly attenuated (67.1 ± 6.6 vs
38.5 ± 8.7). A similar pattern of results was observed when a comparable
concentration of ET-1 to that estimated to be achieved in vivo by the ET-1 infusion
was used in vitro in the same subjects. These results indicate that the ex vivo
inhibition of platelet aggregation by ET-1 is independent of endothelium derived
mediators.
To investigate whether platelet sensitivity to ET receptor agonists is altered in
subjects with high blood pressure two separate studies were carried out. In the first
study platelet aggregation to adrenaline was studied in the presence and absence of
ET-1 in patients with essential hypertension and age/sex matched controls. Platelet
cyclic nucleotide responses to ET-1 and SRTX S6c were also studied in the same
subjects. In the second study subjects involved in a '4 corner study' designed to
investigate familial predisposition to hypertension were recruited. Subjects
participating in this study had not developed hypertension but represented
individuals identified as having either high or low blood pressure, in addition they
were also classified according to parental blood pressure. This allowed subjects with
7
a predisposition to hypertension, on the basis of having raised blood pressure, to be
distinguished from subjects with a familial predisposition to hypertension, that is
subjects with raised blood pressure who also have parents with raised blood
pressure. Platelet aggregation to adrenaline was studied in the presence and absence
ofET-1.
In the first study there was no difference in the ET-1 mediated potentiation of
adrenaline-induced primary aggregation between the two groups. However, although
ET-1 inhibition of secondary aggregation was observed in the control group
(p=0.001, n=10) this effect was not observed in the hypertensive subjects. ET-1
tended to increase cGMP in platelets from the control patients but this did not
achieve statistical significance. SRTX S6c did significantly stimulate cyclic GMP
accumulation in platelets from the control subjects (p=0.04, n=10), but did not
significantly alter cyclic GMP levels in platelets from the hypertensive subjects.
Neither SRTX S6c nor ET-1 altered platelet cyclic AMP levels in either group. It
would appear from this study that patients with established essential hypertension
have a reduction in the anti-aggregatory response to ET-1 and may have impaired
platelet cyclic GMP responses.
In subjects from the '4 corner' study there was a tendency for ET-1 to potentiate
adrenaline-induced primary aggregation in all 4 corners. However, this effect was
only significant in the corner representing subjects with high blood pressure who had
parents with high blood pressure (p=0.04, n=ll). ET-1 inhibition of secondary
aggregation did not achieve statistical significance in any of the 4 corners, although a
consistent tendency was observed in all 4 corners. The potentiation of adrenaline
-induced primary aggregation by ET-1 may be associated with a familial
predisposition to hypertension and therefore the progression of hypertension in these
individuals may be associated with increased ET-1 sensitivity.
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In conclusion, the work in this thesis presents evidence for ET-1 modulation of
adrenaline mediated platelet aggregation in vitro and ex vivo. The receptor sub-type
mediating the potentiation of adrenaline-induced primary aggregation by ET-1
appears to be the ETb receptor sub-type. In addition the ETb receptor appears to
mediate an increase in platelet cyclic GMP levels. Both the inhibition of aggregation
and the stimulation of cyclic GMP by ET receptor agonists is altered in platelets
from patients with essential hypertension, which might contribute to the pro-
aggregatory state of platelets from such patients. This would suggest that the actions
of ET-1 could be a possible site for pharmacological intervention to prevent some of
the consequences of hyperactive platelets in hypertensive patients. Finally, the fact
that the potentiation of primary aggregation by ET-1 might be associated with a
familial predisposition to hypertension would suggest that in some individuals the
development of hypertension may be related to an increase sensitivity of the ETb
receptor.
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ANOVA Analysis of variance
ATP Adenosine triphosphate
[Ca2+]j, Intracellular calcium ion concentration
cyclic AMP Adenosine 3',5'-cyclic monophosphate
cAMP-PK cAMP dependent protein kinases
cyclic GMP Guanosine 3',5'-cyclic monophosphate
cGMP-PK cGMP dependent protein kinase






ECE Endothelin converting enzyme








MAP Mean arterial pressure
MMLV Moloney murine leukaemia virus reverse transcriptase
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NO Nitric oxide




PPP Platelet poor plasma
PRP Platelet rich plasma
RIA Radio immunoassay
RNA Ribonucleic acid
RTPCR Reverse transcriptase polymerase chain reaction
SAH Sub arachnoid haemorrhage
SccAMP TME Succinyl cyclic AMP tyrosinemethylester
SccGMP TME Succinyl cyclic GMP tyrosinemethylester




VASP Vasodilator stimulated phosphoprotein,
%
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The vascular endothelium is involved in mediating the constriction and relaxation of
the underlying smooth muscle by the release of a number of agents, such as nitric
oxide (NO) and ET-1. The factors may be released basally or when activated by
physical and chemical stimuli. By regulating the lumen size of the vessels the
endothelium is able to modulate local blood flow. Many endothelium-derived factors
are released both luminally and abluminally. In the former case they may act to
regulate blood platelet activity. In healthy vessels the expected role of the
endothelium may be the prevention of unnecessary platelet aggregation and
thrombus formation. However, at sites of vascular injury the inhibitory role of the
endothelium on platelet aggregation may be modified to allow platelets access to the
site of damage to commence repair. In many cardiovascular conditions the platelet-
endothelium interaction may be impaired, thus facilitating thrombus formation,
further vessel constriction and consequently ischaemic damage. The key regulatory
role of the endothelium on platelet function and the prevalence of cardiovascular
disease in Western society has made the topic of platelet-endothelium interaction an
area of increasing interest.
The Platelet
Platelets are cell fragments which circulate in the vascular system at counts of
between 150-400 x 109/L, in the healthy adult human. With an approximate mean
diameter of 2-3 pm and thickness of 1 pm platelets are the smallest blood 'cells'.
Highly reactive to external stimuli, the principal function of platelets is to ensure
haemostasis. In response to exposure of sub-endothelial collagen, indicating a
disruption of the lining of the vasculature, platelets may, adhere to the site of
damage, form aggregates and release some of the contents of platelet storage
granules. These responses, the stimuli that provoke them, and some of the intra-
platelet biochemical signalling that mediate them, will be discussed before
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examining the putative role of the powerful vasoconstrictor peptide ET in the
regulation of platelet activity. The anucleate status of platelets means that they are
not strictly speaking cells, but the similarity of much of their biochemistry allows
them often to be referred to as such and hence in this thesis they will be referred to
as cells and their attributes as cellular.
Platelets are derived from megakaryocytes in the bone marrow. As early as 1943
(Jappa, 1943) megakaryocytes were identified as having nuclear lobes and it was
concluded that during maturation the megakaryocyte increases its' nuclear material
without undergoing cell division. The significance of the differing number of nuclear
lobes of mature megakaryocytes on the reactivity of the resulting platelets has
become a topic of some interest (Kristensen & Martin, 1991). Mature
megakaryocytes become amoeboid and develop pseudopodia which enter into the
circulation through the marrow sinusoids. Some pseudopodia break off to form
proplatelets, but whole megakaryocytes also enter the circulation. Proplatelets and
megakaryocytes remain in the pulmonary circulation until they fragment to produce
discoid platelets (Kaufman et al., 1965). The production of platelets from
megakaryocytes might indicate that regulation of the circulating platelet number
depends completely on an alteration in megakaryocyte maturation or egress into the
circulation. However, a more rapid form of control is afforded by the fact that
approximately one third of platelets are stored in the spleen, as an interchangeable
reservoir with platelets in circulation.
Platelets are described as having four zones, which relate the structure of the platelet
to the functions. The peripheral zone consists of the glycoprotein-rich outer
membrane and submembrane filaments. This outer membrane, although differing in
thickness and precise constituents, is similar to that of other cell types consisting of a
lipid bilayer containing a variety of receptors and ion pumps. The sol-gel zone
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contains the cytoplasmic matrix of the platelet. The various filaments of the sol-gel
zone are responsible for the maintenance of the quiescent discoid shape of the
platelet and, on polymerisation of actin proteins, for the characteristic shape change
induced by most platelet activating agents. The organelle zone contains
mitochondria and ribosomes as well as the three types of platelet granules;
lysosomes, dense bodies and alpha granules. The three types of granules have
distinct functions: the lysosomes contain degradative enzymes; the dense bodies
contain serotonin, ADP and calcium involved in platelet aggregation and
maintenance of vessel tone; and the alpha granules contain platelet derived growth
factor, platelet factor 4 and (3-thromboglobulin, the last often being used as an
indicator of in vivo platelet activation. The fourth region is the membrane system.
Two membrane systems exist; the open canalicular system (sometimes referred to as
the surface connecting system) and the dense tubular system. The canalicular system
effectively increases the surface area of the platelet exposed to the plasma. The
dense tubular system interconnects with the canalicular system and appears to be a
storage site for calcium. In addition the dense tubular system may also be a site for
platelet prostanoid production (Blockmans et ai, 1995).
Platelet Function
The highly reactive nature of platelets is integral to the function of the platelet as a
prompt responder to vascular injury, and the diverse nature of the agents that
stimulate platelet activity indicate the complexity of the stimuli which platelets can
respond to. Stimulators of platelet activation include stimuli on the luminal surface
of the blood vessels such as the structural protein collagen, as well as a number of
humoral agents including thrombin, a proteolytic enzyme generated by the
coagulation system; ADP and serotonin, liberated from activated platelets, and the
catecholamine adrenaline and the peptide vasopressin, both of which are present in
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the circulation. These diverse agents all contribute to a common endpoint platelet
activation. However, the process leading to activation can be identified in a number
of distinct but related stages.
The stages of platelet activation following stimulation are adhesion, shape change,
primary aggregation, secretion and secondary aggregation. On exposure to denuded
blood vessels the first measurable response of platelets is to adhere to the exposed
sub-endothelial material and form a monolayer of platelets (Sixma et al., 1987). Two
of the best understood stimulators of platelet adhesion are collagen and von
Willebrand Factor which form physical links to glycoproteins on the platelet surface.
Platelet shape change follows adhesion or, for platelets in suspension, is itself the
first stage in platelet activation. On stimulation by low concentrations of most
aggregating agents, platelets change from discoid shape to spheroid and form
pseudopodia. The formation of pseudopodia greatly increases the surface area of the
platelet, facilitating further chemical and physical interactions. Platelet shape change
is an event distinct from aggregation, not fully induced by adrenaline or phorbol
ester (Affolter & Pletscher, 1982). It is not a prerequisite for aggregation and in the
case of ADP shape change is probably mediated by a separate receptor to that
mediating the aggregatory response (Colman, 1990). However, although a useful
indication of low level platelet activation in vitro, the precise physiological function
of shape change without aggregation is unclear.
In vitro analysis of platelet aggregation has identified two distinct phases of
aggregation termed primary and secondary aggregation. Primary aggregation can be
a reversible event which can be quantified both by light transmittance aggregometry
(Born, 1962) and by measuring the disappearance of single platelets from a
suspension (Reuter & Deter, 1979). The key event in primary aggregation is the
exposure or activation of the fibrinogen receptor (the GPIIb/IIIa molecule) on the
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cell surface. The symmetrical structure of fibrinogen allows the platelets that come
into contact to stick together by the formation of fibrinogen bridges. The precise
trigger that converts GPIIb/IIla into the active state is not known. However, the
principal mechanism appears to be calcium dependent. Activation of a protein kinase
C in the absence of calcium does induce primary aggregation, but it tends to be much
slower than calcium dependent aggregation. Primary aggregation, like shape change,
appears to represent a functional response which is directly dependent on platelet
aggregating agent receptor activation.
Secondary aggregation is associated with platelet granule release. Granule release is
brought about by a synergistic combination of the actions of a protein kinase C and
increased intra-platelet calcium levels which facilitate the fusion of the granule
membranes with either the plasma membrane or the membrane of the open
canalicular system (Walker & Watson, 1993). Although a protein kinase C
independent mechanism for granule release has been proposed (Hashimoto et al.,
1994) the nature of such a mechanism is not known. 'Weak' agonists, such as ADP
and adrenaline induce granule release and, hence, secondary aggregation in a manner
dependent on amplification of the primary aggregation stimulus. This mechanism is
largely facilitated by the activation of the calcium dependent phospholipase A2 and
the consequent production of thromboxane A2 (Mustard et al., 1975). 'Strong'
agonists such as thrombin are able to elicit granule release without primary
aggregation. The release of dense granule contents, including ADP, ATP, serotonin,
adrenaline and calcium, stimulates further platelet aggregation, while the alpha
granule contents, such as thrombospondin and fibrinogen are responsible for the
formation of large, stable, irreversible aggregates. The secondary phase of
aggregation observed in vitro, in the presence of a limited number of platelets, is
thought to represent the formation of large stable aggregates rather than the creation
of more aggregates (Huang & Detwiler, 1987). It is, therefore, clear that the
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difference between primary and secondary aggregation is qualitative rather than
quantitative.
All the known endogenous agents that regulate platelet activity, both stimulatory and
inhibitory, are thought to exert their effects via receptors on the platelet surface
membrane, with the important exception of NO which is discussed later. The two
main receptor types are glycoproteins and guanine nucleotide binding regulatory
protein linked receptors (G protein linked receptors). The principal glycoprotein
activators are collagen, von Willebrand factor and fibrinogen. Of these, collagen
appears to be the only one that significantly stimulates intraplatelet second
messenger activity, von Willebrand factor and fibrinogen acting primarily as
physical linkages. All of the stimulatory G protein linked receptors identified to date
are polypeptides, consisting of an extracellular N terminal, seven transmembrane
domains and an intracellular C terminal, which is responsible for second messenger
generation.
Consideration of the receptors for thrombin, serotonin and adrenaline will be used to
illustrate some of the nature of the pro-aggregatory G protein linked receptors.
Thrombin is a powerful platelet stimulus causing shape change, aggregation and
release of all three types of platelet granule. Thrombin activates its receptor by
cutting off a portion of the N terminal of the receptor leaving the remaining N
terminal capable of activating the receptor (Vu et al., 1991). Thrombin receptor
occupancy stimulates phospholipase C activation leading to an increase in
intracellular calcium.
Serotonin is a much weaker platelet stimulus, capable of inducing shape change and
reversible aggregation (Baumgartner & Born, 1968). The platelet serotonin receptor
is of the 5HT2 type, and consequently its actions can be blocked by ketanserin (De
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Clerck et al., 1982). Although serotonin alone is a weak platelet aggregating agent,
released from platelet granules it is able to amplify the aggregation response elicited
by other agonists. This potentiation depends on the time interval of exposure of the
platelets to the separate agents (De Clerck & Vanhoutte, 1982). Like thrombin,
serotonin activation of platelets is associated with increased phospholipase C
activity.
Adrenaline is also termed a 'weak' platelet activating stimulus, it stimulates primary
aggregation but does not stimulate secondary aggregation uniformly in platelets from
all human donors (Arkel et al., 1977). Adrenaline does not cause platelet shape
change. The ability of adrenaline to induce platelet aggregation in the absence of
other platelet aggregating agents remains a point of debate (Nieuwland et al., 1993;
Siess, 1989; Steen et al., 1993). However, Steen et al concentrated on the failure of
adrenaline to stimulate phospholipase C activity, whilst Nieuwland provided
evidence for a direct a2 adrenergic receptor mediated stimulation of protein kinase
C. The pro-aggregatory effects of adrenaline are indeed mediated by the oe.2
adrenergic receptor. Adrenaline stimulation of the a2 receptor both promotes protein
kinase C activation, by a phospholipase C independent mechanism, and inhibits
adenylate cyclase. It has been suggested that al receptors linked to phospholipase C
may be present on platelets in approximately 30% of humans (Grant & Scrutton,
1979). In addition to the pro-aggregatory intracellular signalling described, thrombin
and adrenaline are also able to increase adenylate cyclase activity, which is an
inhibitory signalling mechanism. In the case of thrombin, adenylate cyclase activity
is thought to be mediated by the same receptor that is linked to increase
phospholipase C activity, but in the case of adrenaline, P2 adrenergic receptors are
coupled to adenylate cyclase activation.
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Prostaglandins (PG) Ej and I2 also act on platelets through a G protein linked
receptor. However, these prostaglandins have an inhibitory effect on platelet
aggregation. Both agonists act via a PGI2 receptor, which stimulates adenylate
cyclase activity and increases platelet cyclic AMP levels. As mentioned above, NO
also inhibits platelet activation (Radomski et al., 1987). In contrast to the various
agonists described above, NO does not act on a cell surface receptor. Instead,
uniquely, NO diffuses across the cell membrane and directly stimulates soluble
guanylate cyclase, and thus inhibits platelet aggregation. The recognition of the
existence of calcium dependent constitutive nitric oxide synthase in platelets
(Radomski et al., 1990) suggests a parallel for the role for NO in platelet as in
endothelial cells, as an intracellular as well as an extracellular messenger.
Platelet Biochemistry
Intracellular signalling in platelets is regulated at many levels by some parallel and
some interacting biochemical pathways. This is further complicated by the existence
of several subtypes of the various key enzymes involved such as; protein kinase C,
a, (3, 8, and £ (Baldassare et al., 1992), phospholipase C, (3, y and 8 (Berridge, 1993),
and calcium dependent and 'independent' phospholipase A2 (Murthy et al., 1995).
The following discourse, therefore, is not intended to be a comprehensive
description of the messengers mediating receptor activation, but an introduction to
those most relevant to this thesis.
Three families of phospholipase enzymes play an important role in mediating
intracellular events in platelets: phospholipase C, phospholipase A2 and
phospholipase D. Phospholipase C is directly activated by a number of G protein
linked receptors, and is one of the major pathways of platelet activation.
Phospholipase C hydrolyses phosphatidylinositol 4,5-biphosphate (PIP2) to form
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inositol trisphosphate (I(1,4,5)P3) and diacylglycerol (DAG). I(1,4,5)P3 elicits a
rapid transient rise in intracellular calcium, [Ca2+]i, by acting on an IP3 receptor on
the dense tubular system and releasing calcium from intracellular stores. DAG, the
other product of PIP2 hydrolysis, is associated with the translocation and activation
of some sub-types of protein kinase C (Baldassare, et al., 1992). Platelet aggregation
induced by DAG, and its synthetic derivatives such as phorbol esters, is mediated by
protein kinase C activation. Phospholipase A2 is involved in the early stages of
prostaglandin and hence thromboxane A2 (TXA2) synthesis. Phospholipase A2
liberates arachidonic acid (AA) from phosphatidyl choline and phosphatidyl
ethanolamine. AA is subsequently converted by cyclooxygenase to prostaglandins
G2 and H2. PGH2 is converted in turn by thromboxane synthase to TxA2. PGG2,
PGH2 and TxA2 are all potent, but labile aggregating agents able to cause shape
change, primary aggregation and secondary aggregation (Armstrong et al., 1983;
Siess et al., 1983). Thrombin and collagen have been shown to activate
phospholipase D in human platelets (Chiang, 1994). Although its precise role is not
clear there is some evidence that the main product of phospholipase D, phosphatidic
acid may be associated with a calcium independent granule secretory mechanism.
Phospholipase D appears to be a secondary response, at least partially dependent on
protein kinase C activation (Chiang, 1994).
Protein kinase C has the potential for bi-directional regulation of platelet activity. It
plays an important role in promoting both platelet adhesion and granular secretion
and, conversely, protein kinase C has inhibitory effects on platelet function,
inhibiting IP3 formation and promoting calcium extrusion (Pollock et al., 1987;
Watson & Lapetina, 1985). As stated above, one of the main pathways for protein
kinase C activation is the phospholipase C mediated production of DAG but other
mechanisms do exist. Recently, Nieuwland described an a2 adrenergic receptor G-
protein linked activation of protein kinase C (Nieuwland, et al., 1993) and Kroll
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described protein kinase C activation by platelets subjected to pathological levels of
shear stress without DAG formation (Kroll et al., 1993). At least two targets exist for
phosphorylation by protein kinase C, the 47 kDa protein pleckstrin and myosin light
chain, although the precise function of the former remains obscure, the latter is
involved in the contractile system in platelets (Watson et al., 1993).
Although protein kinase C can act synergistically with calcium it can also exert
effects in a calcium independent fashion. Recent work has shown that protein kinase
C translocation occurs in two stages, an early transient stage and a sustained stage
(Hashimoto, et al., 1994), and that the early phase is not calcium dependent. The
initial phase appears sufficient to elicit maximal serotonin secretion from platelets.
Although there is a potential role for protein kinase C as an inhibitor of platelet
aggregation, the main intracellular messengers associated with this role are the cyclic
nucleotides, cyclic AMP and cyclic GMP. The predominant regulation of cyclic
AMP levels is by G protein activation of membrane bound adenylate cyclase,
converting ATP to cyclic AMP, and degradation of cyclic AMP by a
phosphodiesterase. Stimulation of cyclic AMP dependent protein kinases, cAMP-
PK, types I and lib , and the consequent phosphorylation mediate the diverse effects
of cyclic AMP (Eigenthaler et al., 1992). There appear to be several substrates for
cAMP-PK including vasodilator stimulated phosphoprotein, (VASP), and myosin
light chain kinase, phosphorylation of the latter by cAMP-PK prevent its activation
by calcium. Platelet cyclic GMP levels are regulated predominantly by soluble
guanylyl cyclase activation by NO, either as an intercellular or extracellular
messenger, and degradation by a phosphodiesterase. There is recent evidence for a
non-NO mediated increase in platelet cyclic GMP (Shen & Hong, 1995). Cyclic
GMP has two main targets, cyclic GMP dependent protein kinase (cGMP-PK) and
the cyclic GMP inhibited phosphodiesterase. The latter allows cyclic GMP to
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indirectly regulate cyclic AMP levels, by decreasing the phosphodiesterase activity,
and may to some extent account for the synergism observed with the actions of the
cyclic AMP mediated PGI2 and the cyclic GMP mediated NO in human platelets
(Radomski, et al., 1987). The only substrate so far identified for cGMP-PK in
platelets is VASP. It would seem more than possible that VASP might mediate the
inhibition of phospholipase C and the consequent reduction in protein kinase C
activity observed as a result of activation of cAMP-PK and cGMP-PK (Waldmann &
Walter, 1989). However, whether VASP is involved in activation of intracellular
calcium pumps by cyclic AMP and cyclic GMP or not is less clear (Johansson &
Haynes, 1992; Johansson et al., 1992; Waldmann & Walter, 1989)
Much of the intracellular regulation of platelet activity described above is involved
in the control of available intracellular calcium; the increase in [Ca2+]j through
I(1,4,5)P3 and the decrease by cyclic AMP and cyclic GMP. Activation of pro-
aggregatory platelet receptors results either directly or indirectly in a rise in [Ca2+]j,
and elevation of [Ca2+]j without receptor occupancy by A23187 also results in
platelet activation (White et al., 1974). Elevation of [Ca2+]i can be brought about by
either the release of calcium from intraplatelet stores in the dense tubular system or
calcium entry from the extracellular medium. The role of I(1,4,5)P3 in the release of
calcium from intracellular store has been considered above. I(1,4,5)P3 independent
pathways of calcium release are less well characterised. Calcium induced calcium
release (CICR) has been described in a number of cells and may be partially
responsible for the complex nature of calcium signalling (Berridge, 1991). Initiation
of this system is dependent on I(1,4,5)P3 and is followed by a CICR mechanism for
propagation of the signal. A similar model has been proposed for platelets (Tsunoda
et al., 1988). Calcium entry may be brought about by receptor operated channels or
intracellular calcium store regulated entry; it is thought that voltage operated calcium
channels do not exist in platelets (Rink & Sage, 1990) and there is little evidence for
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second messenger operated channels. ADP had been shown to activate receptor
operated calcium channels in platelets, calcium entry which occurred without
measurable delay was evinced to be through a receptor operated channel by patch
clamp experiments (MahautSmith et al., 1990). However, to date, no other agonist
has been shown to activate such channels. Prevention of calcium re-uptake into
intracellular stores by the use of thapsigargin prior to the exposure of the platelet to
thrombin, has been used to demonstrate that store depletion leads to calcium entry
(Sargeant et al., 1992).
Platelet activity in health and disease
As stated above one of the primary functions of platelets is the formation of a
haemostatic plug, by the initial formation of the 'white thrombus', in response to
endothelial damage and the consequent prevention of bleeding. This is followed by
the release of platelet growth factors and repair of the damaged area. Many disorders
associated with abnormal platelet function involve reduced platelet activity and
prolonged bleeding. Prolonged bleeding may be associated with reduced platelet
number (thrombocytopenia), due to impaired platelet production or increased
destruction of platelets, or by conditions associated with ineffective coagulation, due
to the absence of specific clotting factors, as seen in the various forms of
haemophilia. The involvement of reduced platelet function in bleeding disorders is a
complex haematological area but lies outside the remit of this thesis. It is the
phenomenon of increased platelet activity and aggregation, often observed in
cardiovascular disease, that will be considered below.
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Essential Hypertension
Platelet function in essential hypertension has been studied for a number of reasons.
Platelets may play a role in the pathophysiology of hypertension by the release of
vasoconstrictors such as serotonin from activated platelets and also as mediators of
risks associated with hypertension. In addition, platelets are often described as a
model for vascular smooth muscle cells due to the parallel control of platelets and
vascular smooth muscle cells exerted by the vascular endothelium and the many
receptors and intracellular pathways that they share, such as 0C2 adrenergic and
angiotensin II receptors, adenylate cyclase activity and calcium regulation.
A number of studies have suggested increased in vitro aggregation of platelets from
patients with essential hypertension (Lechi et al., 1989; Touyz & Schiffrin, 1993b;
Vlachakis & Aledort, 1980). However, other groups have not observed any
significant differences in vitro (Cadwgan & Benjamin, 1993; Mehta & Mehta, 1981).
These apparent discrepancies may be due to the conditions under which these studies
have been carried out and the population of hypertensive subjects studied.
Measurements of indices of in vivo platelet activation do suggest a greater level of
activity in hypertensives than controls (Islim et al., 1992; Mehta & Mehta, 1981).
Increased platelet calcium concentrations observed in hypertensive patients (Biihler
& Resink, 1988; Islim, et al., 1992; Le Quan Sang & Devynck, 1986; Mehta &
Mehta, 1981) are consistent with the hypothesis that hypertension is associated with
excess calcium mobilisation (Robinson, 1984). Other abnormalities observed in
platelets from patients with essential hypertension include decreased NO synthesis
after stimulation with collagen (Cadwgan & Benjamin, 1993) and lower platelet
magnesium concentrations (Touyz & Schiffrin, 1993b), both traits may be associated
with altered platelet function.
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Pre-eclampsia
Pre-eclampsia is a condition associated with hypertension in pregnancy. However,
several aspects of this condition clearly distinguish it from transient hypertension
including proteinuria and raised growth factor activity (Roberts & Redman, 1993).
An increased arterial sensitivity to exogenous angiotensin II precedes the onset of
hypertension (Brosens et al., 1972). The combined factors of: an early reduction in
platelet count in preeclampsia, increased platelet sensitivity to angiotensin II and;
once again, the similarity of platelets to smooth muscle cells, led to the investigation
of platelet function. Although basal platelet calcium levels are not altered, the
arginine-vasopressin stimulated calcium response is significantly increased as early
as the first trimester (Zemel et al., 1990). Zemel highlights the fact that disturbances
in platelet activity precedes those in vascular smooth muscle cells and consequently
increased platelet activity may contribute to the pathogenesis of the disease.
Ischaemic Heart Disease
Platelets activation is known to play an important role in the progression of a number
of conditions associated with myocardial ischaemia such as angina and infarction (de
Lorgeril et al., 1994; Flores & Sheridan, 1994; Willerson et al., 1989). Although the
precise underlying causes of these conditions are not always fully understood it is
known that vessel narrowing and occlusion are often part of the final pathway.
Platelets may have two separate but associated functions, the formation of a
thrombus and hence partial blockage of the vessel and the release of vasoconstrictor
agents from aggregating platelets leading to a narrowing of the vessel. In response to
a site of damage and the exposure of the subendothelial layer platelets will tend to
aggregate as described earlier, but also in the case of localised dysfunction of the
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endothelium platelets may also respond by forming aggregates. The efficacy of
aspirin in the reduction of mortality in patients suffering myocardial infarction has
been largely attributed to its ability to inhibit platelet cyclooxygenase .
Studies examining increased circulating platelet aggregates in patients suffering from
unstable angina produced evidence for increased in vivo platelet aggregation
coinciding with angina attacks (Dalai et al., 1980; Robertson et al., 1980). In a
similar study where 44 patients were admitted to hospital with chest pain, the
number of circulating platelet microthrombi were significantly increased in patients
suffering from myocardial infarction but not in the patients without myocardial
infarction (Mehta & Mehta, 1981). These studies, however, were not able to
determine whether the platelets from patients suffering from ischaemic heart disease
had a greater tendency to aggregate or whether aggregating agents were released
during these attacks.
As part of the Caerphilly Collaborative study blood samples were taken from over
1800 subjects for platelet aggregation studies. Significant relations were shown
between past myocardial infarction and ADP-induced in vitro platelet aggregation as
well as significant relations between electrocardiographic evidence of ischaemia and
ADP-induced aggregation (Elwood et al., 1991). Interestingly, no such association
was seen when collagen was used as the aggregating agent. A correlation between
the rate of platelet aggregation to ADP and subsequent mortality from coronary heart
disease was reported in a study in which 487 healthy middle aged men participated
(Thaulow et al., 1991), again no correlation was seen when collagen was the
aggregating agent. A positive association was seen between in vitro platelet hyper¬
reactivity and both mortality and cardiac events in a group of survivors of
myocardial infarction (Trip et al., 1990). The fact that increased platelet reactivity is
agonist specific in some of these studies suggests that there is a particular, but as yet
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undefined, intraplatelet mechanism involved. The identification of such a
mechanism may be of use in understanding the discrepancies between the results of
some of the studies mentioned above.
The understanding of the actions of platelets in ischaemia is further complicated by
the complex nature of the interactions between the vascular endothelium and
platelets. The endothelium of arterioles posses 5HT i receptors, which on exposure to
serotonin released from platelets indirectly relax underlying vascular smooth muscle
cells. In the absence of the endothelium serotonin caused constriction by acting
directly on 5HT2 receptors on the vascular smooth muscle cells (Vanhoutte, 1991)
The endothelium not only has receptors for platelet derived agents, but is a source of
vasoconstrictors and vasodilators which modulate platelet activity
Platelets and the vascular endothelium.
The general structure of the vessel walls is fairly uniform throughout the circulatory
system, with the exception of the capillaries, in that they consist of three separate
layers. These are the tunica intima, tunica media and tunica adventitia. The tunica
intima, the layer closest to the vessel lumen and hence the blood, consists of the
endothelium and the basal lamina. The media is composed primarily of smooth
muscle cells and collagen fibres, it is this layer that is absent in capillaries. The
adventitia is made up of connective tissue and fibroblasts, and contains nerves and,
in larger, vessels the vasa vasorum.
The endothelium is a continuous layer of single cells, lining the whole of the
cardiovascular system. Up until the late 1970s the endothelium was simply seen as
an anatomical barrier between the blood constituents and the vessel wall. However,
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over the past twenty years it has come to be recognised as an important regulator of
vascular tone and platelet activation.
The endothelium releases, both luminally and abluminally, a number of agents
which regulate vascular smooth muscle tone and platelet activity respectively. In
addition, the luminal surface of the endothelium contains factors that inhibit platelet
aggregation, such as thrombomodulin and ADPase. Thrombomodulin binds
thrombin, a strong platelet aggregating agent, making it inaccessible to platelets,
while ADPase converts ADP to inactive AMP. These factors may be of great
significance in the regulation of platelet aggregation. However, for the purpose of
this thesis the following paragraphs will concentrate on factors released from the
endothelium.
Prostacyclin was first discovered in 1976 (Moncada et al., 1976). A member of the
family of prostaglandins, it is synthesised from prostaglandin H2 by the actions of
the enzyme prostacyclin synthase. Its production is initiated by the actions of
phospholipase A2 which liberates arachidonic acid from membrane phospholipids.
Arachidonic acid is converted to prostaglandin G2 by cyclooxygenase, which in turn
is converted to prostaglandin H2. The conversion of prostaglandin G2 by
cyclooxygenase is a common step in the production of both prostacyclin and
thromboxane and is inhibited by aspirin, as stated above. The major metabolites of
prostacyclin are stable derivatives of prostaglandin F2« which are assayed as
indicators of prostacyclin production. Prostacyclin generation can be stimulated by
both endogenous mediators and mechanical stimuli (Bhagyalakshmi & Freangos,
1989). Among the endogenous mediators are platelet derived serotonin and adenine
nucleotides (Miigge et al., 1991).
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As with many endothelium derived mediators prostacyclin is a locally acting
hormone; the ubiquity of the endothelium allows it to give a localised response to
local stimuli. Acting via specific cell surface receptors, the intracellular action of
prostacyclin is similar in both platelets and vascular smooth muscle cells, it
stimulates adenylate cyclase to produce cyclic AMP, inhibiting platelet aggregation
and relaxing vascular smooth muscle cells.
In 1980 Furchgott and Zawadski identified another endothelium derived relaxing
factor (EDRF) (Furchgott & Zawadzki, 1980). EDRF was known not to be a
prostaglandin as its actions were not inhibited by cyclooxygenase blockade. Further
investigation revealed the intracellular messenger for EDRF was cyclic GMP
(Ignarro & Kadowitz, 1985); it had previously been established that NO stimulated
cyclic GMP production (Greutter et al., 1979). In addition the actions of EDRF were
inhibited by haemoglobin (Martin et al., 1985). Furthermore it had been known for
some time that NO binds to the haeme moiety of haemoglobin (Kon, 1968). In 1987
Palmer and colleagues indirectly measured NO in an experiment where bradykinin, a
substance known to release EDRF, was applied to strips of rabbit aorta (Palmer et
al., 1987). The amount of NO measured was calculated to account for the relaxation
of the strips apparently induced by EDRF. It has since been widely accepted that
EDRF is NO.
NO and L-citrulline are synthesised from the substrate L-arginine by the actions of
the enzyme NO synthase (NOS) (Palmer et al., 1988). NO production can be
competitively inhibited by a number of substances with structural similarity to L-
arginine, such as L- A^-monomethyl arginine (LNMMA). To date, three distinct
isoforms of NOS have been identified; two constitutive calcium dependent isoforms
found in the cardiovascular system and the nervous system (eNOS and nNOS
respectively) and an inducible calcium independent isoform, widely distributed and
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expressed during inflammatory reactions (iNOS). Generation of NO by eNOS can be
stimulated by an increase in intracellular calcium (Schulz & Triggle, 1994). NO
freely diffuses into adjacent target cells where it binds to the haeme group in soluble
guanylate cyclase and stimulates the production of cyclic GMP and the consequent
relaxation of vascular smooth muscle cells. In addition to vascular relaxation, NO
inhibits both platelet adhesion and aggregation (Radomski, et al., 1987). The
mechanism for cyclic GMP mediated inhibition of platelet activation is discussed
above. Platelets also contain eNOS (Radomski, et al., 1990) and are consequently a
source as well as a target of NO. Radomski proposed that in platelets NO acts as an
intracellular messenger inhibiting platelet aggregation.
NO generation from endothelial cells can be stimulated by physical stimuli, such as
shear stress; as well as number of chemical agents, including acetylcholine
bradykinin, serotonin and ADP (Shepherd & Katusic, 1991). Platelet aggregation
and the consequent release of platelet derived serotonin, thromboxane and ADP may
therefore be important in NO production from endothelial cells. Endothelium
dependent relaxation induced by aggregating platelets in human mammary arteries
can be inhibited by apyrase, an ADP scavenger and by LNMMA (Fostermann et al.,
1988).
Local infusion of LNMMA, the competitive inhibitor of NO production, into the
human forearm causes a dose dependent reduction in resting forearm blood flow
(Vallance, 1989), demonstrating that NO contributes to basal vasodilator tone by
opposing vasoconstrictor forces. However, whether infusion of LNMMA alters
platelet activity is not unclear. Systemic infusion of LNMMA has been shown to
reduce bleeding time, but without affecting ex vivo platelet aggregation (Sigmon &
Beierwaltes, 1995).
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Impaired endothelium dependent relaxation has been reported in a number of
conditions where abnormal platelet activity is also observed, such as diabetes
(Poston & Taylor, 1995) and hypertension (Panza et al., 1990) Indeed intravenous
infusion of LNMMA has been shown to increase mean arterial pressure in healthy
subjects (Haynes et al., 1993) suggesting that a reduction in NO synthesis in
hypertension might contribute to increased blood pressure. In atherosclerosis a
decrease in endothelium dependent relaxation is likely to be linked to decreased NO
production. This is consistent with the findings of Ludmer and colleagues, who
showed that acetylcholine produced constriction rather than relaxation in
atherosclerotic human arteries in vitro in the presence of the endothelium (Ludmer et
al., 1986). A reduction in NO production could contribute greatly to platelet
deposition and the release of platelet derived growth factors known to be involved in
the progression of atherosclerosis.
Angiotensin II is a potent vasoconstrictor octapeptide. Its substrate, angiotensinogen,
is converted by proteolytic cleavage of the ten N-terminal amino acids by renin
secreted from the kidney, to form the decapeptide angiotensin I. Angiotensin
converting enzyme (ACE) cleaves two C-terminal amino acids from angiotensin I to
form angiotensin II. Although high concentrations of ACE are found in the lung it is
also present in the vascular endothelium, as is angiotensinogen and renin. Evidence
for vascular production has come from isolated vessel studies where angiotensin II
production was observed in the absence of circulating blood (Nakamaru et al., 1986;
Mizuno, 1991). Of the two angiotensin II receptors, it is the type I receptor which is
thought to mediate the physiological actions of the peptide in the cardiovascular
system. Angiotensin receptors were identified on human platelets in 1982 (Moore &
Williams, 1982) and a functional interaction was first described in 1985 (Ding et al.,
1985b). Angiotensin II alone appears to have no direct effect on platelet aggregation.
However, it modulates adrenaline-induced aggregation in a biphasic manner; at low
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concentrations, it potentiates aggregation, and at higher concentrations it inhibits
aggregation. It has also been shown to potentiate the effects of TxA2-
In vascular smooth muscle cells contraction induced by angiotensin II is mediated by
an increase in intracellular calcium (Dostal et al., 1990). A similar mechanism is
observed in platelets (Haller et al., 1989).
Although the physiological significance of the modulation of platelet aggregation by
angiotensin II is not fully understood, angiotensin platelet binding and the effects of
angiotensin on platelet calcium have been studied in a number of conditions where
angiotensin sensitivity is thought to be altered, such as essential hypertension, pre¬
eclampsia and diabetes. Studies of the actions of angiotensin II on platelets in pre¬
eclampsia have demonstrated both an increase in intracellular calcium (Haller, et al.,
1989) and an increase in angiotensin binding (Baker et al., 1991). In hypertension an
increase in the angiotensin mediated calcium response was observed but receptor
binding studies have not produced consistent results (Crabos et al., 1993; Ding et al.,
1985a).
Endothelin
In 1985 Hickey et al described a peptidergic endothelium derived constrictor, present
in culture medium from bovine endothelial cells (Hickey et al., 1985). Three years
later this factor was isolated and sequenced from cultured porcine endothelial cells,
and named ET (Yanagisawa et al., 1988). A 21 amino acid peptide, ET is the most
powerful vasoconstrictor known to date and induces a characteristically sustained
effect.
43
Despite the apparently distinctive structure of ET, analysis of human genome
revealed the existence of three ET peptides (Inoue et al., 1989a; Inoue et al., 1989b),
named ET-1, -2 &-3. The ETs were also shown to have structural similarity to the
snake venoms sarafotoxins (SRTX) isolated from the Israeli burrowing asp (Fig [1]),
and unsurprisingly the SRTXs share some of the effects of the ETs. All ETs and
SRTXs are made up of 21 amino acids, identical at ten positions including the four
cysteines which contribute to the two disulphide bridges. ET-1 and -2 show the






Figure 1.1. A diagramatic representation of ET-1, 2 &3 and SRTX S6c
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ET-1 is initially synthesised as a prepropeptide, as are ET-2 and ET-3, which
undergoes a three step modification for the production of mature ET-1 (Inoue, et al.,
1989b). Prepro-ET-1 consists of 212 amino acids, which is cleaved at Arg52-Cys 53
and at Arg92-Ala93 by dibasic amino acid endopeptidase(s) to form the form,
known as big ET-1. The 38 amino acid big ET-1 then undergoes further cleavage at
Trp21-Val22 by an endothelin converting enzyme (ECE) to form the 21 amino acid
ET-1. ECE is a phosphoramidon sensitive metalloprotease, as phosphoramidon has
been shown to inhibit the conversion of exogenous big ET-1 to ET-1 (McMahon et
al., 1991) as well as causing a concomitant increase in big ET-1 and decrease in
mature ET-1 secretion from cultured endothelial cells (Sawamura et al., 1991). In
1994 Xu et al reported the cloning of ECE-l(Xu et al., 1994), an enzyme that readily
converted big ET-1 to ET-1 at a neutral pH of 6.8, the activity of which was
inhibited by phosphoramidon but not thiorphan distinguishing it from neutral
endopeptidase-24.11. Intact cells transfected with the ECE-1 cDNA construct were
able to secrete ET-1 and convert exogenous Big ET-1 to mature ET-1. They found
that ECE-1 was expressed in a range of cell types, but expressed most abundantly in
endothelial cells.
The following year, members of the same group reported the cloning of ECE-2
(Emoto & Yanagisawa, 1995). In an attempt to find an ECE that might be
responsible for the production of mature ET-2 or ET-3 or explain ET-1 production in
cells not containing ECE-1 they looked for structurally related isoenzymes of ECE-
1, however like ECE-1, ECE-2 converts big-ET-1 to the mature peptide more
efficiently than it does big ET-2 or -3. The main differences between the two
isoforms are that ECE-2 has an acidic pEl optimum (suggesting that it is localised in
acidic intracellular compartments), is more sensitive to phosphoramidon and appears
to be present in neuronal cells. Converting enzymes with preferential activity for big
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ET-2 and -3 remain to be identified. Intracellular ECE activity may be inefficient or
selectively regulated as big ETs are recognised to exist at measurable concentrations
in human plasma (Miyauchi et al., 1989). Blood cells can convert big ET-1 to ET-1
(Watanabe et al., 1991) but this is not thought to be a major site of conversion.
Many stimuli induce ET production, on the basis of induction of ET-1 mRNA or
elevated immunoreactive ET-1, (ir-ET-1), including adrenaline, angiotensin II,
arginine vasopressin, transforming growth factor (31, shear stress and hypoxia
(Elaynes & Webb, 1993a). In addition, aggregating platelets have been shown to
induce ET-1 mRNA and increase ir-ET-1 without physical contact between the
platelets and the endothelial cells (Ohlstein et al., 1991). NO has been demonstrated
to inhibit ET-1 production (Boulanger & Luscher, 1990).
Two ET receptors have been cloned and shown to be expressed in mammalian
tissue. The initial cloning of the ET receptors occurred at approximately the same
time. One receptor, named the ETa, was isolated from bovine lung cDNA (Arai et
al., 1990), and was demonstrated to have a high affinity for ET-1, the isoform
selectivity being ET-l>ET-2»ET-3. The other receptor, named ETb, was identified
from the screening of a rat lung cDNA library (Sakurai et al., 1990) and has equal
affinity for all three ETs. SRTX S6c has been shown to be a selective agonist with a
30 000 fold greater selectivity for the ETb receptor than the ETa (Williams et al.,
1991). Both the ETa and the ETb receptors are similar, sharing the structure of G
protein coupled receptor family, having seven transmembrane domains, separated by
three extracellular and three intracellular loops, with a long extracellular N-terminal.
A third receptor, the ETc receptor, has been cloned from the frog xenopus laevis
(Karne et al., 1993). In the frog ET-3 was shown to activate this receptor with much
greater potency than either ET-1 or ET-2 (ET-3» ET-l=ET-2). Despite
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pharmacological evidence for a receptor with the same rank order of potency in
rabbit saphenous vein (Douglas et al., 1995), the gene for such a receptor has yet to
be identified in mammals. Variants within a receptor subtype may arise from
alternative RNA splicing, such a variant has been identified for the ETg receptor.
However, present evidence would suggest that this type of variant might result in
alternative intracellular signalling rather than altered binding characteristics
(Shyamala et al., 1994).
The intracellular signal transduction mechanisms that mediate the actions of ET can,
in the first instance be separated into pathways mediating short term changes and
pathways mediating long term changes such as mitogenesis. The following section
will address the mechanisms mediating short term changes.
ET intracellular signalling
Several mechanisms may be involved in ET-1 stimulation of cells, such as vascular
smooth muscle cells. ET-1 stimulated increase in calcium may be by calcium influx
as well as mobilisation of intracellular calcium, the latter most probably mediated by
the PI system. Stimulation of phospholipase A2, phospholipase D and protein kinase
C have also been suggested as intracellular pathways.
Much work has focused on direct activation of ET-1 stimulated calcium entry in an
attempt to define the precise channel involved. Conflicting results on the
involvement of L type calcium channels appear to depend on the source of the cells
or tissue being examined. However, investigation into the ability of ET-1 to bind
directly to, and activate, these channels found that ET-1 does not compete with L-
type calcium channel ligand binding (Gu et al., 1989). It remains likely that, at least
48
in part, ET-1 stimulated calcium entry might be subsequent to release of calcium
from intracellular stores.
There is significant evidence for both ETa and ETb mediated stimulation of PI
turnover in both cardiovascular tissues (Hilal-Dandan et al., 1994; Ohlstein et al.,
1989) and transfected cells (Aramori & Nakanishi, 1992). As described above for
platelets, activation of phospholipase C is the main mechanism for stimulation of PI
turnover. Consequently, IP3 mediated release of calcium could in turn mediate
calcium entry. The other messenger generated by PI hydrolysis is DAG, and not
surprisingly ET-1 stimulation of vascular smooth muscle cells is associated with a
dose dependent increase in DAG (Griendling et al., 1989).
Protein kinase C can be activated by DAG. ET-1 induced protein kinase C
translocation has been reported in vascular smooth muscle cells (Lee et al., 1989)
and protein kinase C inhibition inhibited ET-1 induced contraction in rabbit aorta
(Ohlstein, et al., 1989). However, in the last study, like others, an increase in PI
turnover was observed, and therefore, although it is clear that protein kinase C plays
a role in ET induced effects it is not clear whether this kinase is stimulated directly
or only subsequent to phospholipase C. Protein kinase C mediates the effects of the
Na+-H+ antiporter in many cell types, regulating intracellular pH. ET induced
alkalinisation was investigated in human resistance vessels (Richards et al., 1989).
Up to 70 % of contraction induced by ET-1 in these vessels appeared to dependent
on Na+-H+; in vascular smooth muscle cells ET-1 stimulation of Na+-H+ exchange
was blocked by protein kinase C inhibition (Lonchampt et al., 1991). This further
supports the role of protein kinase C in the effects of ET and suggests that these
effects are partly mediated by the regulation of intracellular pH.
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The greatest differences in the intracellular mechanisms between ETa and ETb
mediated responses appear to arise in the study of the cyclic nucleotide second
messengers, cyclic AMP and cyclic GMP. Significant differences also seem to exist
between different cell types. In transfected cells expressing ETa or ETb receptors,
the ETa receptor was linked to a stimulation of adenylate cyclase and a consequent
increase in cyclic AMP, whereas the ETb receptor mediated an inhibition of
forskolin stimulated cyclic AMP (Aramori & Nakanishi, 1992). Care must be taken
in the interpretation of studies involving transfected cells, as transfection with
receptor DNA may not necessarily result in the same signal transduction as cells
naturally expressing these receptors. Nevertheless, in alveolar epithelium cells the
ETa receptor stimulation was associated with prostaglandin synthesis and cyclic
AMP accumulation, and a significant increase in cyclic AMP was still observed in
the presence of indomethacin (Markewitz et al., 1995). However, in rabbit aorta ETa
activation was not associated with any change in cyclic AMP (Ohlstein, et al., 1989).
In intact rat tail arteries ET-3 administration inhibited isoproterenol stimulated cyclic
AMP (Yang et al., 1991). The presence of the endothelium and the efficacy of ET-3
suggest that this may be ETb mediated. This is consistent with ET-3 inhibition of
forskolin stimulated cyclic AMP in bovine endothelial cells (Eguchi et al., 1993).
ET-3 mediated activation is also associated with an increase in cyclic GMP, as seen
in kidney epithelial cells (Ishii et al., 1991).
In the human vasculature, early studies suggested that the ETa receptor, restricted to
the smooth muscle cells, mediates contraction, and the ETb receptor, restricted to the
endothelium, mediates relaxation. However, the recognition that ETb receptors are
also present on smooth muscle cells (Davenport et al., 1995), and can mediate
contraction (Clozel et al., 1992) forced a revision of this perspective. The endothelial
ETb receptor is sometimes distinguished from the muscular ETb receptor by
referring to them as ETbi and ETb2 respectively.
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A number of antagonists have been developed that distinguish between the ETa and
the ETB receptors, as well as some that are thought to distinguish between the ETbi
and ETb2 receptors (Ferro & Webb, 1996). A commonly used ETa antagonist is
BQ-123; potent and highly selective, BQ-123 antagonises ET-1 binding and ET-1
induced contraction at the ETa receptor (Ihara et al., 1992). However, residual
contraction in the presence of BQ-123 provided early evidence for ETb mediated
contraction of rat aortic smooth muscle. An extensively used ETb receptor
antagonist, BQ-788 has been shown not to affect ETa mediated pressor responses
(Ishikawa et al., 1994) but to antagonise both ETbi and ETb2 mediated responses
(Karaki et al., 1994). The partial antagonism exhibited by certain ETb antagonists
helped characterise ETbi and ETb2 receptors. The antagonist PD 142893 is
considered able to distinguish between the two putative subtypes (Douglas, et al.,
1995).
Endothelin in health and disease
Intravenous administration of ET-1 causes a transient vasodilation followed by a
profound and long lasting increase in blood pressure (Yanagisawa, et al., 1988). The
initial vasodilator response was thought to be due to stimulated release of ET-1
derived NO or prostacyclin. However, cyclooxygenase blockade with indomethacin
did not significantly alter the transient dilatation (Rubanyi & Polokoff, 1994)
suggesting that it does not involve prostacyclin synthesis. Inhibition of NO synthesis
has been shown to attenuate this response (Gardiner et al., 1990). Consequently, NO
release appears to be involved. In addition to direct vasoconstrictor effects at low
concentrations, ET-1 also potentiates the effects of other constrictor agents such as
norepinephrine and serotonin (Yang et al., 1990; Nakayama, 1991).
51
The role of ET in disease is very much an open field. Increased circulating
concentrations of ir-ET-1 have been reported in a number of pathophysiological
conditions. Indeed, increased ET mediated responses have also been reported, yet
until ET receptor antagonism, or ECE inhibition result in beneficial effects in man in
a particular disease it remains speculation whether ET-1 has a causative role. The
advent of orally active ET antagonists should help greatly in this respect. The
evidence for a role of ET-1 in a few vascular conditions is discussed below.
Yanagisawa postulated that disturbances in the control of ET production could
contribute to the pathogenesis of hypertension (Yanagisawa, et al., 1988). However,
plasma concentrations are not raised in patients with essential hypertension
compared to age matched controls (Davenport et al., 1990). An increased sensitivity
to exogenous ET-1 has been shown in the dorsal hand vein of untreated hypertensive
patients and if a similar increased sensitivity were to exist in other tissue it remains
possible that ET may be involved in the pathophysiology of this condition.
The powerful vasoconstrictor properties of ET-1 and its role as a locally acting
hormone suggest a possible role in vasospastic or ischaemic conditions. Indeed,
exogenous ET-1 causes coronary vasoconstriction leading to myocardial ischaemia
in a canine model (Kurihara et al., 1989). Plasma levels of ir-ET-1 were reported to
be significantly raised (Lam et al., 1991) and suggested to be an early indicator of
acute myocardial infarction in man (Stewart et al., 1991). The number of cardiac
binding sites for iodinated ET-1 are also reported to be raised after ischaemia (Liu et
al., 1990). Both the extent of infarction (Yasuda et al., 1990) and the prognosis, post
infarction, (Omlamd et al., 1994) correlate with ET levels indicating that plasma ET-
1 levels may be associated with the severity of myocardial infarction. But, perhaps,
the most significant evidence for a direct role of ET-1 is that infusion of BQ-123
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reduces the extent of experimentally induced myocardial infarction by up to 40 % in
animal studies (Grover et al., 1993).
Following subarachnoid haemorrhage (SAH) cerebral vasospasm develops. ET-1 has
been implicated in the development of this potentially fatal secondary event. Both
plasma (Masaoka et al., 1989) and cerebrospinal fluid levels (Seiffert et al., 1995) of
ET-1 are raised in patients with SAH as they are in a canine models of the disease
(Yamaura et al., 1992). However, ECE inhibition, using phosphoramidon, reduced
the vasospasm along with lowering cerebrospinal fluid ET-1 levels in the canine
model (Matsumura et al., 1991). Administration of BQ-123 has also been shown to
reduce SAH induced vasospasm in dogs (Clozel et al., 1993). The beneficial effects
of inhibition of ET-1 production as well as ET receptor antagonism strongly supports
a role for ET-1 in the development of post SAH vasospasm.
Endothelin and platelets
The discovery of an endothelium derived constrictor raised the question of whether
ET-1 might also regulate platelet activity. It was already known that endothelium
derived agents such as prostacyclin and EDRF (NO) inhibited platelet activity.
However, at sites of haemorrhage, the balance is required to change in favour of
platelet activation. ET-1 may play an important role in haemostasis at the site of
haemorrhage, its release being stimulated with factors known to play a role in
coagulation such as thrombin and adrenaline (Yanagisawa, et al., 1988) and the
consequent vasoconstriction limiting blood flow near a site of damage. In conditions
such as hypertension and vasospasm, where ET-1 may have a pathophysiological
role, platelet activity is increased and may contribute to the condition. Consequently,
the possibility of ETs modifying platelet activity was investigated.
53
Early investigations failed to reveal any effect of ET-1 (Patel et al., 1989) or ET-3
(Lidbury et al., 1989) alone or in combination with other platelet aggregating agents
on platelet activation in vitro. In both studies three aggregating agents were used; in
the former ADP, thrombin and U44069, and in the latter ADP collagen and
arachidonic acid. However, ex vivo studies, examining platelet aggregation after
administration of systemic doses of ET-1 to dogs (Herman et al., 1989) and rabbits
(Thiemermann et al., 1989), showed an inhibition of platelet aggregation. In the
canine study the inhibition of platelet aggregation coincided with an increase in
plasma levels of 6-keto PGFia, a metabolite of prostacyclin, and both the inhibition
of platelet aggregation and the rise in 6-keto PGFia were attenuated by pre-
treatment with acetylsalicylic acid, a cyclooxygenase inhibitor. Hence, the inhibitory
action of ET-1 on platelet aggregation was attributed to ET-1 stimulated prostacyclin
release. Similarly, in the study reported by Thiemermann, pre-treatment with the
cyclooxygenase inhibitor indomethacin markedly attenuated the ET-1 mediated
inhibition of platelet aggregation. Interestingly, in this study a residual indomethacin
insensitive ET-1 inhibition of platelet aggregation was observed up to 60 min after
ET-1 administration.
The following year three further studies were published investigating the effect of
ET-1 on platelet aggregation in vitro. Edlund & Wennmalm reported that ET-1 did
not induce platelet aggregation in human plasma for up to 5 min after the addition of
the peptide, nor did it alter aggregation induced by thrombin or ADP, observed for
30 sec after the addition of the aggregating agents (Edlund & Wennmalm, 1990).
The inability of ET-1 to induce platelet aggregation within 5 min of addition to
human plasma was confirmed by Ohlstein et al (Ohlstein et al., 1990). In this study
ET-1 failed to affect platelet aggregation to varying doses of ADP and collagen or
single doses of arachidonic acid or adrenaline selected to elicit half maximal
responses. However, ET-1 did significantly potentiate aggregation to 'low'
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concentrations of ADP (0.625 & 1.25 |iM) in rabbit and canine platelets. The third
study published in 1990 reported a significant potentiation of adrenaline induced
platelet aggregation in vitro in human platelets (Matsumoto et al., 1990). In this
study ET-1 dose dependently potentiated aggregation to 0.08 & 0.2 fig/ml adrenaline
10 min after the addition of the aggregating agent. Interestingly, potentiation of
aggregation was not seen in all subjects in this study. Unfortunately, there was no
data on the subjects that might have helped identify the responders.
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Aims
At the outset of this work, the published outcome of studies investigating the actions
of ET-1 on platelets provided intriguing and inconclusive results. Although the
evidence suggested that ET-1 did not itself elicit platelet aggregation when observed
over a 10 min period, it might potentiate the effect of 'weak' platelet aggregating
agents in vitro. In addition, ET-1 appeared to inhibit ex vivo platelet aggregation in
rabbits by an unidentified mechanism up to 60 min after ET-1 administration.
It was, therefore, the aim of this work: to establish
1. whether ET-1 acts directly on human platelets;
2. to characterise the receptor(s) involved; and
3. to investigate the actions of ET-1 on platelets in diseases where ET-1 is
thought to have a pathophysiological role.
Hypotheses
From the available literature it was hypothesised that ET-1 can both potentiate and
inhibit platelet aggregation by acting on specific platelet surface receptors and that
the pro-aggregatory and inhibitory effects are mediated by different ET receptors. In
Furthermore, it was hypothesised that in essential hypertension the action of ET-1 on
platelets may relate to the pro-aggregatory state of platelets in this condition.
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The studies arising from these hypotheses were:
to investigate: whether or not ET-1 causes aggregation of human platelets in
vitro, by the use of Born light trasmittance aggregometry (Born, 1962) and
whether ET-1 modulates the actions of established platelet aggregating
agents;
to characterise the ET receptor(s) which mediated the putative effects of
ET-1 on human platelets;
to explore the role of second messenger cyclic nucleotides in the modulation
of platelet activity by ET receptor agonists;
to establish the existence of cell surface receptors by ligand binding studies
and analysis of residual platelet mRNA;
to investigate whether human platelets exposed to ET-1 in vivo exhibit
similar responses when analysed ex vivo to responses obtained from in vitro
studies, and to examine the role of cyclooxygenase products on these
responses;
and to investigate the effects of blood pressure and the presence of essential







Subjects participating in aggregation studies were healthy males between the ages of
18 and 50 years. All were required to abstain from caffeine and nicotine for a
minimum of 2 hr prior to venesection, and aspirin or non-steroidal anti-inflammatory
drugs for the ten days prior to venesection. On the day of venesection subjects were
rested supine in a quiet room for 20 to 30 min and blood was taken from a vein in
the cubital fossa via a 19 gauge needle, without tourniquet and with minimum stasis,
into 10 ml plastic tubes containing 1 ml acid citrate dextrose; 9:1, final
concentration: citric acid 8 mg ml"1, sodium citrate 22 mg ml"1, glucose 20 mg mb1.
Blood was promptly centrifuged at room temperature for 10 min at 120 g in a
Gallenkamp Bench-top centrifuge to obtain platelet rich plasma (PRP). PRP was
pooled and 890 p.1 aliquots were pipetted into 2 ml plastic tubes, gassed with 95%
C>2:5% CO2 capped and stored at room temperature until required. The remaining
blood was further centrifuged at 3000 g for 20 min at room temperature to obtain
platelet poor plasma (PPP). PPP was pooled and a single aliquot of 890 pi was
mixed with 110 pi normal saline.
Aggregation studies were carried out 1 hour after venesection to allow responses to
stabilise (Siess et al., 1981). Platelet aggregation was measured by light
transmittance according to the method described by Born (Born, 1962), based on a
decrease in light transmittance through the sample as platelets come out of
suspension to form aggregates (Fig 2.1). Samples are maintained at 37°C, stirred at
1200 rpm and allowed to equilibrate for 3 min prior to the addition of any agents.
Light transmittance through the PRP sample, where all samples remain in
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suspension, was taken as 0% aggregation and through the PPP sample, where there
are no platelets in suspension, as the theoretical maximum aggregation of 100%. The
maximal increase in light transmittance after the addition of the drug is expressed as
a percentage aggregation.
Aggregation studies were performed in a Malin 6 channel aggregometer interfaced to
a Macintosh LC computer by a MacLab analogue digital converter. The computer
application used to record aggregation studies was Chart/8 V3.1.1. and the
spreadsheet application used to calculate percent aggregation was Microsoft Excel
version 3. Using this apparatus the maximum aggregation for each study was
calculated by selecting three areas from the Chart document, where light
transmittance was expressed in mV and transferring them to an Excel spread sheet.
The three areas chosen were: a 10-15 sec period prior to aggregation to establish the
base line 0% aggregation; mean light transmittance through PPP for 10-15 sec, to
record the theoretical maximum; and the maximum light transmittance during the
course of the study.
To establish how long platelets remained viable and produced reproducible
aggregatory responses a validation study was carried out.
Six male subjects participated in this study under the conditions described above.
Aggregatory responses were recorded to vehicle alone and three concentrations of
adrenaline; low (0.01 (ig mT1), medium (0.1 pg mT1), and high (1 |ig ml"1). Platelet
aggregation was measured at 5 time points; 60, 90, 120, 150 and 180 min after
venesection. Aggregatory responses at each time point were recorded in parallel in
separate aliquots of PRP.
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No significant changes in the aggregatory responses were detected by repeated
measure ANOVA up to 150 min after venesection. Aggregation to medium and high




Cyclic AMP and cyclic GMP were extracted from plasma by the following method.
Ethanol was added to plasma, at a ratio of 2:1, the sample was immediately mixed
using a Fisons Whirlimixer for approximately 10 sec, and then incubated at room
temperature for 15 min. Samples were subsequently centrifuged at 1500 g for 15 min
at 4°C, the supernatant decanted into glass tubes, and the protein pellet discarded.
The samples were dried down under air at 55°C and reconstituted in assay buffer,
and frozen at -20°C until assayed.
The efficiency of the cyclic nucleotide extraction protocol was assessed by 'spiking'
plasma with 125I-iodinated cyclic nucleotide. Ten pi of 125I labelled cyclic AMP or
cyclic GMP, with an approximate activity of 10 000 cpm, was added to 1 ml aliquots
of plasma, the plasma was subjected to the extraction protocol described above and
the radioactivity in the sample was measured after reconstitution in assay buffer.
The recovery of 125I-cyclic AMP and 125I-cyclic GMP did not differ significantly.




Cyclic nucleotides were measured by an in-house radioimmunoassay (RIA)
developed according to the method described by Brooker (Brooker et al., 1979).
125I-Iodination of cyclic nucleotides
125I-Iodination procedures were performed in controlled ventilated fume hoods.
Succinyl cyclic AMP tyrosine methyl esters (ScAMP-TME) and succinyl cyclic
GMP tyrosine methyl esters (ScGMP-TME), were prepared in assay buffer at a
concentration of 60 |lM. Na125I, 0.5 mCi was mixed with 10 (il 0.5 M potassium
phosphate buffer pH 7.0, by repeated pipetting; 20 (0.1 of ScAMP-TME or ScGMP-
TME was added and mixed in the same fashion. The reaction was initiated by the
addition of 10 (il chloramine T at a concentration of 1 mg ml"1 in 0.5 M potassium
phosphate buffer, pH 7.0. After 60 sec the reaction was stopped by the addition of 50
|ll sodium metabisulphate, 12 mg ml"1 in 0.5 M potassium phosphate buffer pEl 7.0.
Iodination of ScAMP-TME and ScGMP-TME were performed in parallel.
The cyclic nucleotide derivatives were purified by descending paper
chromatography. The reaction mixture was spotted approximately 4 cm from one
end of a Whatman 31ET paper strip, 2 cm by 40 cm. The end of the strip was
submerged in the mobile phase, consisting of butan-l-ol:glacial acetic acid:distilled
water (12:3:5), and held in position by a glass rod. After chromatography, of
duration of 3-4 hr, the strip was dried, wrapped in cling film and autoradiographed.
The radioactive areas on the strips, identified by superimposing the autoradiograph
over the strip, were cut out and eluted in assay buffer:propan-l-ol (1:1). This
protocol results in three radioactive 'peaks'; with Rf values of approximately 0.4, 0.6
and 0.9-1.0, corresponding to free iodine, i25I-TME cyclic AMP and the solvent
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front respectively for cyclic AMP and Rf values of 0.4, 0.5 and 0.9-1.0
corresponding to free iodine, 125I-TME cGMP and the solvent front for cyclic GMP.
Antibodies
Specific antibodies to cyclic AMP and cyclic GMP were raised in rabbits by Dr B C
Williams and Dr I F Gow using an homologous bridge strategy (Brooker, et al.,
1979). The antibody for cyclic AMP was identified as R1B6 and for cyclic GMP as
ED2-3.
For each new batch of 125I-iodinated cyclic nucleotide prepared, antibody dilution
curves were performed to establish the antibody concentrations required for an
approximate 50% binding of 125I-iodinated ligand in the absence of cold ligand.
Antibody dilution curves
Antibody dilution curves were performed for 125I-iodinated cyclic AMP and cyclic
GMP. The respective antibodies were prepared, by sequential double dilution in
assay buffer, to initial concentrations of 1:1 000 to 1:128 000. 125I-iodinated ligand
(150 pi = 4 - 6 000 cpm) were incubated with 100 [0,1 of antibody of the varying
dilutions and 50 |il of assay buffer, acetylated as described below. Preparation and
incubation of samples were performed in the same manner as for the RIAs described
below. Examples of typical antibody dilution curves are given in Fig 2.3.
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Assay Protocol
Standards for both cyclic AMP and cyclic GMP assays were diluted from stock
solutions of 32 p.M in assay buffer (0.05 M sodium acetate buffer, pH 4.8) at
concentrations of 0, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, and 32.0 nM.
Acetylation
All samples and standards were acetylated in glass tubes prior to assay. Acetylating
reagents, triethylamine and acetic anhydride, were premixed in glass tubes in a ratio
2:1 v/v. The premix of acetylating agents (15 |il) was added to 500 p,l of sample or
standard and immediately mixed for 5 sec.
125I-iodinated ligand (150 jal = 4-6 000 cpm), antibody (100 (il) at the predetermined
dilution and acetylated standard or sample were mixed in 3 ml plastic tubes. Samples
were incubated at 5-8°C for 18 hr. Separation of antibody-bound ligand from free
ligand was performed by centrifugation. Activated charcoal (700 fil) was added to
each tube prior to centrifugation at 1700 g for 30 min at 4°C. The supernatant was
aspirated off and discarded. The radioactivity in the remaining pellet (the 'free'
fraction) was measured. The sample concentrations of cyclic AMP or cyclic GMP
were calculated from the respective standard curves (Fig 2.4). All assays were
performed in duplicate, and additions of RIA agents and charcoal were performed
'on ice'. The cyclic AMP assay has an intra- and inter-assay coefficient of variation
of 5.2% and 8.1% respectively for a sample with assay value of 1.0 nM (n=5). The
cyclic GMP assay has an intra- and inter-assay coefficient of variation of 4.1% and
7.2% respectively for a sample with assay value of 1.0 nM (n=5).
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Platelet cyclic nucleotide measurements
Validation of platelet cyclic nucleotide measurement in response to agonists was
performed with agents known to stimulate cyclic AMP and cyclic GMP, PGEi and
sodium nitropmsside (SNP) respectively.
To distinguish between plasma and platelet concentrations of cyclic nucleotide,
platelets were separated from plasma prior to extraction. After incubation with PGEi
or SNP, PRP was transferred to 1.5 ml conical polypropylene tubes pre-chilled at
4°C and immediately centrifuged at 10 000 g for 2 min at 4°C. The plasma and the
platelet pellet were transferred to separate 4 ml plastic tubes and mixed vigorously
with 2 ml ethanol, and the extraction was carried out as described above. Extracts
from both platelet pellets and plasma were assayed.
Initial time course studies were carried out to establish the required incubation time
with agonists for optimal stimulation of cyclic nucleotide.
Plasma was prepared in the same manner as described for platelet aggregation. After
PRP had been stirred for 3 min at 37 °C, PGE] (1 |iM) or SNP (10 |EM) was added.
The reactions were stopped and extractions performed at 0.5, 1, 3, 5 and 10 min.
Time course studies for each agonists were performed in parallel.
PGEi (1 |lM) produced a significant increase in both platelet and plasma cyclic
AMP with time (p<0.05), peaking at 5 min. However, no significant increase was
seen in either platelet or plasma cyclic GMP levels. Platelet cyclic nucleotide
responses to PGEi are depicted in Fig 2.5. SNP, 10|iM, produced highly variable
cyclic AMP changes with time, which were not statistically significant. SNP did
produce time dependent increases in both plasma and platelet cyclic GMP (p<0.05),
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with a maximum increase in plasma cyclic GMP at 5 min. Platelet cyclic nucleotide
responses to SNP as a function of time are depicted in Fig 2.6.
In the second part of the validation study dose response studies were carried out with
PGEi (0.1-10 |i.M) and SNP (0.1-10 pM).
The protocol for plasma preparation and cyclic nucleotide extraction were carried
out as described above; based on the data from the time course study, incubation of
the agonists in plasma was stopped after 5 min. Dose response studies for each of the
agonists (0.1 -10 |lM) were performed in parallel.
A dose dependent increase in cyclic AMP in response to PGEi was observed in both
plasma and platelet extracts (p<0.05). PGEi also produced a significant increase in
platelet cyclic GMP (p<0.05), but no significant change was seen in plasma cyclic
GMP. Platelet cyclic nucleotide responses to increasing concentrations of PGEi are
depicted in Fig 2.7. SNP did not produce any significant change in platelet cyclic
AMP levels but did appear to produce a slight but significant rise in plasma cyclic
AMP (p=0.05). The rise in plasma cyclic GMP was also slight but statistically
significant whereas, SNP induced a considerable rise in platelet cyclic GMP
(p<0.05). Platelet cyclic nucleotide responses to increasing concentrations of SNP
are depicted in Fig 2.8.
Receptor Binding Studies
Rat cardiac membranes
Cardiac membranes preparation and binding was performed by an adaptation of a
previously described method (Waugh et al., 1992). Ventricles from adult male
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Sprague Dawley rats (250-300 g) were roughly minced manually and washed in 50
ml ice-cold saline (0.9%). The tissue fragments were homogenised in 20 mM
NaHCC>3 buffer, 0.1 mM phenylmethylsulphonylfluoride (PMSF), using two 10 s
bursts of a Ystral Gmb-H homogeniser operating at 8/10 of maximum speed. The
homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was
further centrifuged at 20 000 g for 15 min and the pellet resuspended and
homogenised in 40 ml, 50 mM Tris buffer, 0.1 mM PMSF pH 7.4. Centrifugation
was repeated twice. On the final occasion the pellet was resuspended as above at a
concentration of 2 mg ml"1.
Binding was performed in 12 x 75 mm glass tubes in duplicate for 60 min at 37°C.
All assay constituents were prepared in assay buffer, 50 mM Tris buffer containing
0.1 mM PMSF pH 7.4 The assay consisted; of 'total tubes', incubated in the absence
of cold ET-1, non-specific binding tubes incubated in the presence of 10"6 M ET-1
and tubes containing cold ET-1, final concentration 10"12 - 10-8 M increasing in log
order magnitude Membranes and 125I-ET were diluted in assay buffer to give a final
concentration of 0.25 mg/tube and 0.5 nM respectively. Constituents of the assay are
given in table 2.1.
The reaction was stopped by the addition of 3 ml ice-cold 50 mM Tris buffer pH 7.4.
Bound and free 125I ET-1 were immediately separated by rapid filtration across
Whatman GF/B glass microfibre filters, pre-soaked in 50 mM Tris buffer. The tubes
were rinsed with a further 3 ml of buffer, which was subsequently applied to the
filters. The filters were washed 3 times with 10 ml additions of the above buffer.




Additions Total (pi) NSB (nl) Drug (pi)







Competing Drug _ _ 50
Membrane 100 100 100
Total Volume 500 500 500
Human platelet membranes
Platelet membranes were prepared as previously described (Cheung et al., 1982).
Blood was collected into 3.5% sodium citrate (w/v). PRP was prepared by
centrifugation at 200 g for 10 min at room temperature. PRP was centrifuged at
20 000 g for 15 min at 4°C. The resulting pellet was resuspended in 5 mM Tris
buffer, 5 mM EDTA, pH 7.4. The pellet was washed in the above buffer by
resuspension, homogenisation, using two 10 s bursts of a homogeniser, and
centrifugation. The pellet was resuspended in 50 mM Tris buffer, 0.5 mM EDTA,
pH 7.4, incubated for 15 min at 37°C, then washed in the same manner as described
above. The final pellet was resuspended in 50 mM Tris buffer, 0.5 mM EDTA and
stored at - 80°C until used in the binding assay.
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Platelet yohimbine binding assay
Yohimbine binding studies were carried out as described previously (MacKinnon et
al., 1992). All agents were prepared in the assay buffer, 50 mM Tris buffer, 0.5 mM
EDTA, pH 7.4. The assay, performed in duplicate, consisted of; 'total binding' tubes,
non specific binding tubes, achieved by incubation in the presence of 10 (iM
phentolamine, and tubes containing cold yohimbine (10-11 - 10"5 M final
concentration), increasing in half log order concentrations. Membranes and 3H-
yohimbine were diluted to give final assay concentrations of 0.2 mg/tube of protein
and 2 nM, respectively. Incubation was for 15 min at 37°C. Volumes of the
constituents of the assay are given in table 2.2.
The reaction was stopped by the addition of 3 ml ice-cold 50 mM Tris buffer, 0.5
mM EDTA pH 7.4. Bound and free 3H yohimbine were immediately separated by
rapid filtration across Whatman GF/B glass microfibre filters, pre-soaked in 50 mM
Tris buffer. The reaction tubes were rinsed with a further 3 ml of buffer, which was
subsequently applied to the filters. The filters were washed 3 times with 10 ml
additions of the above buffer. Filters were subsequently placed in scintillation mini-
vials, to which 4 ml of scintillation cocktail was added. Tritium was counted in the
Packard Tri-carb 4000 scintillation counter, with a counting time of 5 min per
sample.
Platelet endothelin binding assay
Binding was performed in 12 x 75 mm glass tubes in duplicate for 60 min at 37°C.
All assay constituents were prepared in assay buffer, 50 mM Tris buffer, 0.5 mM
EDTA, 0.1 mM PMSF pH 7.4. The assay consisted; of 'total tubes', 'non specific
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binding tubes' achieved by incubation in the presence of 10"6 M ET-1 and tubes
containing cold ET-1 (final concentration 10"12 - 10"8 M) increasing in log order
magnitude. Membranes and 125I-ET-1 were diluted to give final assay
concentrations of 0.2 mg/tube of protein and 0.5 nM, respectively. Constituents of
the assay are given in table 2.2.
The reaction was stopped by the addition of 3 ml ice-cold 50 mM, Tris 0.5 mM
EDTA buffer pH 7.4, bound and free 125I-ET-1 were immediately separated by rapid
filtration across Whatman GF/B glass microfibre filters, pre-soaked in 50 mM Tris
buffer. The tubes were rinsed with a further 3 ml of buffer, which was subsequently
applied to the filters. The filters were washed 3 times with 10 ml additions of the
above buffer. Radioactivity of the filters was assessed by counting for 3 min in a
multiwell gamma counter.
Table 2.2
Additions Total (pi) NSB (|al) Drug (|ll)
fcr_









Competing Drug _ _ 100
Membrane 300 300 300
Total Volume 500 500 500
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Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Platelets were prepared by two separate methods. The first protocol was an
adaptation of the method described by Shibata (Shibata et al., 1994). Fifty five ml of
venous blood was mixed with 5 ml of 3.2% sodium citrate. PRP was prepared by
centrifugation at 100 g for 10 min at 22°C. PRP was diluted 20 fold in Medium 199
buffer containing 5 mM EDTA and 0.2% bovine serum albumin, and centrifuged at
1000 g for 10 min at 4°C. The pellet was resuspended in Medium 199 and both
supernatant and resuspended pellet were centrifuged at 1000 g for 20 min at 4°C
both subsequent pellets were snap frozen in liquid nitrogen, and identified as platelet
rich pellet and platelet poor pellet.
Analysis of platelet pellets prepared in this manner was performed by the
Department of Clinical Haematology at the Western General Hospital, Edinburgh.
The platelet rich pellet resulted in approximately 10 fold greater harvest of platelets
compared to the platelet poor pellet, and although both preparations had a mean
contamination of less than 1:1000 white blood cells, white blood cells were only
detected in 2 of 6 platelet poor pellet preparations.
The second protocol for the preparation of platelets involved purification of platelets
on discontinuous gradients of percoll as described by Nubile (Nubile et al., 1989).
Percoll was prepared in saline at 4 densities (1.040, 1.060, 1.070 and 1.080). PRP
was prepared as described above. PRP was mixed with apyrase (7.5 U/ml) and
centrifuged for a further 20 min at 500 g. The resulting pellet was reconstituted in 3
ml of saline and layered gently onto the percoll. The percoll was centrifuged for 30
min at 400 g at 4°C. The relative density of the bands of percoll was verified by
simultaneous centrifugation of percoll containing density marker beads. The band of
percoll containing the platelets, 1.060 density, was removed and centrifuged at 1000
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g for 20 min the subsequent pellet was snap frozen in liquid nitrogen and stored at
-80°C.
The purity of the platelet pellet was verified by the Department of Clinical
Haematology at the Western General Hospital, Edinburgh. No whole cells other than
platelets were detected in three samples prepared from separate 20 ml aliquots of
PRP.
RNA extraction
RNA extraction was performed by an adaptation of the method previously described
by Chomczynski (Chomczynski & Sacchi, 1987). After defrosting, pellets were
mixed with 1 ml of solution D (given in appendix 2.2). The pellet was 'homogenised'
by being repeatedly drawn through a 24 gauge needle. The homogenate was then
transferred to a 14 ml polypropylene tube. Sodium acetate, 2M, pH 4, was added and
mixed by gentle inversion. One ml of water saturated phenol was added and mixed
in the same manner, 0.2 ml of chloroforrmisoamyl alcohol mixture (49:1) was then
added and vigorously mixed for 10 sec. The final suspension was cooled on ice for
15 min. Samples were centrifuged for 20 min at 10 000 g at 4 °C. The aqueous phase
was transferred to a fresh tube and mixed with 4 pi of glycogen (20 p.g/p.1) and 1 ml
of isopropanol, and incubated at -20°C for 60 min. After a further centrifugation at
10 000 g for 20 min at 4°C the supernatant was carefully removed, the pellet was
resuspended in 0.3 ml of solution D and transferred to a 1.5 ml eppendorf tube. The
centrifuged tube was rinsed with 0.1 ml of solution D, which was added to the
eppendorf. Precipitation of RNA was achieved by the addition of 0.4 ml of
isopropanol and incubation for 60 min at -20°C. The eppendorf was centrifuged at
4°C for 20 min and the supernatant carefully removed. The pellet was gently lifted
from the bottom of the eppendorf by the addition of 500 pi of 70% ethanol, and the
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ethanol was subsequently decanted. The pellet was dissolved in 1 mM EDTA pH 8
solution treated with diethyl pyrocarbonate (DEPC), and stored at -20°C.
cDNA synthesis
Before reverse transcription, total RNA was measured by optical density. The total
recovered RNA, in a volume of 13 pi, was mixed with 1.5 nmol of random
nucleotide hexamers, in 1.5 pi and heated to 70 °C for 5 min, then placed on ice. The
RNA was added to a mixture of; 17.5 U RNase inhibitor, 35 U jxl-1, 5 pi of RT
buffer (constituents given in appendix 2), 2.5 pi of dithiothreitol (DTT), final
concentration 10 mM, 1.2 pi of dinucleotide triphosphates (dNTP) mixture 0.6 mM
of each nucleotide and lpl of Moloney Murine Leukaemia Virus reverse
transcriptase (MMLV), 200 U ml"1. The total mixture was incubated at 37°C for 60
min followed by inactivation of the reverse transcriptase by incubation at 95°C for 5
min, centrifuged briefly and placed on ice. An aliquot of 4 pi of DNA was removed
for PCR and the remainder frozen at -20°C.
PCR
The cDNA synthesised by reverse transcription was used for a template for PCR
amplification with selective oligo nucleotide primers for ETa and ETb receptors
(Elshourbargy et al., 1993). The reaction mixture was prepared and 40 pi of paraffin
was gently layered on top. The mixture was heated for a 'hot start' before the primers
were added through the paraffin. Details for the conditions for PCR are given in
table 3.1. The reaction was terminated by 10 min incubation at 72°C and stored at
4°C.
PCR products were purified and identified by gel electrophoresis, in a 1.2% agarose





Forward 5^ (AATCTG)CAGGGC 5V (AACGAATTCA)GC
ATCCTTTTGGCTGGC AAACCGCAGAGATA
Reverse AC ATGAC
5" (ACAGGGATCC)GG 5' (TAAGGATC)CACG
CAAGACTGGCTATCA AACACAAGGCAGGA
GCG CAC
Constituents of mix. 31.7 pi DEP H20, 33.5 pi DEP H20,
0.8 pi dNTP, 12.5 mM, 0.8 pi dNTP, 12.5 mM,
4 pi MgCl2, 25 mM, 4 pi MgCl2, 25 mM,
5 pi Taq buffer, 5 pi Taq buffer,
0.8 pi Taq, 5 UpH, 0.8 pi Taq, 5 Upl"1,
4 pi cDNA 4 pi cDNA
Primers 250 nM in 1.9 pi 250 nM in 3.7 pi
0.9 pi of forward primer 2.0 pi of forward primer
1.0 pi of reverse primer 1.7 pi of reverse primer
Conditions for
Hot Start 92 °C for 5 min 94 °C for 5 min
66 °C for 3 min 64 °C for 3 min
29 cycles of 29 cycles of
Extension 74 °C for 1 min 72 °C for 1 min
Denaturing 92 °C for 1 min 92 °C for 1 min
Annealing 66 °C for 1 min 64 °C for 1 min
Forearm Blood Flow
Forearm blood flow was measured according to the method previously by Haynes
(Haynes et al., 1991). The left brachial artery was cannulated under local anaesthesia
with a 27 gauge steel needle. Saline (0.9%) and ET-1 (infusate concentration 5 nM)
were infused at a rate of 1 ml min1 via a Welmed P 1000 syringe pump. Forearm
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blood flow was measured in the infused and non-infused arm by venous occlusion
plethysmography. The hands were excluded from circulation during each
measurement period by inflation of a wrist cuff to 220 mm Hg. The last 5 individual
flows in each 3 min measurement period were averaged and used for analysis. The
percentage change in blood flow was calculated in accordance with the method
described by Webb (Webb, 1995), as percent change in the ratio of blood flow
(infused arm / control arm) compared with the ratio at the last baseline recording.
Endothelin Radioimmunoassay.
Plasma ET was measured using a commercially available radioimmunoassay kit.
Venous blood was collected into 10 mM EDTA and centrifuged at 2000 g for 15
min. The plasma was transferred to a separate tube with care, to avoid platelet and
white cell contamination, and stored at -20°C.
ET was extracted from 2 ml of plasma, acidified with 3 ml 4% acetic acid in distilled
water, onto a C18 Sep-Pak column, pre-conditioned by sequential additions of 5 ml
ethanol, 5 ml distilled water and 5 ml 4% acetic acid in distilled water. Sep Paks
were washed by separate additions of 3 ml distilled water and 3 ml 25% ethanol, and
allowed to elute under gravity. ET was eluted, under gravity, from the column by
two rinses with 1 ml each of 4% acetic acid in 86% ethanol. The pooled eluant was
dried down at 37°C under nitrogen, reconstituted in ET assay buffer and stored at -
20°C.
The assay kit was a standard radioimmunoassay based on competition between cold
ET-1 and 125I -ET-1 for binding to an anti-ET rabbit antibody. Precipitation of
bound fraction was by incubation with an anti-rabbit IgG antibody. Provided
standards were in the range 8 -192 pg ml-1. The Coefficient of Variation for intra-
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and inter-assay variation were 4.5%, for a mean value of 14.7 pg ml"1- and 6.8%, for
a mean value 10.9 pg ml"1, respectively. The assay has a 52% cross reactivity for
ET-2, a 96% cross reactivity for ET-3 and a 7% cross reactivity for Big-ET. Cross


























Light Transmittance Through Plasma sample
Figure 2.1. A sample aggregation trace with a representation of light transmittance


























Time after venesection, min
Figure 2.2 Reproducibility of aggregatory response with time. Low • , medium ♦
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Antibody dilution
Figure 2.3 Antibody dilution curve for ED2 -3, cyclic GMP antibody, performed in

































































Figure 2.5. Cyclic nucleotide response to PGEi over time. The change in platelet
cyclic AMP (o) and cyclic GMP (•) with time after stimulation with PGEi,








Figure 2.6. Cyclic nucleotide response to SNP over time. The change in platelet
cyclic AMP (o) and cyclic GMP (•) with time after stimulation with SNP, expressed





























Figure 2.7. Cyclic nucleotide dose response to PGEi. PGEi stimulated responses in
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Concentration, pM
Figure 2.8. Cyclic nucleotide dose response to SNP. SNP stimulated responses in
platelet cyclic AMP (o ) and cyclic GMP (•) .
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APPENDIX 2.1
Materials and equipment used.
Aggregation
Anticoagulant
Citric acid Sigma Poole, UK.
Glucose Sigma Poole, UK
Sodium Citrate Sigma Poole, UK
Platelet aggregating agents
Adenosine diphosphate Sigma Poole, UK
Adrenaline hydrochloride Antigen Roscrea,
Pharmaceuticals Ireland
Endothelin agonists/antagonists
Endothelin-1 Novabiochem Nottingham, UK
Sarafotoxin S6c Alexis Corporation Nottingham, UK
BQ-123 SNPE Neosystem Croydon, UK
BQ-788 SNPE Neosystem Croydon, UK
Others
N monomethyl-L-arginine Sigma Poole, UK
Lemakalim (BRL 38227) SmithKline Beecham Welwyn, UK
Vehicle









6 channel Clinical Aggregometer
Micro magnetic bars
Computer Hardware






LP 2 2ml tubes
Malin Electronics
Mackay & Lynn
MacLab Analog Digital Instruments
Macintosh





Prostaglandin Ej Sigma Poole, UK
Sodium Nitroprusside Sigma Poole, UK
Assay Buffer
Acetic acid BDH Poole, UK
Sodium acetate Sigma Poole, UK
Gelatin Sigma Poole, UK
Tracer Preparation
125Iodine Amersham Amersham,
Tyrosine methyl esters Sigma Poole, UK
Chloramine T Sigma Poole, UK
Potassium dihydrogen orthophosphate Sigma Poole, UK
Disodium hydrogen orthophosphate Sigma Poole, UK
Sodium Metabisulphate Sigma Poole, UK
Butan-l-ol BDH Poole, UK
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Plastic LP3 tubes Sterilin
Borosilicate Glass, 12 by 75 mm Sterilin




















125I-ET-1 (2200 Ci / mmol)
3H-Yohimbine(80 Ci / mmol)
Equipment
Homogeniser
J2 MC High Speed Centrifuge
Filtering equipment
12 Well Filtering Manifolds
Filters









































Mercapto ethanol Merck Castelnau France
Sodium Acetate Merck Castelnau France
Chloroform Merck Castelnau France
Isoamyl alcohol Merck Castelnau France
Glycogen Fluka Marseille, France
Isopropanol Prolabo Marseille, France
Hexamer nucleotides Promega Madison, USA
HPRI RNase inhibitor Amersham Amersham, UK
Reverse Transcriptase buffer Promega Madison, USA
Dithiothreitol Merck Castelnau France
MMLV Reverse transcriptase Life Technologies Gaithersburg,
USA
Taq DNA Polymerase Promega Madison, USA
Agarose Merck Castelnau France
Boric Acid Merck Castelnau France
Equipment
L8-S5 ultra Centrifuge Beckman














Classic II computer Macintosh
Endothelin Radioimmunoassay
Radio immunoassay kit Nichols Institute Saffron
(including Ci8 Sep-Paks) Walden, UK
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APPENDIX 2.2
Recipes for buffers used.
Cyclic nucleotide assay buffer
0.05M acetate buffer pH 4.8
at 25 °C
80 ml, 0.1 M acetic acid
120 ml, 0.1 M sodium acetate
200 ml distilled water
0.1% w/v Gelatin
Phosphate buffer 6.8 g potassium dihydrogen
0.5M pH 7.4 at 25 °C orthophosphate
2.84 g disodium hydrogen
orthophosphate
dissolved in 100 ml distilled water
Tris Buffer
0.5M pH 7.4 at 25 °C
6.61 g Trizma HC1
0.97 g Trizma Base
1 L distilled water
Activated Charcoal 1 L 0.1M phosphate buffer
(as described above)
60 g charcoal
6 g dextran T70
Solution D 4 M guanidinium thiocyanate
for RNA extraction 25 mM sodium citrate
pH 7.0 at 25 °C 0.5% v/v sodium N-Lauroylsacrosine
solution (30% in H2O)
0.7% v/v mercapto ethanol
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TBE Buffer 108.9 g Tris
55.7 g boric Acid
4.7 g EDTA
1 L distilled water
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CHAPTER 3




At the time of this work being carried out, studies on the actions of ET-1 on platelets
had consistently reported that ET-1 alone does not induce platelet aggregation.
However, it was reported that ET-1 potentiated aggregation of human platelets
induced by low concentrations of adrenaline in vitro (Matsumoto, et al., 1990). An
inhibition of platelet aggregation was also reported in a study of ex vivo platelet
aggregation after in vivo administration of ET-1 in rabbits (Thiemermann, et al.,
1989). Platelet responses following in vivo administration of ET-1 involve a number
of other factors as well as a direct action of ET-1 itself, the possible role of
endothelium derived mediators is discussed later in this thesis. The phases of
primary and secondary aggregation observed in vitro in response to weak agonists
represent two distinct mechanisms. Primary aggregation is thought to represent the
direct receptor mediated response to the agonist and the subsequent intracellular
signalling. Secondary aggregation represents a response dependent on the positive
'feed forward' actions of intracellular signalling and the release of other pro-
aggregatory agents such as serotonin and ADP. Hence, the apparently contradictory
potentiating and inhibitory actions of ET-1 may be due to the peptide interacting in
different manners with the two separate processes involved in platelet aggregation.
The mechanism of ET-1 mediated actions are not well understood. Initially it was
proposed that ET-1 might be an endogenous agonist of the dihyropyridine-sensitive
voltage operated calcium channels (Goto et al., 1989), subsequent evidence
suggested that this was not the case (Gu, et al., 1989). However, there is
considerable evidence for an interaction with ATP-sensitive K+ channels. K+
channel openers inhibited ET-1 induced contractions in rat arterial vessels
(O'Donnell et al., 1990) and in the human hand vein (Haynes & Webb, 1993c).
Furthermore, the ATP-sensitive K+ channel opener BRL 38227 inhibited the binding
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of 125I-ET-1 to rat cardiac membranes, indicating a possible relationship between
ET-1 receptor binding and K+ channels (Waugh, et al., 1992).
The endothelial ETg receptor mediates NO generation by vascular endothelial cells
(Emori et al., 1991). NO is known to bring about relaxation of vascular smooth
muscle cells and the inhibition of platelet aggregation (Moncada & Higgs, 1993). In
1990, Radomski et al characterised an L-arginine/NO pathway in human platelets
and suggested it may have a role as a negative feedback mechanism for inhibiting
platelet aggregation (Radomski, et al., 1990). NO production is competitively
inhibited by L-NMMA and it can, therefore, be used to investigate the effects of NO
synthesis. In the absence of an accessible, sensitive method of directly measuring
NO, L-NMMA has been employed to identify NO synthase activity.
The aim of the work presented in this chapter was (a) to investigate the direct actions
of ET-1 on human platelet aggregation and (b) the ability of ET-1 to modulate
primary and secondary aggregation induced by the two physiological platelet
activators, adrenaline and ADP. BRL 38227 and L-NMMA were employed in an
attempt to identify mechanisms of action of ET-1.
METHODS
The work described took the form of three separate studies. Study A was designed to
investigate the actions of ET-1 alone and in combination with doses of ADP and
adrenaline that elicited primary and secondary aggregation. Study B examined the
effect of BRL 38227 on ET-1 modulation of adrenaline induced aggregation, and in
study C, L-NMMA was used to investigate whether ET-1-induced platelet NO
production masked either a direct aggregating effect of ET-1 or attenuated ET-1
mediated potentiation of adrenaline induced aggregation.
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Subjects
Healthy male subjects between 21 and 41 years of age participated in these studies.
All subjects complied to conditions stated in chapter 2, that is that no subject
received vasoactive or non-steroidal anti inflammatory drugs in the ten days before
each study or alcohol or caffeine on the day of the studies and all subjects rested
supine for 30 min in a quiet environment prior to venesection. These conditions were
maintained for all aggregation studies reported in this thesis unless otherwise stated.
For all these studies blood was collected into acid citrate dextrose via a 19 g needle
and plasma was prepared as described in chapter 2. Platelet rich plasma was divided
into 890 p,l aliquots and incubated at 37°C for 3 min prior to any additions. Platelet
aggregation was measured by Born aggregometry also as described in chapter 2, and
all studies were carried out within 150 min of venesection. Results are expressed as




Aggregatory responses to ADP and adrenaline were assessed for each subject to
establish appropriate doses of the aggregating agent to induce primary and secondary
aggregation. Subsequently, the effect of pre-incubation with ET-1, 1 |i.M, was
measured alone, and in combination with doses of adrenaline and ADP which
induced primary and secondary aggregation (table 3.1).
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Fourteen volunteers gave blood on two separate occasions. On one occasion the
effects of ET-1 on adrenaline-induced aggregation were tested and on the other the
effects on ADP-induced aggregation were tested. In table 3.1 the sequence of
additions to each tube are given for the three parts of the study carried out on every
subject, adrenaline is given as the aggregating agent but the same protocol was used
for ADP. Although the sequence of additions to each tube were always the same, the
order of the tubes, 1, 2, 3 or 4 first for example was randomised.
Study B
Before investigating the effect of BRL 38227 on ET-1 modulated platelet
aggregation, the effect of BRL 38227, lp.M, was examined alone and in combination
with doses of adrenaline inducing primary and secondary aggregation. The effect of
pre-incubation with BRL 38227 was then investigated in combination with
adrenaline and ET-1 (table 3.2a and 3.2b). Two groups of ten healthy male
volunteers were studied.
94
Tube 1 Tube 2 Tube 3 Tube 4
Run 1 Vehicle Vehicle Vehicle Vehicle
Vehicle Vehicle Vehicle Vehicle
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Tube 1 Tube 2 Tube 3 Tube 4
Run 1 Vehicle Vehicle Vehicle Vehicle
Vehicle Vehicle Vehicle Vehicle




Vehicle Vehicle BRL 38227 BRL 38227
Vehicle Vehicle Vehicle Vehicle




Vehicle Vehicle BRL 38227 BRL 38227
Vehicle Vehicle Vehicle Vehicle
Vehicle Adrenaline Adrenaline Vehicle
Table 3.2a
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Tube 1 Tube 2 Tube 3 Tube 4
Run 1 Vehicle Vehicle Vehicle Vehicle
Vehicle Vehicle Vehicle Vehicle




Vehicle Vehicle Vehicle BRL 38227
Vehicle Vehicle ET-1 ET-1




Vehicle Vehicle Vehicle BRL 38227
Vehicle Vehicle ET-1 ET-1
Vehicle Adrenaline Adrenaline Vehicle
Table 3.2b
Study C
To ascertain whether platelet derived NO masked a direct aggregating effect of ET-1
on human platelets, the effect of pre-incubation of 10 & 100 (iM L-NMMA, prior to
ET-1 (1 pM) exposure was examined (table 3.3a). To determine whether ET-1
induced NO attenuated the potentiation of adrenaline induced primary aggregation,
L-NMMA (100|iM) and ET-1 (lpM) were added to the PRP prior to adrenaline.
(Table 3.3b).
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Vehicle ET-1 ET-1 Vehicle
Table 3.3a
Tube 1 Tube 2 Tube 3 Tube 4 Tube 5 Tube 6
Run 1 Vehicle Vehicle Vehicle Vehicle Vehicle Vehicle
Vehicle Vehicle Vehicle Vehicle Vehicle Vehicle
Adrenaline Adrenaline Adrenaline Adrenaline Adrenaline Adrenaline
Run 2 Vehicle Vehicle Vehicle L-NMMA L-NMMA L-NMMA
Vehicle Vehicle ET-1 ET-1 Vehicle ET-1
Vehicle Adrenaline Adrenaline Adrenaline Adrenaline Vehicle
Run 3 Vehicle Vehicle Vehicle L-NMMA L-NMMA L-NMMA
Vehicle Vehicle ET-1 ET-1 Vehicle ET-1





ET-1 alone caused a slight but significant aggregatory response (3.8 ± 0.4%) when
compared to vehicle (2.7 ± 0.2) (p=0.04, n = 14). No shape change was observed.
Both adrenaline and ADP induced dose dependent platelet aggregation (Figs 3.1 &
3.2). Pre-incubation with ET-1 for 1 min significantly potentiated adrenaline-
induced primary aggregation, (15.7 ±3.1% adrenaline alone vs 25.5 ± 6.6%
adrenaline + ET-1; p = 0.04, n=14), and significantly inhibited secondary
aggregation, (70.3 ± 4.2% adrenaline alone vs 61.5 ± 7.3% adrenaline + ET-1; p =
0.04, n=14)(Fig 3.3). The effect of ET-1 did not appear uniform for all subjects, as
indicated by the dispersion of the data seen with ET-1. ADP induced primary and
secondary aggregations were not significantly affected by pre-incubation with ET-1
(Fig 3.3).
Study B
BRL 38227 alone did not induce platelet aggregation and adrenaline induced
primary and secondary aggregation were not significantly affected by pre-incubation
with BRL 38227.
The pre-incubation with ET-1 again significantly potentiated adrenaline induced
primary aggregation, (9.7 ±1.1% adrenaline alone vs 25.5 ± 6.6% adrenaline + ET-
1; p = 0.04, n=10), but pre-incubation with BRL 38227 did not significantly alter this
effect (fig 3.4).
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ET-1 tended to inhibit secondary aggregation however this did not reach statistical
significance (adrenaline alone 68.4 ± 7.0%, ET-1 + adrenaline 55.6 ± 13.8%; p=
0.18, n= 10). BRL 38227 had no significant effect on secondary aggregation in the
presence of ET-1 (fig 3.4).
Study C
There was no significant difference in the response to ET-1 whether or not L-
NMMA (1 nM & lpM) was present.
Primary aggregation to adrenaline was studied at two concentrations for each
subject; a lower concentration chosen to achieve very low level aggregation,
threshold concentration, and a higher concentration, to attain moderate primary but
not secondary aggregation. At the threshold concentration, ET-1 potentiated the
adrenaline response, and L-NMMA produced a still greater response, (aggregation to
adrenaline alone 5.5 ± 0.7%, adrenaline + ET-1 18.2 ± 5.6%, p = 0.04, n= 12,
adrenaline + ET-1 + L-NMMA 39.0 ± 9.6%, vs adrenaline alone p = 0.01, vs
adrenaline + ET-1 p = 0.05) (fig 3.5). Pre-incubation with L-NMMA alone
significantly potentiated aggregation induced by threshold concentrations of
adrenaline (5.5 ± 0.7% vs 32.2 ± 8.4%, p= 0.01 n=12). However there was no
difference between the aggregation to adrenaline with L-NMMA whether ET-1 was
present or not (fig 3.5).
At the higher concentration of adrenaline, ET-1 again potentiated the adrenaline-
induced aggregation, (adrenaline 10.6 ± 1.9%, adrenaline + ET-1 20.4 ± 6.7%; p =
0.05 n = 12). However, L-NMMA had no significant effect in the presence or
absence of ET-1 (fig 3.5).
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DISCUSSION
The results of these studies demonstrate that ET-1 slightly, but significantly
increases light transmittance through PRP, indicating a very weak aggregatory
effect. However, this direct effect was small and is probably not of physiological
significance. ET-1 potentiated adrenaline-induced primary aggregation, and tended
to inhibit adrenaline-induced secondary aggregation. However, ADP-induced
aggregation was unaffected by ET-1. ET-1 potentiation of adrenaline-induced
aggregation was unaffected by the ATP-sensitive K+ channel opener BRL 38227,
indicating that ATP-sensitive K+ channels are not involved in ET-1 mediated effects
on adrenaline-induced aggregation of human platelets. Pre-incubation with the NO
synthase inhibitor L-NMMA does not reveal a greater effect of ET-1 alone. The
potentiation of low level platelet aggregation to adrenaline by ET-1 was further
increased by LNMMA. However, this is not significantly greater than the effect of
LNMMA on adrenaline-induced aggregation in the absence of ET-1. Therefore, ET-
1 does not appear to stimulate NO synthase to a degree that inhibits platelet
aggregation.
ET-1, at threshold concentrations, is know to potentiate the vasoconstrictor actions
of other agonists, notably noradrenaline and serotonin (Yang, et al., 1990). The
potentiation of primary aggregation by ET-1 in platelets appears to be dependent on
the aggregating agent employed. The lack of potentiation of ADP-induced primary
aggregation suggests that ET-1 either directly interacts with the adrenergic a2
receptors, the receptor mediating the aggregatory actions of adrenaline, or acts upon
an intracellular pathway associated with adrenaline but not ADP platelet activation.
Protein kinase C is linked to a2 receptor activation on human platelets, but may only
play a part in ADP-induced secondary aggregation (Nieuwland, et al., 1993). Since
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ET-1 is known to stimulate protein kinase C in other cells (Lee, et al., 1989) this
enzyme may be a possible target for ET-1 in platelets. The inhibition of secondary
aggregation by ET-1 did not achieve the same statistical significance in study B as it
did in study A, though the trend was the same, and it is possible that this effect may
be more clearly defined if a 'strong' platelet aggregating agent, capable of directly
eliciting secondary aggregation such as thrombin, were to be used.
The fact that BRL 38227 did not affect ET-1 potentiation of aggregation suggests
that the mechanism of action of ET-1 in platelets differs from that seen in other cells
types such as rat cardiac cells. The ATP sensitive K+ channel opener pinacidil has
been shown to inhibit in vitro platelet aggregation to ADP by the attenuation of
thromboxane generation, suggesting a role for K+ channels in the modulation of
platelet aggregation (Goodman et al., 1985) In the work presented here, BRL 38227
(1 pM) did not modulate platelet primary or secondary aggregation to adrenaline in
the presence or absence of ET-1. This is consistent with a study published in 1994,
which showed no effect on adrenaline-induced aggregation of pinacidil at 100 pM
(Patelunas Hoffman et al., 1994). However, in the study reported by Goodman
pinacidil was used at 10~4 to 10"2 M, which is by their own admission several orders
of magnitude higher than the serum concentration required for antihypertensive
effects and it is likely that Goodman observed an effect not directly related to
platelet potassium channels.
In study C, L-NMMA did not significantly alter the effect of ET-1 alone or in the
presence of adrenaline suggesting that NO inhibition in platelets does not unmask a
direct aggregatory response to ET-1. An interesting result of study C was the
potentiation by L-NMMA of primary aggregation induced by threshold
concentrations of adrenaline but not higher concentrations. This might suggest that
platelet derived NO is more important in the modulation of low level platelet
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aggregation, and when a stronger intracellular signal is elicited NO is of less
importance. There is some controversy over the importance of platelet derived NO in
attenuating platelet aggregation. NO production has been measured directly, by the
use of a microsensor from platelets stimulated with collagen (Malinski et al., 1993).
However, it has been suggested that platelets do not produce sufficient NO to
attenuate the aggregatory response to all agonists (Mollace et al., 1991). In the
original description of the L-arginine:NO pathway in platelets L-arginine only
inhibited thrombin induced platelet aggregation in the presence of phosphodiesterase
inhibitors (Radomski, et al., 1990). The inhibitory actions of cyclic GMP, the second
messenger of NO are thought to be mediated by a decrease in [Ca2+]j. Increased
[Ca2+]j is not thought to play a major role in adrenaline-induced platelet activation,
although a slight rise is detectable using the luminescent calcium sensitive dye
aequorin (Powling & Hardisty, 1987). It may be that at low concentrations of
adrenaline the slight rise in [Ca2+]j is functionally important but that at higher
concentrations of agonist an alternative intracellular mechanism supercedes the
slight calcium effect.
In conclusion this chapter provides evidence for ET-1 potentiation of adrenaline
induced primary aggregation that is independent of ATP-sensitive K+ channels and
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Figure 3.1 Dose dependent platelet aggregation induced by adrenaline, mean ±
s.e.mean, n=14.




Primary aggregation Secondary Aggregation
Figure 3.3. The effect of ET-1 on adrenaline and ADP induced primary and
secondary aggregation, mean ± s.e.mean. Adrenaline-induced primary aggregation
■ was significantly potentiated by pre-incubation with ET-1 E2 , p = 0.04, and
adrenaline-induced secondary aggregation ■ was significantly inhibited by ET-1 0
p= 0.04. ADP induced primary and secondary aggregation □ was not significantly
affected by incubation with ET-1 0 . Statistical analysis was by paired Student's t
test, n=14 for all comparisons.
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Figure 3.4. Aggregation to adrenaline □ , adrenaline + ET-1 E3 and adrenaline + ET-
1 + BRL 38227 0 , mean ± s.e.mean, * p < 0.05 compared to adrenaline alone.
Adrenaline-induced primary aggregation was significantly potentiated by ET-1, p=
0.04, this effect was unaltered by BRL 38227. Secondary aggregation to adrenaline
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Figure 3.5. The effect of ET-1 and L-NMMA on threshold, and high primary
aggregation to adrenaline; adrenaline alone E3, adrenaline + ET-1 E3, adrenaline +
ET-1 + L-NMMA E3 and adrenaline + L-NMMA E2,.* p < 0.05, ** p < 0.01 vs
adrenaline alone, + p < 0.05 vs adrenaline + ET-1, mean ± s.e.mean. ET-1
potentiated both levels of platelet aggregation, L-NMMA further potentiated the
effect of ET-1 on the threshold concentration of adrenaline, but this was not
significantly different from the effect of L-NMMA alone on adrenaline.
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CHAPTER 4
CHARACTERISATION OF THE RECEPTOR ON PLATELETS




ET-1 acts on cell surface G protein linked receptors. To date, two receptors have
been cloned from mammalian tissue, the ETa and ETb receptors (Arai, et al., 1990;
Sakurai, et al., 1990). In the human vasculature the ETa receptor is found primarily
on smooth muscle cells. It preferentially binds ET-1 with relative affinity for the ETs
of ET-l>ET-2»ET-3. The ETb receptor was initially thought to be primarily
located on the endothelial cells, where it mediates relaxation through the release of
prostacyclin and NO. The ETb receptor is isopeptide non-selective having
approximately equal affinity for all three ETs (Haynes & Webb, 1993a). Subsequent
work has identified ETb receptors on vascular smooth muscle cells mediating
contraction (Clozel, et al., 1992; Douglas, et al., 1995).
The snake venom peptide, sarafotoxin 6c (SRTX S6c), a peptide of similar structure
to the ETs, has been demonstrated to be a selective ETb receptor agonist (Williams,
et al., 1991) inducing vasodilatation (Kloog & Sokolovsky, 1989) and constriction
(Haynes et al., 1995). It is, at least, a thousand fold less potent than ET-1 in
activating ETa receptors to produce a functional response in the rat vasculature
(Williams, et al., 1991).
A number of selective antagonists have been developed for both ETa and ETb
receptors including antagonists that distinguish putative functionally different ETb
receptors (Warner et al., 1993). The pentapeptide BQ-123 is a selective antagonist at
the ETa receptor, inhibiting both ET-1 binding and ET-1 induced contraction (Ihara,
et al., 1992). IC50 values for BQ-123 have been calculated as 7.3 nM at the ETa
receptor and 18 jlM at the ETb receptor, in rat vascular smooth muscle and
cerebellum respectively (Ihara, et al., 1992). The antagonist BQ-788 is selective for
ETb receptor, acting as an antagonist at both of the proposed sub -types of the ETb
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receptor (Karaki, et al., 1994). IC50 values for BQ-788 have been calculated as 1.3
|iM at the ETa receptor and 0.9 nM at the ETb receptor in a human neuroblastoma
cell line and porcine cerebellum respectively (Ishikawa, et al., 1994).
The work described here was designed to investigate the ET receptor that mediates
the potentiation of adrenaline-induced aggregation described in the previous chapter.
It may be useful to briefly consider what is currently known about ET receptors on
platelets in general. A number of groups have investigated the ET receptor mediated
inhibition of platelet aggregation. A recent report looking at a number of different
platelet aggregating agents, showed that ET-1 inhibited platelet aggregation to
thrombin, ADP, collagen and noradrenaline (Touyz & Schiffrin, 1995). However,
characterisation of the receptor involved, by the use of various agonists and
antagonists, has produced inconclusive results. Astarie-Dequeker (Astarie-Dequeker
et al., 1992) observed an equal inhibition by ET-1 and ET-3 of thrombin-induced
aggregation in vitro, suggesting that the ETb receptor may be mediating this effect.
However, Touyz reported a dose dependent inhibition of platelet aggregation and an
increase in platelet pHj by ET-1; the latter blocked by BQ-123. Touyz inferred that
the ETa receptor mediated inhibition of aggregation (Touyz & Schiffrin, 1993b). It
would appear, therefore, that platelets express ETa and ETb receptors and that ET-1
inhibition of aggregation may be mediated by both receptor sub-types.
The work described in this chapter consists of three separate studies: the first
examined the effects of receptor agonists, ET-1 and SRTX S6c on adrenaline-
induced primary aggregation; the second assessed whether the effect of ET-1 was
reproducible on different aliquots of plasma from the same subjects (that is whether
repeated aggregation studies would produce similar results); and the third examined
the effect of pre-incubation with the selective antagonists BQ-123 and BQ-788 on




Healthy male subjects between the ages of 21 and 41 years of age participated in
these studies.
Preparation of PRP from venous blood and platelet aggregation studies were carried
out as described in chapter 2. Briefly, blood was taken via a 19 gauge needle into
acid citrate dextrose; 9:1. Blood was promptly centrifuged at room temperature for
10 min at 120 g to obtain PRP and the remaining blood was centrifuged for a further
20 min at 3000 g to obtain PPP. PRP was transferred carefully into 2 ml tubes and
stored under 95% O2 5% CO2 at room temperature until required. Samples were
heated to 37°C and stirred at 1200 rpm and allowed to equilibrate for 3 min prior to
each study.
In all studies aggregatory responses to adrenaline were assessed for each subject to
establish appropriate doses of the aggregating agent to induce primary aggregation.
Study 1
Samples were pre-incubated with ET-1 (10~12 to 10~9 M), SRTX S6c (10~12 to 10~9
M) or vehicle (normal saline) for 1 min prior to the addition of either adrenaline, at
the individually pre-determined concentration or vehicle. The order of addition, that
is whether ET-1 or SRTX S6c was used first, was randomised.
Study 2
Samples were pre-incubated with ET-1 (1(T12 to 10-9 M) or vehicle for 1 min prior
to the addition of adrenaline or vehicle. In samples from individuals displaying a
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potentiation to adrenaline (an increase of 5% or more compared to adrenaline alone
at two concentrations of ET-1) the dose response to ET-1 was repeated.
Study 3
Samples were pre-incubated with ET-1 (10"12 to 10"9 M) or vehicle for 1 min prior
to the addition of adrenaline or vehicle. In samples from individuals displaying a
potentiation to adrenaline, as described for study 2, samples were then incubated
with BQ-123 l|lM or BQ-788 0.1 (iM for 1 min prior to the addition of ET-1 (10"12
to 10"9M) or vehicle and after a further minute the predetermined dose of adrenaline
was added.
Statistical Analysis
Results are expressed as mean ± s.e.mean, statistical analysis was by repeated
measure ANOVA. Differences are considered to be statistically significant at the 5%
level. For comparisons giving a significant result by ANOVA the Fisher test was
used to identify individual points that were significantly different from adrenaline
alone for study 1 or ET treatment in the absence of an antagonist for study 3.
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Results
Pre-incubation with ET-1 (1(H2-10-9) modestly but significantly potentiated
adrenaline induced aggregation (p=0.03, n=12). The response to SRTX S6c and
adrenaline was more variable with mean standard deviations approaching double
those of ET-1, SRTX S6c potentiation of adrenaline-induced aggregation was of
borderline significance (p=0.05, n=12) (fig 4.1). A comparison of the effect of both
agonists at the maximum concentration, 10~9 M, reveals a positive relationship, with
the exception of one marked outlier (fig 4.1b). In general, subjects displaying little or
no potentiation of primary aggregation by ET-1 display little or no potentiation by
SRTX S6c, and similarly, with the exception of the one outlier, subjects displaying a
greater effect, do so to both agonists. However, at this concentration of agonist the
effect of SRTX S6c is greater than that of ET-1 for all subjects. Even subjects
showing little or no potentiation to ET-1 appear to show a greater potentiating effect
to SRTX S6c.
When a dose response to ET-1 was repeated in plasma from subjects in whom
potentiation of adrenaline-induced aggregation was observed ET-1 again
significantly potentiated primary aggregation (p=0.02, n=6). There was no
significant difference between the first and second ET-1 challenge (p=0.86, n=6) (fig
4.2).
A one minute incubation with BQ-123, 10~6 M, did not significantly alter the
potentiation of aggregation by ET-1 (p=0.88, n=6) (fig 4.3). However, BQ-788, 10-7
M, did significantly attenuate the ET-1 mediated response (p=0.04 n=6) (fig 4.4).




In platelets from healthy control subjects, adrenaline-induced in vitro primary
platelet aggregation was potentiated in a dose dependent manner by ET-1 and SRTX
S6c. The potentiation was neither universal nor uniform. Potentiation to SRTX S6c
was particularly variable as demonstrated by the large s.e.means seen in figure 4.1.
In figure 4.1b the subjects appear to fall into 2 clusters, with the exception of the
outlier, those who show a potentiation to ET-1 and those who show no effect. This
would be consistent with the proposition by Matsumoto that some individuals
display potentiation of aggregation by ET-1 and some do not (Matsumoto, et al.,
1990). However, in the study presented here the difference between these groups is
relatively small compared to the variability among the responders. Consequently, in
any study designed to directly test the proposition that a bimodal distribution of
response exists a greater number of subjects would be required.
Study 2 was designed to test whether the potentiation of aggregation by ET-1 was
reproducible. Separate aliquots of plasma from individuals showing a response were
subjected to the same doses of ET-1 as in study 1. A similar profile of responses was
observed, and consequently potentiation of aggregation by ET-1 was considered to
be reproducible. The aim of this work was to characterise the receptor mediating the
potentiation of adrenaline-induced primary aggregation by ET-1 therefore the
antagonist studies were only performed in subjects exhibiting potentiation of
aggregation by ET-1. These subjects are referred to hereafter as 'responders'.
In 'responders' (those subjects showing an increase of 5% or more compared to
adrenaline alone at two concentrations of ET-1) the effect of ET-1 was not
antagonised by the ETa selective antagonist BQ-123 but was significantly attenuated
by the ETb selective antagonist BQ-788. This indicates that the ETa receptor does
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not play a significant role in potentiation of adrenaline-induced primary aggregation
by ET-1 and that the major contribution is mediated by the ETb receptor.
In figures 4.2, 4.3 and 4.4 the aggregatory response to adrenaline alone appears to be
higher than that observed in study 1, shown in figure 4.1. This raises the questions of
whether the higher initial extent of aggregation is responsible for the greater
potentiation by ET-1. This is answered, to a certain extent, by the result described in
chapter 3 where the potentiating effect of ET-1 was at least as great, if not greater,
when a threshold concentration of adrenaline was used compared to a higher
concentration.
The term 'responded is used to describe the effect observed in this study. Although
this is consistent with the proposition of Matsumoto, discussed above, from these
studies it is not possible to establish an intrinsic difference between subjects. Platelet
activity is affected by a number of environmental factors, such as diet, exercise and
stress, and although attempts were made to control for some of these it is still
possible that activity and responses of platelets may differ from day to day. To
establish whether there are subgroups of responders, it would not only be useful to
study a large group of subjects but also to study subjects repeatedly on several
occasions.
As mentioned in the introduction to this chapter Touyz and Schiffrin described a
dose dependent increase in platelet pHj by ET-1. Although these researchers
suggested that the alkalinisation was associated with an inhibition of aggregation,
they also demonstrated that alkalinisation induced by angiotensin II correlated with
an increase in intracellular Ca2+ (Touyz & Schiffrin, 1993b). It is, therefore, possible
that the alkalinisation reported may be associated with a pro-aggregatory effect.
However, in the work presented in this chapter no effect of the ETa receptor
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antagonists BQ-123 on ET-1 potentiation of aggregation in the 'responded group was
observed, suggesting this is not mediated by the BQ-123 inhibitable increase in pH;
described by Touyz.
In conclusion, the potentiation of adrenaline induced aggregation by ET receptor
agonists appears to be variable between subjects but reproducible in individual
subjects. This pro-aggregatory effect is observed with SRTX S6c as well as ET-1,
and the actions of ET-1 are inhibited by BQ-788 but not BQ-123. This indicates that
platelets from at least some individuals possess ETb receptors and that these
receptors mediate ET-1 potentiation of adrenaline induced primary aggregation.
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Figure 4.1. Potentiation of adrenaline-induced primary aggregation by ET-1 o (p=
















Figure 4.1b The increase, in percent aggregation, by ET-1, InM, plotted against the
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Figure 4.2 Reproducibility of ET-1 potentiation of adrenaline-induced primary
aggregation in responders; o adrenaline + vehicle or ET-1, • repeated dose response
to ET-1 in platelet from the same donors, n=6.
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Figure 4.3. Platelet aggregatory response to adrenaline + ET-1 in the presence of
vehicle o and BQ-123* (n=6).
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Adrenaline
Figure 4.4 Platelet aggregatory response to adrenaline + ET-1 in the presence of
vehicle o and BQ-788 • (p = 0.03, n=6).
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CHAPTER 5




As described in the preceding chapter ET-1 acts on target cells via cell surface ETa
and ETB receptors. By binding to these receptors ET stimulates intracellular second
messengers which in turn activate a functional change in the cell. Some
physiological actions result directly from the intracellular messengers such as
vascular smooth muscle cell contraction, while others, such as relaxation, can be
induced indirectly through activation of an endothelial ETb receptor leading to
release of the endothelium derived dilators prostacyclin and NO.
A number of intracellular signalling pathways have been associated with ET
stimulation of cells; these include the phosphatidylinositol cycle (PI system), protein
kinase C, cyclic AMP and cyclic GMP. Studies in preparations of isolated bovine
vascular smooth muscle cells have shown that ET-1 increased cyclic AMP levels via
the ETa receptor, presumably coupled to a Gs protein, while in bovine endothelial
cells the ETb receptor attenuated forskolin stimulation of adenylate cyclase (Eguchi,
et al., 1993). In transfected Chinese hamster ovary cells a similar pattern was
observed (Aramori & Nakanishi, 1992). In rat aortic strip preparations, however,
ETb receptor activation caused an increase in cyclic GMP which was abolished by
pre-incubation with the NO synthase inhibitor N-monomethyl-L-arginine (Fujitani et
al., 1993). This suggests that ETb receptor activation could lead to an increase in
NO production, which in turn increases cellular cyclic GMP levels, the second
messenger for NO.
The work described in the previous chapters and published by others suggests that
platelet aggregation is modulated in a bi-directional manner by ET receptor agonists.
As described in chapter 1 platelets share may of the intracellular signalling
mechanisms described above. The 'indirect' stimulation of guanylate cyclase
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mediated by NO may also have a parallel in platelets due to presence of NO
synthase in platelets. The modulation of platelet activity by both cyclic AMP and
cyclic GMP has been extensively studied. To investigate the possible modulation of
cyclic nucleotide second messengers in platelets by ET receptor activation the work
presented in this chapter examined the effects of incubation of ET-1 and sarafotoxin
S6c (SRTX S6c) in vitro on platelet cyclic AMP and cyclic GMP concentrations in
human platelet rich plasma. The effect of in vitro incubation of platelet rich plasma
with adrenaline on cyclic AMP and cyclic GMP has also been examined.
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METHODS
Healthy male subjects, aged 27 to 35 years, participated in this study.
PRP was prepared as for aggregation studies. PRP was divided into sub-aliquots and
stored at room temperature under 95% 02:5% CO2 until required. PRP was stirred at
37°C for 4 min prior to the addition of adrenaline (5 x 10~7 - 5 x 10~5), ET-1 (10-11-
IO-7 M), SRTX S6c (10_1 MO7 M) or vehicle (0.9% saline). Dose-response studies
to each agonist were performed in separate parallel aliquots. After 5 min, the platelet
rich plasma was immediately centrifuged at 10 000 g for 2 min at 4°C, the plasma
was removed, the platelet pellet resuspended in 2 ml ethanol and left at room
temperature for 15 min. This suspension was centrifuged at 1200 g for 15 min and
the supernatant decanted and dried down under air. The samples were resuspended
in 500 pi assay buffer and stored at -20°C prior to assay.
Cyclic nucleotide (cyclic AMP and cyclic GMP) concentrations were measured
using in-house radioimmunoassays described in chapter 2. Five hundred pi samples
were acetylated; 50 pi of the samples were incubated for 18 hr at 4°C with 100 pi of
antibody and 150 pi of [125I]-iodinated tracer. Antibody-bound tracer was separated
from free tracer by centrifugation with activated charcoal at 4°C for 30 min at 1700
g. Free radioactivity in the charcoal was measured using an LKB multiwell gamma
counter.
Cyclic nucleotide levels are expressed in pmol ml1 PRP.
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Statistics
Statistical analyses were by repeated measure ANOVA. For comparisons giving
significant result by ANOVA the Fisher test was used to identify individual points
that were significantly different from basal. For comparisons between separate dose
response curves two way repeated measure ANOVA was used. Differences were
considered to be statistically significant at the 5% level.
RESULTS
Adrenaline caused a dose dependent increase in platelet cyclic AMP concentration
(p = 0.004) (fig. 5.1a) and an increase in platelet cyclic GMP concentration (p =
0.001) (fig. 5.1b).
Neither ET-1 (p = 0.11) nor SRTX S6c {p = 0.15) caused a significant change in
platelet cyclic AMP concentrations (fig 5.2). However, both ET-1 and SRTX S6c
caused a significant dose-dependent increase in platelet cyclic GMP concentrations,
(p < 0.05 and p < 0.01 respectively, fig 5.3.)
DISCUSSION
Adrenaline, at a concentration of 5 x 10~5 M, increased platelet cyclic AMP and
cyclic GMP concentrations. The effect of adrenaline on platelet cyclic AMP levels is
not clearly understood. Co-incubation of adrenaline with PGEi for 30 sec attenuated
the prostaglandin stimulated increase in platelet cyclic AMP, interpreted by the
authors as an adrenaline mediated inhibition of adenylate cyclase (Clare et al.,
1984). However, adrenaline increased platelet cyclic AMP concentrations in the
presence of a phosphodiesterase inhibitor suggesting that adrenaline may also
stimulate adenylate cyclase (Haslam & Taylor, 1971). Adrenaline can act on two
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separate receptors on platelets, the 0(2 receptor, which is linked to Gj protein which
inhibits adenylate cyclase, and the P2 receptor, linked to a Gs protein which
stimulates adenylate cyclase. It is possible that when platelet cyclic AMP is already
elevated the effect of subsequent exposure to adrenaline is mediated by the Gi
protein but in the absence of pre-elevated cyclic AMP levels the effect of adrenaline
is mediated by the Gs protein. In the results reported in this thesis incubation of PRP
with adrenaline for 5 min results in a significant increase in cyclic AMP, supporting
the findings of Haslam & Taylor that adrenaline is able to stimulate adenylate
cyclase in the absence of other adenylate cyclase activators. Cyclic GMP is known
to be a second messenger for NO. The increase in cyclic GMP observed is consistent
with adrenaline stimulating platelet NO, proposed in chapter 3 as a result of the
potentiation of adrenaline-induced aggregation by the NO synthase inhibitor
LNMMA. This could be further investigated by the use of a porphyrinic
microsensor, as described by Malinski in the measurement of collagen induced
platelet NO production (Malinski, et al., 1993).
Incubation of platelet rich plasma with the non-selective ETa/ETb receptor agonist
ET-1 or with the ETb selective agonist SRTX S6c did not significantly alter platelet
cyclic AMP levels. However, both agonists significantly increased platelet cyclic
GMP. This would suggest that human platelets contain an ET receptor which is
responsible for increasing platelet cyclic GMP concentrations either through
stimulation of guanylate cyclase or by inhibition of a specific cyclic GMP
phosphodiesterase. The precise mechanism could be explored by investigating the
effect of an ET receptor agonist either in the presence of an inhibitor of soluble
guanylate cyclase or maximal inhibition of phosphodiesterase activity. On the basis
of the findings with SRTX S6c, this is most likely an ETb receptor. SRTX S6c
increased platelet cyclic GMP by up to approximately 80%. Bode-Boger
demonstrated that L-arginine infusion caused a 45% increase in platelet cyclic GMP
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which was associated with an inhibition of ex vivo aggregation to ADP of
approximately 30% (Bode-Boger et al., 1994). This would suggest that the SRTX
S6c effect on cGMP observed here would be capable of causing a significant
modulation of platelet aggregation. The marked elevation of cyclic GMP by SRTX
S6c contrasts with the lesser response in cGMP seen with ET-1.
Although the difference in the cyclic GMP response to ET-1 and SRTX S6c was not
statistically different, the disparity in the magnitude of the response was a curious
and unexpected finding. ET-1 has previously been shown to inhibit sodium
nitroprusside stimulated increase in cyclic GMP in human pulmonary vessels
(Pussard et al., 1995), and consequently it is possible that the difference in the
effects of ET-1 and SRTX S6c observed here may reflect an ETa mediated
inhibition of guanylate cyclase stimulation, or of an increase in cyclic GMP
degradation. This could be investigated by comparing the effect of ET-1 in the
presence and absence of the ETa antagonist BQ-123. There remain two other
possibilities to explain the discrepancy. It has been reported that ET-1 is more
sensitive to degradation by a neutral endopeptidase than SRTX S6c (Sokolovsky et
al., 1990). The receptor agonists were incubated in the plasma for 5 min, whereas
the degradation times reported by Sokolovsky were hours rather than minutes,
consequently it seems unlikely that this would have been an important factor.
Nevertheless, it may be useful to measure the plasma ET and SRTX S6c levels over
the incubation period to confirm this. The third possible explanation is based on the
proposition that a receptor with the binding characteristics of the ETC receptor may
be present in mammals. Although there is pharmacological evidence for such a
receptor (Douglas, et al., 1995) it has yet to be cloned from mammalian tissue.
However, if such a receptor were to exist on human platelet it could be responsible
for the apparent increased cyclic GMP accumulation evoked by SRTX S6c.
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The mechanism responsible for the ET receptor mediated rise in cyclic GMP is not
clear. Selective activation of the ETb receptor in rat aorta, in the presence of an
intact endothelium, stimulates an increase in cyclic GMP and leads to relaxation of
the aorta by a mechanism which can be blocked by the inhibition of NO synthase
(Fujitani, et al., 1993). This demonstrates that the ETb receptor is able to induce an
increase in cyclic GMP in neighbouring vascular smooth muscle cells by stimulation
of NO production in endothelial cells. In cultured epithelial cells both ET-1 and ET-
3 were able to cause an increase in cyclic GMP in the target cell, by a mechanism
which was also blocked by LNMMA (Ishii, et al., 1991) demonstrating that ETb
stimulated NO can have an autocrine as well as paracrine role.
The platelet L-arginine:NO pathway which was characterised in 1990, (Radomski, et
al., 1990) demonstrated that platelet derived NO could inhibit platelet aggregation
through elevation of intra-platelet cyclic GMP. However, there is evidence for an
insulin receptor linked mechanism for increasing platelet cyclic GMP which is
independent of NO synthase, (Trovati et al., 1994) and recently the benzylindazole
derivative YC-1 has also been shown to inhibit platelet aggregation and activate
soluble guanylate cyclase through a NO independent mechanism in human platelets
(Wu et al., 1995). This not only indicates that platelet guanylate cyclase may be
activated by several different mechanisms but also confirms that the elevation of
cyclic GMP per se inhibits platelet aggregation, probably by stimulation of cyclic
GMP dependent protein kinases. To investigate the role of NO production, the ET-
1/SRTX S6c stimulated rise in cyclic GMP studies could be performed in the
presence of LNMMA.
In conclusion, the work presented in this chapter supports the proposition of an ET
ETb receptor on human platelets. Activation of this receptor stimulates cyclic GMP
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Figure 5.1. Adrenaline induced accumulation of platelet cyclic nucleotides, n=6
Figure 5.1a, adrenaline induced an increase in platelet cyclic AMP, (o ), p= 0.004
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Figure 5.2 Effect on platelet cyclic AMP in response to treatment with ET-1 (o), p=
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Figure 5.3. Change in platelet cyclic GMP in response to treatment with ET-1 (o), p
= 0.03 and SRTX S6c (• ), p = 0.008, n=6.
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CHAPTER 6
FURTHER INVESTIGATION INTO ENDOTHELIN RECEPTORS




In the preceding chapters modulation of platelet aggregation by ET-1 has been
described. In addition, evidence for activation of a second messenger system, platelet
cyclic GMP, has also been given. ET-1 exerts effects on cells by binding to specific
cell surface receptors, which in turn stimulate intracellular messengers. Other groups
have also produced results for ET mediated responses in platelets indicating the
involvement of specific ET receptors. These included changes in intracellular
calcium and intracellular pH which, at least in the latter case, were inhibited by
specific ET receptor antagonists (Astarie-Dequeker, et al., 1992; Touyz & Schiffrin,
1993a). These findings provide strong evidence for the existence of ET receptors on
platelet membranes. However, strictly speaking they only describe an association of
a stimulus and an effect which is consistent with the existence of cell surface ET
receptors.
To date, however, no ET receptor has been conclusively identified on platelets.
Ligand binding experiments provide more direct evidence for the existence of a
receptor. A dissociation constant (Kd), derived from competition binding studies
with a fixed concentration of radio-labelled agonist and increasing concentrations of
unlabelled agonist, can be used to describe the equilibrium between receptor-bound
and unbound ligand.
Molecular biology provides an alternative method for indicating the existence of a
specific receptor. As described in chapter 1, platelets do not possess nuclei. They are
formed from the fragmentation of the cytoplasm of nucleated megakaryocytes.
Platelets do not, therefore, contain DNA and, consequently lack the template for the
synthesis of mRNA. However, in 1989 Roth and colleagues detected mRNA for the
glycoproteins lba and lbp, in platelet preparations from patients with essential
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thrombocythaemia, but not in preparations of other blood cells (Roth et al., 1989).
They concluded that vestigial amounts of platelet parent megakaryocyte mRNA
remained detectable in circulating 'young' platelets. More recently, platelet
angiotensin receptor mRNA was quantified, and found to correlate inversely with
plasma angiotensin II levels (Shibata, et al., 1994).
In 1992, Diochot showed that the MEG 01 cell line, a model for megakaryocyte cells
that expresses the glycoprotein GP lib, responds to ET-1, suggesting that
megakaryocytes have, and therefor platelets might have, ET receptors (Diochot et
al., 1992). Recently the same group isolated ETb receptor mRNA from MEG 01
cells (Hamroun et al., 1995).
It was the aim of the work described in this chapter to identify specific ET binding
sites by using ligand binding experiments which would indicate the presence of an
ET receptor on platelet membranes. Before performing competition binding curves,
preliminary studies were carried out to determine optimal assay conditions. Two sets
of controls were performed. The first to confirm the validity of the methods used for
identifying ET-1 receptor binding and the second to confirm that receptor binding
sites on platelets could be identified. Competition binding studies were performed in
rat cardiac membranes, a tissue-type known to express ET receptors, and on platelet
membranes using the adrenergic a2 receptor antagonist yohimbine. To further
strengthen the evidence for a specific receptor and to link the existence of the
proposed binding with an ET receptor gene a second study was devised with the aim





Optimisation of incubation time
Three aliquots of platelet membranes, 0.2 mg of protein /tube, prepared as described
in chapter 2, were incubated with [125I]-ET-1 (0.5 nM, = 100 000 cpm) and either
buffer or ET-1 (10~6 M) to determine total and non specific binding respectively.
Incubations were performed at 37°C for 0, 15, 30, 60, 90 & 120 min. The reaction
was stopped by the addition of ice cold buffer, bound and free [125I]-ET-1 were
separated by rapid filtration, and the bound fraction was quantified by counting the
filters for three min in a gamma counter. Experiments were performed in duplicate.
Optimisation of protein concentration
Three aliquots of platelet membranes were incubated with [125I]-ET-1 (0.5 nM ~
100 000 cpm) and either buffer or ET-1 (10~6 M) at 37°C for 60 min, to determine
total and non specific binding respectively. Incubations of platelet membranes were
performed using protein concentrations of 0.03, 0.06, 0.12, 0.25 and 0.5 mg ml"1.
The reaction was stopped, by the addition of ice-cold buffer followed by rapid
filtration, and the bound radioactive fraction was prepared and radioactivity
measured as described above.
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Competition curves
Competition binding curves were performed for ET-1 using rat cardiac and platelet
membranes and for yohimbine using platelet membranes. Precise assay conditions
are given in chapter 2. Briefly, rat cardiac membranes were incubated at 37°C at a
final concentration of 0.5 mg protein/tube and platelets at 0.4 mg /ml, [125I]-ET-1
was used at a final concentration of 0.5 nM (~ 100 000 cpm) and incubation was for
60 min, [3H]-yohimbine was used at a final concentration of 2 nM 20 000 cpm).
All binding studies were performed at 37°C. Binding curves with a fixed
concentration of radio-labelled agonist and increasing concentrations of unlabelled
agonist were performed and dissociation constants (Kd) were determined using the
computer programme Ligand (Munson & Rodbard, 1980).
Protein concentration
All protein concentrations were determined by the Bio-Rad protein assay based on
the Bradford dye binding procedure. Protein standards were prepared containing 0,
0.1, 0.2, 0.4, 0.8, 1.0 mg protein/ml of albumin. A 40 (il aliquot of standard or
sample was incubated for 10 min at room temperature, after which optical density
was measured, and protein concentration calculated.
Statistical analysis was by repeated measures ANOVA.
RT-PCR study
Platelet preparation
Platelets were prepared by two separate methods.
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Method I
The first method was an adaptation of the method described by Shibata (Shibata, et
ai, 1994). Plasma was prepared from venous blood by centrifugation. The plasma
was then diluted in 20 vol. Medium 199 and centrifuged for 10 min at 1000 g. The
pellet was resuspended in the above medium and both supernatant and resuspended
pellet were centrifuged at 1000 g for 20 min. Both subsequent pellets were frozen in
liquid nitrogen and identified as platelet poor and platelet rich pellets respectively.
The platelet rich pellet resulted in approximately 10 fold greater harvest of platelets
compared to the platelet poor pellet. Both preparations had a contamination of less
than 1:1000 white blood cells, however white cells were only detected in 2 of 6
platelet poor samples.
Method 2
The second protocol for platelet preparations involved purification of platelets on
discontinuous gradients of percoll as described in chapter 2. No whole cells other
than platelets were detected in samples prepared by this method.
RT-PCR Protocol
Extraction of RNA was performed using chloroform as described in chapter 2. RNA
was also extracted from MEG 01 cells to act as a positive control.
RT-PCR was performed using selective oligonucleotide primers for ETa and ETb
receptors, described in chapter 2. Samples prepared by method 2 were only tested
using primers for the ETb receptor. MEG 01 RNA and a blank sample containing
water in place of RNA were analysed as positive and negative controls respectively.
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Elution of the RT-PCR product on the agarose gel was always performed in the
presence of molecular weight markers. A result was considered positive if a single
band was visible at the expected position compared to the molecular weight marker
and the positive control. The predicted sizes for the amplified receptor cDNA






Specific binding, calculated by the subtraction of non-specific binding, that is
binding in the presence of ET-1 (10-6 M), from total binding appeared to peak at 60
min. However, specific binding did not change significantly as a function of time
(p=0.11, n=3) (fig 6.1).
Protein concentration
There was a linear relationship between specific binding and protein concentration
over the concentrations examined (fig. 6.2). The relationship between non-specific
binding and protein concentration was linear up to approximately 0.5 mg ml"1. In
subsequent competition binding curves protein concentrations of 0.4 mg ml"1 were
used.
Competition Binding Curves
Unlabelled ET-1 dose dependently reduced the binding of [125I]-ET-1 to rat cardiac
membrane preparations (p=0.0001; n=6) in a manner similar to that previously
reported (Waugh, et al., 1992). The mean Kd for 6 experiments was 0.85± 0.52 nM
(Fig 6.3).
Unlabelled yohimbine dose dependently reduced the binding of [3H]-yohimbine in
platelet membrane preparations (p=0.0001; n=3), the mean Kd for 3 experiments
was 1.28 ± 0.60 nM (Fig 6.4).
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In platelet membranes, unlabelled ET-1 did not consistently influence [125I]-ET-1
binding (p=0.18; n=6) (Fig 6.5). The larger standard errors were due to an apparent
dose dependent reduction in binding in platelet preparations from two subjects only,
while the other four subjects appeared to show only non-specific binding. For the
two subjects who appeared to show reduced binding with increasing concentrations
of cold ligand data analysis produced Kds of 1.1 and 0.4 nM.
RT-PCR study
Extraction method 1.
The platelet rich pellet obtained using this extraction method was positive for mRNA
for both the ETa and the ETb receptors, however the platelet poor pellet was only
positive for ETb receptor mRNA (fig 6.6). MEG 01 cells were positive for both
receptor types.
Extraction method 2.
In the first run of samples prepared by the use of percoll, n=3, all samples were
positive for ETb receptor mRNA. However, the blank sample containing water in
place of RNA appeared to exhibit a faint band, indicating slight cross contamination
(fig 6.7). In the second run only 1 of the 3 samples analysed produced a positive
result.
DISCUSSION
Dissociation constants obtained for the competition binding studies of ET-1 on rat
cardiac membranes and for yohimbine on platelet membranes, 0.85 ± 0.52 nM and
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1.3 ± 0.6 nM respectively were consistent with previous findings (Brown et al.,
1990; Gu, et al., 1989). This suggests that the experimental procedures employed in
the ligand binding study were valid. The preliminary studies which examined
varying incubation time and protein concentration showed a small, but in the latter
case significant specific binding of [125I]-ET-1 to platelet membranes. However,
there was not a consistent reduction of binding with incubation of increasing
concentrations of ET-1 in all subjects. Nevertheless, two subjects did display
apparent competitive binding curves with KDs of similar order of magnitude to that
observed in the cardiac membranes.
The competition binding studies with yohimbine were successful in producing
results consistent with the findings of other groups, confirming the presence of the
0C2 receptor. However, the mean number of (X2 receptors is between 200 and 300 per
platelet (Blockmans, et al., 1995). The potentiating effect of ET-1 on platelet
aggregation is similar to that of angiotensin II, and human platelets have only 4 to 6
receptor sites/platelet for angiotensin II (Ding et al., 1984). It is possible therefore,
that when receptor numbers are low, as seem likely for ET-1, this method of
membrane preparation and analysis may be insensitive in their detection. A possible
option to overcome low receptor number might be to increase the protein
concentration, and hence the amount of platelet membrane, in the assay. However,
experience suggests that this would result in greater non-specific binding. Another
possibility is that detection of binding sites is hampered by a rapid down-regulation
of the platelet receptors. Consequently, it may be possible to identify the receptors
by altering assay conditions, such as performing the incubation at low temperatures.
This may introduce other possible complications such as a long incubation time,
where the integrity of the membranes and the stability of the agonists would have to
be verified.
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An alternative to using platelet membrane preparations would be to use whole
platelets. Studies of angiotensin II binding to human platelets have tended to use
whole platelets (Ding, et al., 1984; Mann et al., 1985). The use of whole platelet
may reduce non-specific binding of the ligands and may therefore give greater
'signal to noise ratio' enhancing the sensitivity of detection. Difficulties in using
whole platelets involve receptor internalisation and the inability to freeze and defrost
intact platelets.
In the second study looking at receptor mRNA, the results obtained from samples
prepared by the method described by Shibata (1994) indicated that platelet
preparations contain mRNA for the ETa and the ETb receptors. However, although
a contamination by other blood cells of 1:1000 may not be important in functional
studies, RT-PCR is a highly sensitive procedure involving exponential amplification
of the reverse transcriptase product. Nucleated cells, such as neutrophils, would be
expected to contain much more RNA than platelets, and consequently contamination
by such cells might affect the results obtained by RT-PCR. The platelet poor
samples, which contained less contamination may be a better indicator of platelet
mRNA. The results from these samples indicate that platelets contain only ETb
receptor mRNA. However, these samples were not completely free of contamination.
The second platelet preparation protocol produced samples with no evidence of
contamination by other cells. Unfortunately, although these results suggest the
presence of ETb mRNA, analysis of these samples produced inconsistent results,
with samples from some subjects producing positive results for the presence of ET
receptors and others producing negative results.
One possible explanation for the results obtained by using method 1 is that platelets
may contain ETb mRNA and that other blood-borne cells contain ETa mRNA. It is
known that ET-1 acts on other circulating cells apart from platelets, including
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monocytes and neutrophils (Elferink & Dekoster, 1994; Heslet et al., 1993).
Although the receptor subtype on monocytes has not yet been identified, the effects
of ET on neutrophils are thought to be mediated by the ETa receptor (Elferink &
Dekoster, 1994). It is, therefore, possible that the presence of ETa mRNA in the
platelet rich sample can be accounted for by neutrophil contamination.
The fact that in the ligand binding study platelets from two volunteers appeared to
display competition binding curves might suggest that part of the problem may be
due to the fact that not all individuals express platelet ET receptors or that some have
higher numbers of receptors. This would be consistent with the suggestion by
Matsumoto of responders and non-responders to ET (Matsumoto, et al., 1990) and
the rather variable responses reported in chapters 3 and 4 (see figures 3.5 and 4.1b).
This would also explain why receptor mRNA was not detectable in all the samples in
the second study in this chapter. (It is important to note that two separate groups of
volunteers were used in the two studies in this chapter). This hypothesis could be
explored by screening volunteers for responders and non-responders using functional
studies, and subsequently investigating receptor binding in the two groups.
With regards to the RT-PCR study it is important to be aware of possible limitations
in the methods employed for purifying the platelet preparations. Platelets were
separated from other blood cells on the basis of density, using centrifugation in
method 1, and using centrifugation in percoll in method 2. These methods were used
to obtain purified platelet preparations. However, by choosing the purest fraction,
platelets of a greater density may be excluded. It has been suggested that greater
platelet density and volume, features that are determined by the size of the parent
megakaryocyte, are associated with increased platelet activity (Martin et al., 1983).
For this to be true it is likely that influences on platelet activity, such as receptor
type, receptor number, or platelet biochemistry differ with platelet size. Therefore,
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although the platelet rich fraction obtained using method 1 may have contamination
by other blood cells, it also may contain a broader spectrum of platelet densities.
(These problems would also apply when obtaining whole platelets for ligand binding
studies.) It would, then, be incorrect to assume that the presence of ETa receptor
mRNA is solely due to contamination from other blood borne cells. It may, therefore
reflect ETa receptors being present on larger, denser platelets. There are at least two
ways this problem might be addressed.
If a size distribution for the platelets were obtained from the whole blood sample and
the resulting platelet sample, the two could be compared. This would allow
confirmation that the platelet sample analysed represented the same distribution of
platelets present in the blood. Alternatively, platelets could be collected and purified
on the basis of a criterion other than density. For example, platelets could be isolated
using an antibody raised against a platelet specific antigen, such as the GP Ilb/IIIa
complex. Although this method of preparation may produce the best results it would
require some validation and would have to be practicable, for dealing with relatively
large volumes of blood.
In conclusion the results of the studies reported in this chapter suggest that, firstly
platelets from some, but not all, individuals posses receptors for ET-1 and secondly
that preparations of blood-borne cells contain mRNA for both the ETa and the ETg






















Figure 6.1 Specific binding of [125I]-ET-1 to platelet membranes as a function of
time. Despite an apparent peak in specific binding as a percentage of total
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Figure 6.3 [125I]-ET-1 binding to rat cardiac membranes in the presence of cold
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Figure 6.4 [3H] yohimbine binding to human platelet membranes in the presence of
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Figure 6.5 [125I]-ET-1 binding to human platelet membranes in the presence of ET-
1 (n=6).
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Figure 6.6 A photograph of a gel, after loading with 3 'platelet poor' (pp) samples,
showing bands of 238 base pairs, consistent with the presence of ETb mRNA. The
gel was loaded as follows; lane 1 blank, lane 2 sample ppl, lane 3 molecular weight
markers, lane 4 pp2, lane 5 pp3 and lane 6 MEG 01.
Figure 6.7 A photograph of a gel, after loading with 3 samples prepared as
described in method 2, showing bands of 238 base pairs, consistent with the
presence of ETb mRNA, including a faint band in lane 5. The gel was loaded as
follows; lane 1 molecular weight, lane 2 sample 2.1, lane 3 sample 2.2, lane 4
sample 2.3 and lane 5 blank.
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CHAPTER 7
INVESTIGATION INTO THE EFFECTS OF ENDOTHELIN-1,




In chapters 3 and 4 of this thesis the effect of ET-1 on aggregation of human
platelets in vitro was studied. Evidence was presented for a biphasic effect on
aggregation, a potentiation of primary aggregation and an inhibition of secondary
aggregation. Several other studies have been published, including some of the
earliest studies on the effects of ETs on platelets, examining the in vivo and ex vivo
effect of ET-1 and ET-3 on platelet aggregation. These studies used systemic doses
of peptide in animal models and consistently reported an inhibition of aggregation in
the dog and the rabbit (Herman, et al, 1989; Lidbury, et al., 1989; Thiemermann, et
al., 1989). Several of these studies concluded that the effect of ETs observed was
largely or wholly the result of ETb mediated prostacyclin release (Herman, et al.,
1989; Herman et al., 1993; Thiemermann, et al., 1989). No pro-aggregatory effect
was reported.
Although prostacyclin mediated increase in platelet cyclic AMP and the subsequent
inhibition of aggregation may be an important regulatory mechanism of platelet
activity in vivo, platelets do not produce prostacyclin. Hence, this mechanism can
not be responsible for the inhibitory action of ETs seen in vitro reported in earlier
chapters and by others (Astarie-Dequeker, et al., 1992; Touyz & Schiffrin, 1995).
Although it is possible that the powerful inhibition of platelet aggregation by
prostacyclin might have masked a potentiation of aggregation, one might expect this
effect to have been revealed when prostacyclin synthesis was inhibited, but no such
effect was reported (Thiemermann, et al., 1989). Consequently, it would appear that
the effects of ET-1 reported in these animal studies are not completely consistent
with the effect observed in in vitro human platelet studies.
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ET mediated responses are know to display interspecies variation in the vasculature
(Reynolds et al., 1995) and in platelets (Ohlstein, et al., 1990). Consequently, it is
not necessarily appropriate to extrapolate from previous studies in animals to effects
of ET-1 in humans. In addition, the ETs are thought be locally acting hormones. In
the animal studies mentioned above systemic doses of ET were used and local
actions of ET-1 may be obscured by the effects of systemic administration on the
heart and kidney and the consequent change in blood flow and hormone production.
The actions reported may not necessarily be consistent with a paracrine role of ET-1.
The aim of the work presented in this chapter was to investigate the effect of locally
acting concentrations of ET-1 on ex vivo platelet aggregation in man. By using a
dose of ET-1 known to act selectively to decrease blood flow in the infused forearm
(Clarke et al., 1989; Haynes & Webb, 1994) we have an effective bioassay of ET-1
efficacy in vivo. To assess the effects of prostanoid generation on the actions of ET-
1, ex vivo studies were carried out in the presence and absence of cyclooxygenase
inhibition by aspirin. At the dose used the local concentrations of ET-1 achieved are
lower than those previously used for in vitro platelet aggregation studies.
Consequently, we also examined the in vitro effect of ET-1 at a low concentration in




Healthy male subjects, aged 20 - 36 years participated in these studies. No subject
received vasoactive or non-steroidal anti-inflammatory drugs in the week before
each study or alcohol or caffeine on the day of the studies. Clinical studies were




Forearm blood flow measurements are given in detail in chapter 2, therefore only an
outline is given below.
The left brachial artery was cannulated under local anaesthesia (1% lignocaine).
Saline (0.9%) and ET-1 (5 pmol mH) were infused at a rate of 1 ml mim1. Blood
flow was measured in both arms by venous occlusion plethysmography. The hands
were excluded from the circulation during each measurement period. The percentage
change in blood flow was calculated as percentage change from basal in the ratio of
blood flow between the infused and non-infused arms.
Platelet aggregation
Platelet aggregation studies were carried out as described in previous chapters.
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Endothelin Radioimmunoassay
Blood for Ir-ET-1 assay was taken into EDTA and measured using a commercial
radioimmunoassay kit as described in chapter 2.
Study design
The study consisted of three phases, two ex vivo phases (± aspirin) and an in vitro
phase. There was a minimum interval of seven days between phases and the order of
phases was randomised for each volunteer. In the two ex vivo phases subjects
received brachial artery infusions of saline (0.9%) for 30 min followed by ET-1, at 5
pmol min-1, for 60 min. Forearm blood flow was measured before, and 10, 20, 40
and 60 min after the start of the ET-1 infusion. Blood was sampled at +60 min from
indwelling cannulae in both infused and control arms for ex vivo platelet aggregation
and plasma ET concentrations. In platelet aggregation studies, platelets were
challenged in vitro with ADP or adrenaline; both at concentrations of 1, 10 and 100
|!M. Dose response studies to ADP and adrenaline were performed in parallel. In the
phase of the ex vivo study involving aspirin administration, aspirin 600 mg, was
given intravenously 30 min before and 30 min after the start of ET-1 infusion.
In a third phase blood was sampled via a 19 g needle from subjects who had rested
supine for 20-30 min. Platelets were incubated with either vehicle or ET-1, 100 pM
for 1 min prior to the addition of vehicle, ADP or adrenaline at the same
concentrations as described above.
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Statistical Analysis
Results are expressed as mean ± s.e.mean. Statistical analysis was by repeated
ANOVA for forearm blood flow studies. Student's Mest was used for comparisons
of primary and secondary platelet aggregation and the plasma ET-1 comparison,




Brachial artery infusion of ET-1 caused significant forearm vasoconstriction, with a
32.8% ± 5.3 reduction in blood flow at 60 min (p < 0.001). Pre-treatment with
intravenous aspirin 600 mg significantly increased the forearm vasoconstriction,
with a 50.3% ± 5.9 reduction in blood flow at 60 min (p < 0.001 vs basal; p< 0.05
ET-1 alone) (Fig 8.1).
Plasma ET-1 levels were significantly higher in venous blood collected from the
infused arm compared to the control after 60 min, control arm vs infused arm, (2.5 ±
0.7 vs 15.1 ± 1.3 pM, p< 0.001).
ET-1 infusion did not significantly alter ex vivo adrenaline or ADP induced primary
aggregation or ADP induced secondary aggregation (n = 12). However, adrenaline
induced secondary aggregation was significantly attenuated in plasma from the
infused arm compared to the control (38.5 ± 8.7 vs 67.1 ± 6.6, p< 0.05, n = 8) (Fig
8.2). Secondary aggregation to adrenaline was only seen in 8 of the 12 subjects.
Aspirin infusion did not significantly affect basal blood flows, blood pressure, heart
rate or basal platelet aggregation (Table 7.1).
In aspirin treated volunteers, there remained no significant difference in the extent of
primary aggregation to ADP in plasma from the non-infused (16.9 ± 3.3) compared
to the ET-1 infused arm (12.4 ± 3.3). Similarly, secondary aggregation to ADP was
not altered by ET-1 infusion in the presence of systemic aspirin (62.7 ± 4.0 vs 61.2 ±
5.9 control arm vs ET-1 infused arm). No difference was seen in adrenaline induced
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primary aggregation in plasma from the control arm compared to the ET-1 infused
arm (13.8 ± 1.7 vs 14.6 ± 2.2). Only 3/12 aspirin treated volunteers demonstrated
adrenaline induced secondary aggregation with 54.3 ± 10.0% aggregation in plasma
from the control arm and 47.5 ± 14.7 % in plasma from the infused arm.
In vitro
Adrenaline and ADP induced primary aggregation tended to be increased by
pre-incubation with ET-1, 100 pM, in vitro but this was not statistically significant,
(Fig 3). However, secondary aggregation to adrenaline in the presence of ET-1 (39.7
± 8.7 %) was significantly attenuated compared to control (76.8 ± 6.0 %; p < 0.01, n
= 8). Secondary aggregation to ADP was not significantly altered by pre-incubation
with ET-1 (Fig 8.3).
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Discussion
This study confirms that ET-1 causes sustained forearm vasoconstriction (Clarke, et
al., 1989; Haynes & Webb, 1994) and demonstrates for the first time that inhibition
of prostanoid production potentiates ET-1 induced constriction in forearm resistance
vessels. ET-1 did not significantly potentiate primary aggregation to ADP or
adrenaline in any of the three phases of the study. However, both ex vivo and in vitro
secondary aggregation to adrenaline was inhibited by pre-incubation with ET-1.
ADP-induced aggregation was not significantly altered. The specificity of the
inhibition of adrenaline induced secondary aggregation, is consistent with the
findings presented in chapter 3 and indicates an attenuation of a mechanism of
secondary aggregation response not present in ADP induced aggregation.
Pre-treatment with aspirin significantly potentiated the vasoconstriction elicited by
ET-1, suggesting a role for vascular generation of vasodilator prostanoids in the
modulation of ET-1 induced vasoconstriction in the human forearm resistance
vessels. The inability of aspirin to influence basal resistance (Linder et al., 1990)
would indicate that prostanoids are not produced basally, in contrast to NO
(Vallance, 1989). Consequently, one can conclude that ET-1 stimulates prostanoid
generation. This is consistent with in vitro evidence that ET-1 stimulates
prostacyclin generation from cultured endothelial cells (Filep et al., 1991). ET-1 also
stimulates the generation of prostaglandin E2 (Miura et al., 1991) and thromboxane
A2 (De Nucci et al., 1988). However, the fact that aspirin caused increased
constriction to ET-1 would indicate that any generation of thromboxane is less
important than prostanoid induced dilation in the presence of a healthy endothelium.
These findings are consistent with the findings of Haynes (Haynes & Webb, 1993b)
that venoconstriction to ET-1 is modulated by prostanoids in the human hand vein.
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The ET-1 mediated inhibition of adrenaline-induced aggregation is consistent with
the results presented in chapter 3. However, in the ex vivo studies presented in this
chapter the platelets were exposed to ET-1 an hour before being challenged with
adrenaline. This would imply that the effect of ET-1 on platelets is sustained for a
prolonged period after the initial exposure. This is analogous to the prolonged
vasoconstriction observed in the forearm, discussed above. It is an interesting part of
the profile of the actions of ET-1 that it induces such a sustained effect.
Herman (Herman, et al., 1989) reported that ET-1 mediated inhibition of ex vivo
platelet aggregation in dogs was accompanied by an increase in 6-keto PGFia; the
hydrolysis product of prostacyclin. In Herman's study inhibition of aggregation was
inhibited by aspirin. From this he concluded that prostacyclin was involved in ET
mediated inhibition of platelet aggregation. To investigate the role of prostacyclin in
the actions of ET-1 in man, in one phase of the study presented in this chapter,
subjects were given aspirin. However, in addition to blocking endothelial prostanoid
production, aspirin also inhibits platelet thromboxane A2 production. Thromboxane
A2 production is one of the mechanisms that promotes secondary aggregation to
adrenaline, and after receiving aspirin, secondary aggregation to adrenaline was only
observed in plasma from 3 of the 12 subjects. Therefore, no statistical analysis could
be performed. Secondary aggregation to ADP in this study, was both aspirin
insensitive and ET-1 insensitive. This might suggest that ET-1, like aspirin, alters
platelet thromboxane production. However, this would be better investigated by
measuring thromboxane B2, a stable metabolite of thromboxane A2, levels after in
vitro exposure of platelets to ET-1. Recent work has provided evidence that rather
than altering thromboxane A2 production, ET-3 attenuates Ca2+ mobilisation from
internal stores linked to thromboxane receptor stimulation (Astarie-Dequeker et al.,
1995). Significantly, with a regards to the lack of effect of ET-1 on ADP-induced
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secondary aggregation, the same publication reported that ET-3 did not affect Ca2+
changes induced by ADP.
The fact that prostacyclin is not responsible for ET-1 inhibition of platelet
aggregation is better demonstrated in the in vitro phase of the study. Platelets do not
produce prostacyclin and it has been reported that the anti-aggregatory activity of
prostacyclin is 'completely diminished' after 20 min (Moncada, et al., 1976). As the
studies in this chapter were performed at least 60 min after venesection, it is unlikely
that prostacyclin was involved in the inhibition of aggregation observed after the
exposure to ET-1.
No significant potentiation of aggregation was observed in any of the phases of the
study presented in this chapter, although there was a non-significant trend for ET-1
to potentiate primary aggregation in the in vitro phase. It is possible that the
concentration of ET-1 used was not sufficient. However, in chapter 4, a slight but
significant potentiation was observed at the same concentration of ET-1 (100 pM).
The in vitro concentration of 100 pM was used because this was estimated to be
approximately the same concentration as would be achieved in vivo during the ex
vivo phases of the study. It might have been useful to have also used a higher
concentration in vitro to confirm that the subjects studied did, indeed, display a
potentiating effect, in light of the suggestions in earlier chapters that this effect might
not be seen in all individuals. In this particular study it would not have been
practicable to have done this as it would not only have required more blood but
would also have extended the duration of the study beyond the time established in
chapter 2 for achieving reproducible results for adrenaline-induced aggregation.
As mentioned in the preceding paragraph, the concentration of ET-1 achieved in vivo
after infusion was approximately 100 pM. This was estimated on the basis that
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resting FBF is approximately 50 ml min-1, and thus a dose of 5 pmol mim1 would
achieve local arterial concentrations of 100 pM. However, venous plasma ET
concentrations, as determined by radioimmunoassay, were only raised to 15 pM. In
addition to neutral endopeptidase breakdown Plumpton suggested that other
mechanisms may be involved in the control of circulating concentrations of ET-
l(Plumpton et al., 1995). Rapid internalisation of receptor bound ET-1 by arterial
and nutritive vessels (Anggard et al., 1989) may be one possible mechanism. The
combination of ET-1 metabolism and internalisation of receptor bound ET-1 might
account for the discrepancy between this result and the expected value.
The discrepancies between the results presented in this chapter and other studies on
the role of prostacyclin in modulating the effect of ET-1 on ex vivo platelet
aggregation may be due to a number of factors. In addition to possible interspecies
variation, the most significant methodological differences are the fact that other
workers used systemic concentrations of ET-1 and studied different aggregating
agents. Many of the reports, including those by Lidbury and Thiemermann (Lidbury,
et al., 1989; Thiemermann, et al., 1989), only described the use of ADP as the
platelet aggregating agent. As discussed above, ADP-induced aggregation appears to
be ET insensitive.
In summary, endogenous endothelium derived dilator prostanoid production limits
the vasoconstriction observed in response to exogenous ET-1 in the human forearm.
ET-1 inhibits ex vivo and in vitro platelet aggregation to adrenaline but not to ADP.
The ex vivo inhibitory effect was long lasting, still present two hours after the
infusion of ET-1 was complete.
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- Asp. 3.1 ±0.7 3.0± 0.6 2.3 ±0.3 2.4 ±0.3 80.4 ± 3.0 62.6 ±2.4
+ Asp 2.4 + 0.2 2.9 + 0.2 2.1 ±0.3 2.0 ±0.3 84.7 ± 2.6 59.1 ±2.2
Table 7.1. This table provides a comparison of the mean basal data for forearm
blood flow, platelet aggregation, mean arterial pressure (MAP) and heart rate (HR)
on the days without (- Asp) and with (+ Asp) aspirin administration. Mean forearm
blood flow is given for pre-ET-1 infusion and mean platelet aggregation with the in
vitro addition of vehicle only.
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Time (min)
Figure 7.1. Forearm blood flow responses to ET-1, 5 nM infused at a rate of 1 ml
min-1 for 60 min, n=12, in the absence (o) and presence (•) of intravenous aspirin
infusion. ET-1 reduced forearm blood flow compared to baseline P< 0.0001 for the
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Figure 7.2. Primary and secondary aggregatory responses to adrenaline (adr) ■ and
ADP H of platelets from either the control arm or the infused arm, ET-1, adr from
infused armE, ADP from infused arm E3n=12. ET-1 significantly inhibited
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Figure 7.3 Primary and secondary aggregatory responses to adrenaline (adr) ■ and
ADP □ pre-incubated in vitro with either vehicle or ET-1 (0.1 nM) adr + ET-1 E3,




ABNORMAL ENDOTHELIN-1 MEDIATED RESPONSES IN
SUBJECTS WITH HIGH BLOOD PRESSURE
165
INTRODUCTION
In the original identification of ET Yanagisawa and colleagues suggested that
'disturbances in the control of ET production might contribute to the pathogenesis of
hypertension' (Yanagisawa, et al., 1988). Indeed, the potent vasoconstrictor
properties of ET-1 and its potential for increasing peripheral vascular resistance,
suggest that it might have a role in the maintenance of blood pressure. Elowever,
plasma concentrations are not raised in patients with essential hypertension
compared to age matched controls (Davenport, et al., 1990). This would not
necessarily rule out a role for ET-1 in hypertension for at least three reasons. (1)
circulating plasma levels of ir-ET may not represent local production of ET, (2)
increased sensitivity to ET could occur by increased receptor number or increased
post receptor activity, and (3) a decrease in the ET mediated counter-balancing
dilator activity of agents such as NO. All of these, either separately or in
combination, might result in increased blood pressure. Although studies which have
examined increased sensitivity to ET-1 in animal models of hypertension are
inconclusive (Rubanyi & Polokoff, 1994), an increased sensitivity to exogenous ET-
1 has been demonstrated in dorsal hand veins of untreated hypertensive patients
compared to normotensive subjects (Haynes et al., 1994).
The work reported in earlier chapters of this thesis suggests that ET-1 sensitivity
could also be examined in the platelets of patients with hypertension. Platelets may
play a role in the pathophysiology of hypertension by the release of several
vasoactive agents, including thromboxane A2, serotonin, ADP and platelet derived
growth factor from activated platelets. A number of functional abnormalities have
been described in the platelets of patients suffering from essential hypertension.
These include increased sensitivity to several platelet activating agents (De Clerck,
1986; Vlachakis & Aledort, 1980), increased platelet [Ca2+]j (Le Quan Sang &
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Devynck, 1986) and raised intracellular pH (Astarie et al., 1992). In chapter 3 and 4
of this thesis evidence was presented for a potentiation of adrenaline-induced
aggregation by ET-1 and an increased sensitivity to ET-1 in hypertensive subjects
could result in increased platelet aggregation. Alternatively, an ET mediated
inhibition of platelet aggregation has also been described both ex vivo and in vitro in
chapter 7. Although the precise mechanism of this inhibitory action is not known, a
reduction in this inhibition may also result in increased platelet aggregation. The aim
of the work presented in this chapter was to examine whether platelet sensitivity to
ET receptor agonists is altered in subjects with high blood pressure. In order to
investigate this two separate studies were carried out.
Platelet responses were studied in patients with untreated hypertension and age and
sex matched controls to examine whether platelet responses to ET-1 were altered in
subjects with established hypertension. Platelet aggregation was studied in response
to adrenaline in the presence and absence of ET-1. Platelet cyclic nucleotides were
also measured in response to adrenaline, ET-1 and sarafotoxin S6c.
Studies of platelet responses in patients with hypertension may provide evidence of
an association of hypertension and aberrant platelet activity, and may provide
information on a potential role of platelets in the consequences of this condition.
However, they do not necessarily establish whether altered platelet activity is a cause
or a consequence of the hypertension. In an attempt to distinguish between the two a
separate study was carried out using subjects from a 'four corners' epidemiological
study. In this 'four corners' study young adult subjects were identified as having
either high or low blood pressure, in addition they were also classified according to
parental blood pressure. Hence, subjects with a predisposition to hypertension, on
the basis of having raised blood pressure, can be identified and distinguished from
subjects with a familial predisposition to hypertension, that is, subjects with raised
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blood pressure who also have parents with raised blood pressure. Consequently, it
should be possible to identify effects which may be involved in the development of
hypertension. In this study, adrenaline-induced platelet aggregation and the effect of
ET-1 on adrenaline-induced primary and secondary aggregation were studied.
Adrenaline has been chosen as the platelet aggregating agent for both of the studies
presented in this chapter. In previous chapters ET-1 mediated modulation of platelet
aggregation has been described to adrenaline but not to ADP. In addition adrenaline
may be a particularly appropriate aggregating agent to study as there is considerable





Ten untreated patients with essential hypertension and 10 age and sex matched
normotensive control subjects were recruited. Age and blood pressure data is given
in table 8.1. Venous blood samples were collected and plasma was prepared as
described in chapter 2. A preliminary dose response to adrenaline was performed for
each subject and subsequently the effect of pre-incubation with vehicle or ET-1 (10"
1 MO"8 M) on adrenaline-induced primary and secondary aggregation was examined.
Cyclic nucleotide measurements were carried out as described in chapter 2. Briefly,
PRP was pre-incubated for 3 min at 37°C before the addition of adrenaline (0.3-0.03
pg ml"1), ET-1 (10-n-10-7 M), SRTX S6c (lO-H-lO"7 M) or vehicle (0.9% saline).
The reaction was stopped after a further 5 min by centrifugation at 5°C. The platelet
pellet was isolated and cyclic nucleotides were extracted using ethanol. Samples
were dried down at 55°C and the residue resuspended in assay buffer and frozen
until required for assay. Acetylated samples were assayed for cyclic AMP and cyclic
GMP.
Study 2
In 1977, in the screening for the MRC Mild Hypertension Trial blood pressure was
measured in 603 couples at the Ladywell Medical Centre. In 1985 blood pressure
was measured in 864 of their offspring, aged 16-24 years. Offspring blood pressure
was plotted against mean parental blood pressure using age adjusted Z-scores. These
were divided into tertiles, thus defining members of 4 extreme corners: A low
parental/high offspring; B high parental/high offspring; C low parental/low
169
offspring; and D high parental/low offspring(Watt et al., 1992). Eleven male subjects
drawn at random from each corner were studied.
Blood was collected in sodium citrate to give a final concentration of 3.5% and
centrifuged at 800 g for 5 min to produce platelet rich plasma (PRP). A 2 ml aliquot
of PRP was centrifuged at 3000 g to give platelet poor plasma. The remaining PRP
was divided into 12 aliquots of 890 pi and stored under 95% 02:5% CO2 at room
temperature until required, but for no longer than 120 min. For the aggregation
studies, PRP was incubated at 37°C for 3 min before the addition of either vehicle or
ET-1, (1 nM). After 1 min a second addition of vehicle or adrenaline, (0.5 to 5.0
pM) was made.
Comparisons for dose responses to adrenaline alone between the 4 corners was by
repeated measures ANOVA. The effect of ET-1 on adrenaline-induced primary and




Adrenaline induced dose dependent platelet aggregation in plasma from both the
hypertensive group and the age/sex matched controls (p=0.0001 for both), with no
difference between the groups (Fig. 9.2).
ET-1 potentiated primary aggregation in a dose dependent manner in both groups
(p= 0.002 for the hypertensive group and p= 0.04 for the control group) with no
difference between groups (Fig. 9.3). Adrenaline-induced secondary aggregation was
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significantly inhibited by ET-1 in the control group (p=0.001) but not in the
hypertensives (p=0.41) (Fig. 9.4).
Platelet Cyclic Nucleotide Measurement.
Basal platelet cyclic AMP levels were not significantly different between the groups.
Treatment with adrenaline, ET-1 and SRTX S6 did not significantly affect platelet
cyclic AMP levels in either group (data not shown), this is consistent with the
findings reported in chapter 5.(see figure 5.2).
Basal cyclic GMP levels were not significantly different between the groups.
Adrenaline produced a change in platelet cyclic GMP in both groups of borderline
statistical significance (p=0.05, for both the hypertensive group and the controls)
(Fig. 9.5). However the apparent difference between the groups was not attributable
to the increasing concentration of adrenaline, as determined by repeated measure
ANOVA of the difference between the groups (p= 0.23).
ET-1 did not induce a statistically significant change in cyclic GMP in either group
(Fig 9.6). However, SRTX S6c did produce a dose-dependent accumulation of cyclic
GMP in platelets from the control group (p= 0.04), but a non-significant decrease in
cyclic GMP in platelets from the hypertensive group (p= 0.07) (Fig 9.7). The platelet
cyclic GMP response to SRTX S6c was significantly greater in the normotensive
group than in the hypertensives (p=0.009).
Study 2.
Adrenaline elicited dose dependent platelet aggregation in all 4 groups (Fig 9.8,
p=0.001 for all groups). Analysis by 2 factor repeated measure ANOVA indicated a
difference in the response to adrenaline between groups, (p=0.03). This difference
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appeared to be due to the difference in response to adrenaline between corners A and
C, (p=0.003). The mean response also tended to be greater in corner C than in B and
D but this did not reach statistical significance, (p=0.07 and 0.18 respectively).
Pre-incubation with ET-1 tended to increase adrenaline-induced primary aggregation
in all groups (Fig 9.9). However, this only reached statistical significance in group B
(p=0.04). Inhibition of adrenaline-induced secondary aggregation by ET-1 did not
achieve statistical significance in any of the corners, although a consistent tendency
was observed in all 4 corners. When the results from all 4 corners were taken
together ET-1 significantly potentiated primary aggregation (p=0.02), but inhibition
of secondary aggregation was not significant (p=0.10).
DISCUSSION
In study 1, no difference was observed between the hypertensive subjects and the
normotensive controls in the aggregatory response to increasing concentrations of
adrenaline, or the potentiation of adrenaline-induced primary aggregation by ET-1.
However, platelets from the hypertensive subjects failed to exhibit a significant ET
mediated inhibition of secondary aggregation observed in platelets from the
normotensive subjects. This is consistent with the findings of Touyz and Schiffrin,
who reported an ET-1 mediated inhibition of thrombin induced platelet aggregation
in normotensive but not hypertensive subjects (Touyz & Schiffrin, 1993b).
The study of platelet cyclic GMP produced two interesting differences between the
hypertensive and normotensive subjects. Adrenaline stimulated an increase in
platelet cyclic GMP. As can be seen in figure 8.5 the levels in the normotensive
subjects appear to be almost double that in the hypertensives. However, by analysing
differences between the groups it can be seen that the difference does not increase
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with increasing concentrations of adrenaline and, therefore, one can conclude that
the difference between the groups is not related to the increasing concentration of
agonist, but is probably related to a generalised impairment of cyclic GMP
production in the hypertensive subjects. The fact that basal cyclic nucleotide levels
were not different suggests that there is an impairment of stimulated cyclic GMP
production or an increase in phosphodiesterase activity leading to less cyclic GMP
remaining in the platelet. Further cyclic nucleotide studies, in the presence of
phosphodiesterase inhibitors, would have made it possible to distinguish between
increased cyclic nucleotide production and altered cyclic nucleotide metabolism.
Cyclic GMP is associated with both vasodilatation and inhibition of platelet activity,
and reduced cyclic GMP levels may be a significant factor in hypertension.
ET-1 appeared to raise platelet cyclic GMP in the normotensive subjects as can be
seen in figure 8.8. However, this was not statistically significant. SRTX S6c did
produce a significant rise in cyclic GMP levels in the normotensive but not the
hypertensive subjects. Unlike the effect of adrenaline, the difference observed
between the two groups of subjects with SRTX S6c is related to increasing agonist
concentration. Hypertensive patients did not show an ET receptor mediated
inhibition of aggregation, nor did they show SRTX S6c stimulated accumulation of
cyclic GMP. However, the inhibition of platelet aggregation mediated by ET
receptors may not be solely mediated by an increase in cyclic GMP because ET-1
inhibited platelet aggregation at 10-8 M without significantly affecting cyclic GMP
levels. A further experiment which may shed light on the role of cyclic GMP in ET
receptor mediated inhibition of platelet aggregation would be to perform aggregation
studies with ET-1 and SRTX S6c in the presence and absence of either a guanylate
cyclase inhibitor or an inhibitor of cyclic GMP dependent protein kinase. The fact
that SRTX S6c appeared to have a greater effect than ET-1 may be an important
observation. It is consistent with the trends reported in earlier chapters, where the
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effect of the ETb receptor agonist appeared to be greater than ETa/b agonist on
platelet aggregation and cyclic GMP accumulation. This possibly reflects opposing
effects mediated by different platelet ET receptors, and will be discussed in the
following chapter.
Study 2 identified an altered platelet response to adrenaline between the four corners
of the Ladywell study. Interestingly, the corner that displayed the greatest
aggregatory response was corner C, the group representing subjects with low blood
pressure whose parents have low blood pressure. The least aggregatory response was
seen in the subjects from corner A, the group representing subjects with high blood
pressure from parents with low blood pressure. This would suggest that in vitro
platelet responsiveness to adrenaline can be determined by the subject's blood
pressure and is not dependent on parental blood pressure. Study 2 also demonstrated
a difference between the four corners on the potentiation of primary aggregation by
ET-1. Corner B was the only group that displayed a significant potentiation of
adrenaline induced aggregation. The fact that corner A did not show a significant
potentiation suggests that this effect is not related to high blood pressure per se but
possibly to a genetic element of raised blood pressure. In addition, the dose response
to adrenaline was similar for these two corners reinforcing the proposition that the
effect is ET-1 dependent.
The fact that subjects from corner C displayed the greatest aggregatory response to
adrenaline was an unexpected finding. Some studies which have examined the
relationship between platelet aggregation and blood pressure would suggest that
increased blood pressure would be associated with increased platelet activation. A
study which examined the relationship between platelet free calcium and blood
pressure found that the two factors were positively correlated in both hypertensive
and normotensive subjects (Erne et al., 1984). In addition, Brodie reported a positive
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correlation between mean arterial pressure and adrenaline-induced platelet
aggregation (Brodde et al., 1985). However, in this latter study they found that some
hypertensive patients had normal responses while others had increased responses,
and they suggested that the degree of hypertension was an important factor. Many
factors that are associated with increased vascular resistance are also associated with
increased platelet activation, as discussed in chapter 1. However, the exception to
this rule may be cyclooxygenase activity.
In the vasculature, the predominant result of cyclooxygenase activity is the
production of the vasodilator prostacyclin. Conversely, in the platelets the main
active products, such as thromboxane A2, are pro-aggregatory. Although this is
speculation, it may have been interesting to examine cyclooxygenase activity in
these subjects. From this work it is not possible to know whether the effects
observed are due to differences specifically related to adrenaline, such as 0C2 receptor
density, or platelet responsiveness in general. It would, therefore have been useful to
have employed more than one platelet aggregating agent. Additionally, measurement
of in vivo markers of platelet activation such as thromboxane B2, the stable
metabolite of thromboxane A2 and PGF2a, the metabolite of prostacyclin, would
have helped identify both the in vivo activity of platelets and endothelial
cyclooxygenase activity.
The two studies presented in this chapter were designed to examine the effect of
blood pressure and essential hypertension on endothelin modulation of platelet
aggregation and the possible role of platelet aggregation on the development of high
blood pressure. There is however, an apparent inconsistency in the results obtained.
In study 1 both groups showed potentiation of adrenaline-induced primary
aggregation by endothelin-1, whereas in study 2 only 1 of the 4 corners
demonstrated potentiation. An important element here is that the subjects in study 2
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do not have hypertension and the data may reflect variability in the effect of
endothelin-1 observed with healthy control subjects in previous chapters. Although
study 2 was designed to study differences between the 4 corners, it is worth noting
that when the effect of ET-1 on adrenaline-induced primary aggregation is calculated
for all four corners together as a single population a significant potentiation is seen.
In addition to this the subjects studied and the precise method employed in the
preparation of the plasma were different. Study 1 used subjects of both sexes with
ages as high as 63 years whereas in study 2 the subjects were young males. In study
1 PRP was prepared by centrifugation at 120 g for 10 min, in keeping with the
methods used in studies reported in previous chapters, whereas in study 2 PRP was
prepared by centrifugation at 800 g for 5 min. This difference was due to the fact that
in study 2 the plasma was prepared for use in a number of different studies. The
result is that denser, and potentially more active platelets may not have been
collected. Consequently, although comparisons within the studies remain valid,
comparisons between the two studies may be inappropriate. It would have been
useful if platelet size profiles had been carried out in plasma prepared by
centrifugation at 800 g for 5 min and compared with those obtained by
centrifugation at 120 g for 10 min.
Where study 1 was designed to examine and compare platelet responses between
subjects with established hypertension with age matched controls, study 2 was
designed to look at subjects who possibly had a familial predisposition to
hypertension, corner B, compared to those who may be predisposed to hypertension
by simply having raised blood pressure, corner A. Consequently, the hypertensive
subjects involved in study 1 are probably a heterogeneous population involving
subjects with a clear familial predisposition and those without (that is a combination
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of individuals who would fall into corner A and B). It is also possible that sustained
raised blood pressure may itself cause altered platelet activity.
From these studies it is possible to draw three conclusions. First, in essential
hypertension, a significant ET mediated inhibition of secondary platelet aggregation
is not observed. Secondly, platelets from subjects with essential hypertension have a
reduced response to SRTX S6c mediated increase in platelet cyclic GMP. Thirdly,
potentiation of adrenaline-induced primary aggregation occurs in subjects who are
predisposed to hypertension by virtue of raised blood pressure and familial factors
but not in those with raised blood pressure alone, suggesting a genetic component to




Age (years) 48 + 3 48 + 3
Sex (M:F) 7:3 7:3
Blood Pressure (mm Hg)
Systolic 119 ± 3 172 + 5
Diastolic 74 + 3 105 ± 1
Table 8.1a Data for subjects in study 1
Corners A B C D
Age (years) 28 ±1 29 ± 1 30 ± 1 28 ± 1
Sex (M:F) 11:0 11:0 11:0 11:0
Blood Pressure
(mm HG)
Systolic 117 ± 2 118 + 3 112 + 2 108 ± 1
Diastolic 76 ± 1 80 ±2 72 ±2 72 ± 1
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Figure 8.3 The effect of ET-1 on adrenaline-induced primary aggregation in
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Figure 8.4 The effect of ET-1 on adrenaline-induced secondary aggregation in


















Figure 8.5 The effect of adrenaline on platelet cyclic GMP concentrations in






















Figure 8.6 The effect of ET-1 on platelet cyclic GMP concentrations
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Figure 8.7 The effect of SRTX S6c on platelet cyclic GMP concentrations


























Figure 8.8 Aggregatory response to adrenaline in samples from the 4 corners of



















Figure 8.9 The effect of ET-1 (1 nM) on adrenaline-induced primary and secondary
aggregation in the 4 corners of study 2. Adrenaline-induced primary aggregation
(M), the same concentration of adrenaline in the presence of ET-1 (%%) Adrenaline-
induced secondary aggregation (IB), the same concentration of adrenaline in the





In the introduction to this Thesis three main aims were set out: to establish whether
ET-1 acts directly on human platelets, to characterise the receptors involved, and to
investigate the actions of ET-1 on platelets in diseases where ET-1 is thought to have
a pathophysiological role. These aims were largely fulfilled in the experiments
described in chapters 3 to 8.
In chapter 3, investigative studies were described and a number of conclusions were
reached. ET-1 alone caused a slight but statistically significant aggregation of
platelets, which in isolation is unlikely to be of any substantial biological
significance. Perhaps of more physiological importance, ET-1 modulated the actions
of adrenaline but not ADP, potentiating primary aggregation and inhibiting
secondary aggregation. The ET-1-mediated potentiation of adrenaline-induced
primary aggregation was consistently significant in all three studies described in this
chapter. However, the inhibition of aggregation only achieved statistical significance
in one of the two studies in which it was examined. From this it appeared that the
pro-aggregatory effect of ET-1 was specific to the aggregating agent used. However,
other 'weak' agonists that are reported to produce a quantifiable primary phase of
aggregation were not studied and it would be inappropriate on the evidence to
conclude that the potentiating effects of ET-1 are specific to adrenaline. Other 'weak'
physiologically important agonists that could have been studied include angiotensin
II and serotonin. However, in the absence of another aggregating agent angiotensin
II does not appear to cause platelet aggregation and the extent of serotonin-induced
aggregation was so low that it was, at this time, not considered a useful agent to use
in these preliminary studies. Further work might consider the interactions of one or
more of these modulators of platelet aggregation. As described in chapter 1
secondary aggregation to agonists such as adrenaline and ADP is dependent on a
positive feedback mechanism involving amplification of the original signal and the
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release of platelet granules. Possible differences between ADP and adrenaline
induced aggregation are discussed below.
The receptor mediating the pro-aggregatory effect of ET-1 was characterised in the
studies described in chapter 4. Adrenaline-induced primary aggregation was
significantly potentiated by the non-selective receptor agonist, ET-1 and the ETb
selective agonist SRTX S6c. The response to both ET receptor agonists appeared to
vary within the subject group and, although not statistically different, SRTX S6c
appeared to have a greater effect than ET-1. Both of these trends were also observed
in studies described in other chapters. The pro-aggregatory effect of ET-1 was
inhibited by the ETb antagonist, BQ-788, but not the ETa antagonist BQ-123. From
these results it was concluded that, the pro-aggregatory effect of ET-1 on human
platelets was primarily mediated by the ETb receptor.
In the antagonist studies described in chapter 4 only samples where a potentiation of
aggregation by ET-1 was observed were used. Although the number of subjects
studied was not large enough to establish a bimodal distribution of response, where
potentiation was observed it was seen to be reproducible. It was thought that
including all subjects, where the mean potentiation to ET-1 though significant was
relatively small (see figure 4.1b), might have made it difficult to discern significant
inhibition by the antagonist, and therefore draw a clear conclusion.
In the studies reported in chapter 5, the effects of ET-1 and SRTX S6c on platelet
cyclic AMP and cyclic GMP were examined. Platelet cyclic AMP levels were not
significantly affected by either agonist. However, both agonists caused a dose
dependent accumulation of platelet cyclic GMP. As for studies described in chapter
4, the effect of both agonists was variable and SRTX S6c again appeared to have a
greater effect. However, as in chapter 4, there was no statistical difference between
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the effects of the two agonists. These results suggest that an ET receptor is
associated with the accumulation of platelet cyclic GMP and that this receptor is
probably of the ETb type. As these experiments were carried out in the absence of
phosphodiesterase inhibitors it is not possible to conclude whether the accumulation
of cyclic GMP is due to increased guanylate cyclase activity or decreased
phosphodiesterase activity. Nor is it possible, on the basis of the studies presented in
this chapter, to associate the change in cyclic GMP levels with a particular
directional modulation of aggregation. An increase in cyclic GMP is normally
associated with an inhibition of platelet aggregation and that might suggest that the
inhibitory actions of ET are also mediated by the ETb receptor. However, the study
reported in chapter 8 is better designed to interpret this relationship as the
modulation of platelet aggregation and the effect on platelet cyclic nucleotides were
examined together.
Platelets contain a number of intracellular second messengers, including inositol
trisphosphate (IP3) and [Ca2+]j as well as cyclic nucleotides. Other groups have
studied the effects of ET receptor agonists on both platelet [Ca2+]i and IP3.
However, there were no published reports on the effects of ET receptor agonists on
platelet cyclic nucleotide levels at the time of this work, and consequently it was
considered that this may be a valuable area to investigate. ET receptor mediated
effects on cyclic AMP depend on the tissue type or cell type studied. In cultured rat
vascular smooth muscle cells ET-1 stimulated cyclic AMP formation (Eguchi, et al.,
1993) whereas in the rat tail artery ET decreased cyclic AMP concentrations (Yang,
et al., 1991). Although our study did not detect any effect of either ET-1 or SRTX
S6c on platelet cyclic AMP levels, an interesting further study might be to examine
the effect of ET-1 in the presence of an agent known to increase platelet cyclic AMP
levels. Although, due to the putative ET receptor mediated potentiation of
adrenaline-induced aggregation, adrenaline may appear an appropriate adenylate
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cyclase activator to use, the complex nature of the effects of adrenaline on platelet
cyclic AMP, described in chapter 5, may suggest that PGEi would be a better
adenylate cyclase activator to use in the first instance.
In chapter 6 techniques were used to find supporting evidence for the existence of
specific binding sites for ET-1 on platelets in addition to the functional evidence.
First, in chapter 6, ligand binding experiments were described. The techniques were
validated by performing binding studies in tissues known to express ET receptors
and by performing binding studies with platelets using an a2 adrenergic receptor
agonist. The binding characteristics of yohimbine to platelet membranes have been
previously well documented. In addition, in view of the putative interaction between
adrenaline and ET-1 described in the other chapters of this thesis (chapters 3, 4, 7
and 8) it was seen as an appropriate positive control that might allow for further
investigation into the possible regulation of a2 adrenergic receptors by ET-1. Of the
six subjects studied in the platelet/ET binding study, two produced dose dependent
displacement of [125I]-ET-1 with increasing concentrations of cold ligand, the other
four showed no significant binding. The non-specific binding of [125I]-ET-1 to the
platelet membranes was relatively high; this could not be attributed to the ligand
alone since the non-specific binding to the cardiac membranes was approximately
half that seen in the platelets. Non-specific binding of [3H]-yohimbine to platelet
membranes approached zero.
It would, perhaps, have been useful to have had access to non-radioactive I-ET-1 to
use in competition with [125I]-ET-1 to assess whether this would have resulted in
less non-specific binding. Alternatively, another peptide agonist to platelets could
have been used as a positive control, such as angiotensin II. As discussed in chapter
6 many of the ligand binding studies with angiotensin II used whole platelet
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preparations rather than platelet membranes, as studied here. The two platelet
membrane preparations that did show dose-dependent displacement of [I25I]-ET-1
by unlabelled ET-1 gave Kqjs of the same order of magnitude as seen with [125I]-ET-
1 in the rat heart preparations.
In chapter 6 the results of RT-PCR studies were also reported. As in the ligand
binding studies this gave inconclusive results because platelet preparations from
some individuals did not appear to possess mRNA for ET receptors. Since platelets
are anucleate the source of mRNA in platelets is assumed to have come from the
parent megakaryocyte. The factors that control the quantity of residual platelet
mRNA are not well understood, and the absence of platelet mRNA should not be
taken to mean that platelets do not express the receptor. The fact that samples from
only some individuals appeared to contain ET receptor mRNA may reflect inter-
individual differences in receptor expression but may also reflect differences in other
factors, such as RNase activity for example.
In vitro work from a few authors (discussed below) has produced evidence for a
direct effect of ET-1 on human platelets. However, ex vivo studies in animals have
suggested that the predominant influence of ET-1 on platelets is indirect and a result
of endothelium derived prostanoids. Early studies established interspecies
differences in platelet responses to ET-1 (Ohlstein, et al., 1990). In chapter 7 this
issue was addressed by comparing the results of ex vivo and in vitro studies in
humans. In addition to assessing the role of the endothelium this study also afforded
the opportunity to investigate any effect of other blood cells. In vivo exposure to
exogenous ET-1 resulted in inhibition of adrenaline, but not ADP induced secondary
aggregation. No significant effect was observed on primary aggregation. In vitro
studies using a concentration of ET-1 estimated to be approximately the same as that
achieved in vivo (0.1 nM) produced similar results. This study was designed to limit
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the effect of endothelium derived prostacyclin, and supported the proposition that
ET-1 can act directly on human platelets.
The third aim outlined in chapter 1, to investigate the actions of ET-1 on platelets in
diseases where ET-1 is thought to have a pathophysiological role, was addressed in
chapter 8. Chapter 8 described two studies; one to examine the effects of ET-1 and
SRTX S6c on platelet aggregation and cyclic nucleotide levels in patients with
essential hypertension and one to investigate whether altered platelet reactivity to ET
is secondary to hypertension or possibly involved in its aetiology. In this latter study
a group was studied in whom predisposition to high blood pressure has been defined
on the basis of their own blood pressure and the blood pressure of their parents. In
the study of essential hypertension ET-1 caused a significant inhibition of secondary
platelet aggregation in the control group but not in the hypertensive subjects.
However, although there was not a significant difference between the groups in the
secondary aggregation to adrenaline alone, it did tend to be higher in the control
group and this may have contributed to the significant effect of ET-1 in this group.
In addition, subjects with essential hypertension showed a reduced cyclic GMP
response to SRTX S6c, compared to the controls. The stimulation of platelet cyclic
GMP does not appear to be causally linked to ET-1 inhibition of platelet
aggregation, because ET-1 inhibited platelet aggregation in the control group at 10~8
M without significantly affecting platelet cyclic GMP levels.
In the study which investigated the effect of ET-1 on platelet aggregation in subjects
with a predisposition to hypertension, significant potentiation of primary aggregation
only occurred in subjects with blood pressure in the upper tertile and parental blood
pressure in the upper tertile. This result suggests that there is a genetic component to
increased sensitivity to ET-1 in subjects with a predisposition to hypertension, and
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that increased platelet sensitivity to ET-1 may contribute to the development of
hypertension.
There were two trends that appeared repeatedly throughout the work described in
this thesis. The first was a large inter-individual variation in the effects of ET-1 on
platelets. Reproducibility of platelet aggregation studies depend on a number of
factors such as concentration of sodium citrate, storage time, temperature and stirring
speed. The protocol for aggregation studies was maintained throughout all the
studies reported in this Ph.D. project (with the exception of study 2 in chapter 8,
which was amended as specified), and hence all conditions both within studies and
between studies were constant. Some researchers standardise platelet number for all
samples, to reduce variability. However, this was not done in the work of this thesis
in order to reflect that variability and not to exclude subjects with a lower platelet
number yet still within the normal range.
Marked inter-individual variability within studies (with, presumably, standardised
protocols) has been reported for a number of platelet aggregating agents, including
vasopressin (Roos et al., 1986), ADP (Arkel, et al., 1977) and adrenaline (Siess,
1989). Furthermore, Vittet reported variability in platelet cyclic AMP regulation and
proposed that two separate groups of healthy platelet donors could be distinguished
on the basis of adenylate cyclase activity (Vittet et al., 1988). It had been suggested
that the variable platelet responses to adrenaline were due to the balance between
two adrenaline activated receptors with conflicting actions, the a and the (3
adrenergic receptors. However, a heterogeneous response was demonstrated for an
0C2 agonist suggesting a more complex explanation (Nieuwland, et al., 1993).
Clearly, human platelets from different donors show considerable variability in their
responses and, therefore, variability in their responses to ET-1 is not novel.
However, from the results of chapter 8 it appears that a possible bimodal distribution
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of platelet responses and possibly platelet receptor expression for ET-1 may be in
part associated with a genetic factor linked to a predisposition to high blood
pressure.
The second trend that was observed in a number of the studies within this thesis was
the apparently greater response to SRTX S6c than to ET-1. Although this difference
was not statistically significant, it was observed in the aggregation study reported in
chapter 4, and the cyclic nucleotide studies in chapter 5 and 9, and should therefore
be given some consideration. As discussed above, it does not appear that the ET
mediated rise in cyclic GMP is related to the ET mediated inhibition of secondary
aggregation. It could, in fact, be related to the ET mediated potentiation of
adrenaline-induced primary aggregation. It has been proposed that platelet
aggregating agents can stimulate platelet NO synthase and consequently increase
platelet cyclic GMP (Radomski, et al., 1990). Although there is no direct evidence
for ET-1 stimulation of platelet NO synthase, the report by Radomski establishes
that there is a precedent for pro-aggregatory agents stimulating the inhibitory second
messenger cyclic GMP. It would appear from the results of chapters 4 and 5 that
both the ET-1 mediated potentiation of aggregation and accumulation of cyclic GMP
are mediated by the ETb receptor and the profiles depicted in figures 4.1 and 5.3 are
similar, although the active concentrations of the agonists in the two studies are
different. However, although the apparently greater effect of SRTX S6c in
potentiating aggregation and causing an accumulation of cyclic GMP may be due to
the same mechanism, this is not proven and it is possible that they may be purely
coincidental.
The apparently greater effect of SRTX S6c could be mediated at any one of several
different stages; availability of agonist to the receptor, multiple receptor involvement
or post-receptor regulation. The possibility that differential enzymatic degradation of
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the peptides might be responsible was discussed in chapter 5, and does not appear to
be a likely explanation for the different magnitude of the effects of ET-1 and SRTX
S6c. Another possibility is that the effects are being mediated by more than one
receptor. If ETa receptor mediated responses were acting in opposition to ETb
receptor mediated responses, to create an equilibrium, it would be possible that the
ETa receptor was mediating an inhibition of aggregation and of cyclic GMP
accumulation, and thus limiting the observed effect of ET-1 compared to that of
SRTX S6c. However, if this were the case one would expect that ETa antagonism
by BQ-123 would increase the potentiation of aggregation by ET-1. This was not
observed when this experiment was performed, as can be seen in figure 4.3. If,
alternatively, the proposed ETc receptor was a second receptor type present on
platelets, and mediating potentiation of aggregation and accumulation of cyclic GMP
this would support a greater effect of SRTX S6c. It is difficult, however, to
formulate a priori reasoning for this latter argument unless an endogenous agonist
for the ETc receptor, such as ET-3, was involved in the regulation of platelet
activity.
The third possibility is that there is different post-receptor modulation of the
responses to the two agonists. In 1994 Shraga-Levine demonstrated that sarafotoxins
and ETs stimulated cyclic GMP production in the rat cerebellum via the ETb
receptor (Shraga-Levine et al., 1994). However, the mechanisms responsible for the
increase in cyclic GMP were different. ETs stimulated NO production, which
resulted in the rise in cyclic GMP, but the increase in cyclic GMP by sarafotoxins
was a result of carbon monoxide production. To explain this he proposed that there
might be ligand selective coupling of the ETa receptor to specific G proteins. To test
this in the platelet it would first be necessary to identify at least one of the pathways
that result in either the ETb mediated accumulation of platelet cyclic GMP or the
ETb mediated potentiation of aggregation.
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Before considering the implications of the work presented in this thesis it would be
useful to consider the published results of other groups concerning the effects of ETs
and other ET receptor agonists on platelets. In general two types of studies have been
performed, in vivo/ex vivo and in vitro . All of these studies are discussed in some
detail in the following paragraphs. The in vivo and ex vivo studies involved the
introduction of the ET receptor agonists, either by bolus or continuous infusion, into
whole animals, and consequently the effect of other endothelium derived platelet
modulators, such as prostacyclin and NO, are also brought into play. All of these
studies were performed in animals and the majority by the same research group. In
vitro studies have investigated the effect of ET receptor agonists on platelets in the
absence of the vascular endothelium, and, consequently, these studies may be better
designed to investigate the direct effects of the agonists on platelets. Studies of this
type have been performed using platelets form humans and animals.
The in vivo and ex vivo studies are fewer in number, have generally studied similar
parameters, and appear more consistent in their findings. In 1989, three papers were
published which concluded that ET-1 and ET-3 inhibited ex vivo aggregatory
responses in rabbits and dogs, and that this antiaggregatory effect was mediated by
prostacyclin (Herman, et al., 1989; Lidbury, et al., 1989; Thiemermann, et al.,
1989). However, Thiemermann also observed a delayed antiaggregatory effect of
ET-1 that was not blocked by cyclooxygenase inhibition. The following year
Thiemermann published a report on the effect of ET-1 on in vivo platelet aggregation
in rabbits, where he showed an inhibition of ADP-induced platelet aggregation, by
the release of 'an anti-aggregatory cyclooxygenase product' (Thiemermann et al.,
1990). Finally, three publications in 1993 suggested that the ex vivo anti-aggregatory
effect of ET-1 was mediated by the ETb receptor (Herman, et al., 1993; McMurdo et
al., 1993a; McMurdo et al., 1993b). All these studies used systemic concentrations
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of agonists and, as stated above, were performed in animals. This is in contrast to the
study reported in chapter 7 of this thesis which used a locally acting concentration of
ET-1 in man.
The publications that have reported in vitro studies have examined a variety of
parameters in platelets from animals, healthy human subjects, patients with
hypertension and patients with chronic renal failure. The results obtained are more
disparate than those obtained from the ex vivo studies, this appears to be due to a
greater variety of experimental conditions. Many of the early studies, those up to
1992, found little evidence for a direct effect of ET-1 on human platelets either alone
or in combination with other aggregating agents (Edlund & Wennmalm, 1990;
Joseph et al., 1991; Ohlstein, et al., 1990; Patel, et al., 1989). The aggregating agents
studied were generally ADP and thrombin, but Ohlstein also studied collagen and
adrenaline. However, although Ohlstein and colleagues did not observe any effect in
human platelets, they did report a pro-aggregatory effect of ET-1 on ADP-induced
aggregation in rabbit platelets indicating inter-species differences in platelet
responses to ET-1. In contrast to these other reports, Matsumoto described a pro-
aggregatory effect of ET-1 on human platelet aggregation induced by sub threshold
concentrations of adrenaline (Matsumoto, et al., 1990). Although not all publications
give a complete description of the methods employed, the main difference between
the study performed by Matsumoto and the others appears to be the length of time
over which the aggregatory response was studied. Matsumoto studied the course of
aggregation for 10 min, whereas the others, where specified, used 5 min or less.
In 1992-93 a number of groups reported an inhibitory effect of ET-1 on in vitro
platelet aggregation and [Ca2+]j mobilisation (Astarie-Dequeker, et al., 1992; Takada
& Takada, 1992; Touyz & Schiffrin, 1993b). Pietraszek and colleagues proposed
that the length of time between the ET challenge and challenge with the aggregating
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agent determined whether a pro-aggregatory or an antiaggregatory effect was
observed (Pietraszek et al., 1992). He found that ET-1, 2 or 3 could potentiate
serotonin responses in platelets when added at or about the same time, but when pre-
incubated with the platelets before the addition of serotonin, the ETs inhibited the
response. This time-dependent pattern of response is similar to that observed for
protein kinase C (Siess, 1989).
In 1995 further work investigated the mechanisms of ET receptor mediated
modulation of platelet aggregation. ET-3 inhibited [Ca2+]j mobilisation by thrombin
and thromboxane A2 but not by ADP (Astarie-Dequeker, et al., 1995), providing a
possible explanation for the absence of ET receptor mediated inhibition of ADP
induced secondary aggregation observed in chapters 3 of this thesis. Inhibition of
protein kinase C limited the ET-1 inhibition of thrombin-induced aggregation and of
the thrombin-induced rise in [Ca2+]j (Touyz & Schiffrin, 1995) suggesting that
activation of protein kinase C may occur at an early stage of ET-1 stimulation. The
mechanism for potentiation of aggregation was investigated by Halim and
colleagues, who demonstrated that in single adherent platelets ET-1 induced
oscillations in [Ca2+]i and in washed platelet preparations ET-1 induced inositol
trisphosphate production (Halim et al., 1995). Platelet NO synthase is Ca2 +
dependent, and the [Ca2+]i oscillations described by Halim and colleagues could
provide a mechanism for the increased cyclic GMP observed in chapter 5 of this
thesis, which would be consistent with a rise in cyclic GMP being associated with a
pro-aggregatory response. However, the precise implications of Halim's study are
difficult to discern. Although it demonstrates the ability of ET-1 to evoke a rise in
[Ca2+]i and IP3 formation, it does so in platelets treated with aspirin and
prostaglandin Ei. It is not clear, therefore, what role these particular intracellular
signalling mechanisms would have in mediating platelet aggregatory responses to
ET-1.
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Whole blood aggregation studies using ET-1 may involve more complex
mechanisms. ET-1 has been shown to have a pro-aggregatory effect on platelets in
whole blood due to increased production of platelet activating factor by neutrophils
(Lopez-Farre et al., 1991). Hence, the ET-1 potentiation of ADP-induced
aggregation described by Knofler (Knofler et al., 1995) and the increased
potentiation of ADP-induced aggregation observed in patients with chronic renal
failure (Heintz et al., 1994) may not be associated with the direct action of ET-1 on
platelets, as both these studies were performed in whole blood.
The work presented in this thesis is consistent with the findings of Matsumoto, that
ET-1 can potentiate adrenaline-induced platelet aggregation in at least some
individuals (Matsumoto, et al., 1990) and has shown that this potentiating effect of
ET-1 is dose dependent and mediated by the ETb receptor. It also supports the
findings of other workers who showed a direct inhibitory action mediated by ET
receptors on human platelets and has been able to discriminate between the two
opposing effects by studying the functionally and temporally, distinct phases of
primary and secondary aggregation. It would appear that ET-1 can modulate platelet
aggregation. Plasma concentrations of ET-1, as measured in the study reported in
chapter 7, are low at around 2.5 pM, and therefore, it is unlikely that ET-1 acts to
regulate basal platelet activity. As the primary function of platelets is to respond to
localised areas of damage, it would be more likely for a modulator of platelet
activation to have raised levels at or around sites of damage rather than raised
systemically.
In 1991 Ohlstein demonstrated that quiescent platelets could stimulate ET-1
synthesis from cultured bovine artery endothelial cells and human umbilical vein
endothelial cells (Ohlstein, et al., 1991). It would, therefore, appear possible that the
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consequent ET-1 release may act to restrict platelet aggregation. Alternatively, if an
increase in plasma ET-1 were to occur coincidentally with increased adrenaline or
serotonin, as may occur during ischaemic attack the result may be an increase in
platelet aggregation contributing to vasospasm or vessel occlusion.
There is clearly a theoretical role for an agent that might contribute to the formation
of platelet aggregates at site of damage but limit the extent of aggregation in order to
prevent unnecessary vessel occlusion and excessive release of growth factors.
However, if the balance of anti- and pro-aggregatory effects were altered the said
agent might contribute to disturbances of blood flow and an increase in shear stress
by encouraging repeated platelet aggregation and disaggregation. Alternatively, if
the inhibitory mechanisms were absent, as observed in patients with essential
hypertension (chapter 8), the same agent might contribute to pathological vasospasm
by contributing to the release of platelet derived vasoactive substances such as
serotonin and thromboxane A2.
The preceding paragraphs speculate on a possible role for ET-1 in platelets in health
and disease. However, it requires less speculation when considering the results of
chapter 8 to envisage possible clinical implications of the results contained within
this thesis. ET receptor mediated responses were altered in subjects with a genetic
predisposition to high blood pressure and in patients with established hypertension.
In neither of these groups was the effect of adrenaline alone altered suggesting that
the effects observed were not simply a generalised increase in the reactivity of
platelets due, for example, to higher resting [Ca2+]j. In the case of the hypertensive
subjects the ETb mediated rise in cyclic GMP was attenuated but the pro-
aggregatory actions mediated, evidently, by the same receptor type were unaltered.
This suggests that there may be multiple signalling pathways linked to a single
receptor type and that one or more of these pathways may be altered in essential
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hypertension. If the model proposed by Pietraszek (1992), of both anti - and pro-
aggregatory effects being mediated by a single receptor type is correct, then the same
scenario is evident in the subjects with a genetic pre-disposition to high blood
pressure, where a difference was observed in the potentiation of aggregation by ET-1
but not in the inhibitory effect. The obvious question that arises is, are the aberrant
ET receptor mediated signalling pathways only involved in platelet activation or are
they important intracellular mechanisms in other cells, such as vascular smooth
muscle cells ?
Before extrapolating from the platelet to the whole vascular system, further work
remains to be carried out in order to completely characterise the effects of ET-1 on
human platelets. The receptor which mediates the anti-aggregatory actions of ET-1
in vitro remains to be characterised. Both Astarie-Dequeker and Pietraszek suggested
equal efficacy of all three ET peptides for the inhibitory actions, this would imply
that the effect is ETb mediated (Astarie-Dequeker, et al., 1992; Pietraszek, et al.,
1992). However, there do not appear to be any published studies reporting the effects
of selective antagonists. There also remains the findings of Touyz of a BQ-123
sensitive pH effect of ET-1 in human platelets (Touyz & Schiffrin, 1993b).
The precise second messengers mediating the effects of the ETs are not been well
established. Although a number of groups have produced evidence for ET receptor
agonists altering second messenger systems (including chapter 5 of this thesis), only
Touyz has demonstrated inhibition of a specific intraplatelet pathway and an
attenuation of the effect of ET-1 on platelet aggregation pharmacologically (Touyz
& Schiffrin, 1995). Even in these experiments the effects of ET-1 were not
completely abolished by protein kinase C inhibition. It is not known whether protein
kinase C is activated directly or as a result of the formation of diacyl glycerol, or
which isoform of the kinase is involved. There are a number of protein kinase C
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enzymes in platelets (Wang et al., 1993), and the identification of the precise
enzyme and the evaluation of its translocation would help considerably in
elucidating the intracellular mechanism for ET-1 in platelets.
In conclusion, the work presented in this thesis was designed to test the hypotheses
set out in chapter 1. These hypotheses were that; ET-1 can both potentiate and
inhibit platelet aggregation by acting on specific platelet surface receptors and that
the pro-aggregatory and inhibitory effects are mediated by different ET receptors,
furthermore that in essential hypertension the action of ET-1 on platelets may relate
to the pro-aggregatory state of platelets in this condition. ET-1 was shown to
modulate platelet aggregation in a biphasic manner. The potentiation was shown to
be mediated by the ETb receptor. However, the receptor which mediated the
inhibitory actions of ET-1 was not characterised, and hence it was not established
whether the opposing actions are mediated by different receptors or not. In essential
hypertension the ET-1 mediated inhibition of aggregation observed in normal
controls was absent, consequently the altered response to ET-1 on platelets may
relate to the pro-aggregatory state of platelets in hypertension. Furthermore, the
potentiation of platelet aggregation by ET-1 may be associated with a genetic
predisposition to high blood pressure.
199
REFERENCES
Affolter, H. & Pletscher, A. (1982). Rheo-optical shape analysis of human blood
platelets. Thrombosis and Haemostasis, 48, 204-207.
Anggard, E., Galton, S., Rae, G., Thomas, R., McLoughlin, L., De Nucci, G. &
Vane, J. R. (1989). The fate of radioiodinated endothelin-1 and endothelin-3 in the
rat. J Cardiovasc Pharmacol, 13, s46-s49.
Arai, H., Hori, H., Aramori, I., Ohkubo, H. & Naknishi, S. (1990). Cloning and
expression of a cDNA encoding an endothelin receptor. Nature, 348, 730-732.
Aramori, I. & Nakanishi, S. (1992). Coupling of two endothelin receptor subtypes to
differing signal transduction in transfected Chinese hamster ovary cells. J Biol
Chem, 267, 12468-12474.
Arkel, Y. S., Haft, J. I., Kreutner, W., Sherwood, J. & Williams, R. (1977).
Alteration in second phase platelet aggregation associated with emotionally stressful
activity. Thrombos. Haemostas., 38, 552-561.
Armstrong, R., Jones, R. & Wilson, N. (1983). Ligand binding to thromboxane
receptors and on human platelets: Correlation with biological activity. Br. J.
Pharmacol, 79, 953-964.
Astarie, C., Le Quan Sang, K. H., David Dufilho, M. & Devynck, M.-A. (1992).
Further investigation of platelet cytosolic alkalinisation in essential hypertension. J
Hypertension, 10, 849-854.
Astarie-Dequeker, C., Iouzalen, L., David-Dufilho, M. & Devynck, M.-A. (1992). In
vitro inhibition by endothelins of thrombin-induced aggregation and Ca2+
mobilization in human platelets. Br J Pharmacol, 106, 966-971.
Astarie-Dequeker, C., Korichneva, I. & Devynck, M.-A. (1995). Different effects of
endothelin-3 on the Ca2+ discharge induced by agonists and Ca2+-ATPase inhibitors
in human platelets. Br J Pharmacol, 114, 524-530.
201
Baker, P., Broughton Pipkin, F. & Malcolm Symonds, E. (1991). Platelet
angiotensin II binding sites in normotensive and hypertensive women. British
Journal ofObstetrics and Gynaecology, 98, 436-440.
Baldassare, J. J., Henderson, P. A., Burns, D., Loomis, C. & Fisher, G. J. (1992).
Translocation of protein kinase C isozymes in thrombin-stimulated human platelets.
J Biol Chem; 267,15585-15590.
Baumgartner, H. R. & Born, G. V. (1968). Effects of 5-hydroxytryptamine on
platelet aggregation. Nature, 218, 137-141.
Berridge, M. (1991). Cytoplasmic calcium oscillations: A two pool model. Cell
Calcium, 12, 63-72.
Berridge, M. (1993). A tale of two messengers. Nature, 365, 388-389.
Bhagyalakshmi, A. & Freangos, J. (1989). Mechanisms of shear-induced
prostacyclin production in endothelial cells. Biochem Biophys Res Commun, 158,
31-37.
Blockmans, D., Deckmyn, H. & Vermylen, J. (1995). Platelet activation. Blood
Reviews, 9, 143-156.
Bode-Boger, S. M., Boger, R. H., Creutzig, A., Tsikas, D., Gutzki, F.-M., Alexander,
K. & Frolich, J. C. (1994). L-arginine infusion decreases peripheral arterial
resistance and inhibits platelet aggregation in healthy subjects. Clin Sci, 87, 303-310.
Born, G. V. R. (1962). Aggregation of blood platelets by adenosine diphosphate.
Nature, 194, 927-929.
Boulanger, C. & Luscher, T. F. (1990). Release of endothelin from the porcine aorta.
Inhibition of endothelium-derived nitric oxide. J Clin Invest, 85, 587-590.
Brodde, O. E., Stuka, N., Demuth, V., Fesel, R., Bergerhausen, J., Daul, A. & Bock,
K. D. (1985). Alpha and beta-adrenoceptors in circulating blood cells of essential
hypertensive patients: increased receptor density and responsiveness. Clin Exp
Hyper-Theory Practice, 7, 1135-1150.
202
Brosens, I., Robertson, W. & Dixon, H. (1972). The role of the spiral arteries in the
pathogenesis of preeclampsia. Obstet Gynecol Ann; 1, 177-191.
Brown, C. M., MacKinnon, A. C., McGrath, J. C., Spedding, M. & Kilpatrick, A. T.
(1990). Heterogeneity of a2-adrenoceptors in rat cortex and not human platelets can
be defined by 8-OH-DPAT, RU 24969 and methysergide. Br. J. Pharmacol, 99, 481 -
486.
Biihler, F. & Resink, T. (1988). Platelet membrane amd calcium control
abnormalities in essential hypertension. Am J Hypertens, 1, 42-46.
Cadwgan, T. M. & Benjamin, N. (1993). Evidence for altered platelet nitric oxide
synthesis in essential hypertension. J Hypertens, 11, 417-20.
Cheung, Y.-D., Barnett, D. B. & Nahorski, S. R. (1982). 3[H]Rauwolscine anh
3[H]yohimbine binding to rat cerebral and human platelet membranes: possible
heterogeneity of a2-adrenoceptors. Eur J Pharmacol, 84, 79-85.
Chiang, T. M. (1994). Activation of phospholipase D in human platelets by collagen
and thrombin and its relationship to platelet aggregation. Biochimica et Biophysica
Acta, 1224, 147-155.
Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA isolation and
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 162,
152-159.
Clare, K. A., Scrutton, M. C. & Thompson, N. T. (1984). Effects of (^-adrenoceptor
agonists and of related compounds on aggregation of, and on adenylate cyclase
activity in, human platelets. Br. J. Pharmacol, 82, 467-476.
Clarke, J. G., Benjamin, N., Larkin, S. W., Webb, D. J., Davies, G. J. & Maseri, A.
(1989). Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol,
257, H2033-H2035.
Clozel, M., Breu, V., Burri, K., Cassal, J. M., Fischill, W., Gray, G. A., Hirth, G.,
Loffler, B. M., Muller, M., Neidhart, W. & Ramuz, H. (1993). Pathophysiological
203
role of endothelin revealed by the first orally active endothelin receptor antagonist.
Nature, 365, 759-761.
Clozel, M., Gray, G. A., Breu, W., Loffler, B. M. & Osterwalder, R. (1992). The
endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo.
Biochem Biophys Res Commun, 186, 876-873.
Colman, R. W. (1990). Platelet receptors. Hematology and Oncology Clinics of
North America, 4, 27-41.
Crabos, M., Bertschin, S., Buhler, F., Rogg, H., Evequoz, D., Eberhard, M. & Erne,
P. (1993). Identification of ATI receptors on human platelets and decreased
angiotensin II binding in hypertension. J Hypertens; 11, S230-S231.
Dalai, J., Sheridan, D., Bloom, A. & Henderson, A. (1980). Platelet aggregates and
coronary spasm. Lancet, ii, 1146-1147.
Davenport, A. P., Ashby, M. J., Easton, P., Ella, S., Bedford, J., Dickerson, C.,
Nunez, D. J., Capper, S. J. & Brown, M. J. (1990). A sensitve radioimmunoassay
measuring endothelin-like immunoreactivity in human plasma: comparison of levels
in patients with essential hypertension and normotensive control subjects. Clin Sci,
78, 261-264.
Davenport, A. P., O'Reilly, G. & Kuc, R. E. (1995). Endothelin ETA and ETR
mRNA and receptors expressed by smooth muscle in the human vasculature:
majority of the ETA subtype. Br J Pharmacol, 114, 1110-1116.
De Clerck, F. (1986). Blood platelets in human essential hypertension. Agents and
Actions, 18, 563-580.
de Lorgeril, M., Boissonnat, P., Mamelle, N., Martin, J.-L., Monjaud, I., Guidollet,
J., Dureau, G., Ninet, J. & Renaud, S. (1994). Platelet aggregation and HDL
cholesterol are predictive of acute coronary events in heart transplant patients.
Circulation, 89, 2590-2594.
De Nucci, G., Thomas, R., D'Orleans Juste, P., Antunes, E., Walder, C., Warner, T.
D. & Vane, J. R. (1988). Pressor effects of circulating endothelin are limited by its
204
removal in the pulmonary circulation and by the release of prostacyclin and
endothelium-derived relaxing factor. Proc Natl Acad Sci, 85, 9797-9800.
Ding, Y.-A., Kenyon, C. J. & Semple, P. F. (1984). Receptors for angiotensin II on
platelets from man. Clin. Sci., 66, 725-731.
Ding, Y. A., Kenyon, C. J. & Semple, P. F. (1985a). Regulation of platelet receptors
for angiotensin II in man. J Hypertens; 3, 209-212.
Ding, Y. A., Maclntyre, D. E., Kenyon, C. J. & Semple, P. F. (1985b). Potentiation
of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemostas;
54,717-720.
Diochot, S., Vittet, D., Mathieu, M.-N., Launay, J. M. & Chevillard, C. (1992).
Effects of endothelins on the human megakaryoblastic cell line MEG-01. Eur J
Pharmacol, 221,427-431.
Dostal, D., Murahashi, T. & Peach, M. (1990). Regulation of cytosolic calcium by
angiotensin in vascular smooth muscle. Hypertension, 15, 815-822.
Douglas, S. A., Beck, G. R., Elliott, J. D. & Ohlstein, E. H. (1995). Pharmacological
evidence for the presence of three distinct functional endothelin receptor subtypes in
the rabbit lateral saphenous vein. Br. J. Pharmacol., 114, 1529-1540.
Edlund, A. & Wennmalm, A. (1990). Endothelin does not affect aggregation of
human platelets. Clin Physiol, 10, 585-590.
Eguchi, S., Hirata, Y., Imai, T. & Marumo, F. (1993). Endothelin receptor subtypes
are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in
vasculature. Endocrinology, 132, 524-529.
Eigenthaler, M., Nolte, C., Halbrugge, M. & Walter, U. (1992). Concentration and
regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one
of their major substrates in human platelets. Estimating the rate of cAMP-regulated
and cGMP regulated protein phosphorylation in intact cells. Eur. J. Biochem., 205,
471-481.
205
Elferink, J. G. R. & Dekoster, B. M. (1994). Endothelin-induced activation of
neutrophil migration. Biochem Pharmacol, 48, 865-871.
Elshourbargy, N. A., Koram, D. R., Wu, H. L., Sylvester, D. R., Lee, J. A.,
Nuthalaganti, P., Bergsma, D. J., Kumar, C. S. & Nambi, P. (1993). Molecular
characterisation and regulation of the human endothelin receptors. /. Biol. Chem.,
268, 3873-3879.
Elwood, P., Renaud, S., Sharp, D., Beswick, A., O'Brien, J. & Yarnell, J. (1991).
Ischaemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart
Disease Study. Circulation, 83, 38-44.
Emori, T., Hirata, Y., Ohta, K., Kanno, K., Eguchi, S., Imai, T., Shichiri, M. &
Marumo, F. (1991). Cellular mechanism of endothelin 1 release by angiotensin and
vasopressin. Hypertension, 18, 165-170.
Emoto, N. & Yanagisawa, M. (1995). Endothelin-converting enzyme-2 is a
membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH
optimum. J Biol Chem, 270, 15262-8.
Erne, P., Boli, P., Burgisser, E. & Buhler, F. R. (1984). Correlation of platelet
calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med, 310,
1084-1088.
Ferro, C. J. & Webb, D. J. (1996). The clinical potential of endothelin receptor
antagonists in cardiovascular medicine. Drugs, 51, 12-27.
Filep, J. G., Battistini, B., Cote, Y. P., Beaudoin, A. R. & Sirois, P. (1991). Sirois, P.
Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells.
Biochem Biophys Res Commun, 177, 171-176.
Flores, N. & Sheridan, D. (1994). The pathophysiological role of platelets during
myocardial ischaemia. Cardiovasc Res, 28, 295-302.
Fostermann, U., Miigge, A., Alheid, U., Haverich, A. & Frolich, J. (1988). Selective
attenuation of endothelium-mediated vasodilatation in atherosclerotic human
coronary arteries. Circ Res, 62, 185-190.
206
Fujitani, Y., Ueda, H., Okada, T., Urade, Y. & Karaki, H. (1993). A selective agonist
of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric
oxide formation in rat aorta. J Pharmacol Exp Ther, 267, 683-689.
Furchgott, R. & Zawadzki, J. (1980). The obligatory role of endothelial cells in the
realxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
Gardiner, S. M., Compton, A. M., Kemp, P. A. & Bennett, T. (1990). Regional and
cardiac haemodynamic responses to glyceryl trinitrate, acetycholine, bradykinin and
endothelin-1 in conscious rat: effects of N(G)-nitro-L-argignine methyl ester. Br J
Pharmacol, 101, 632-639.
Goodman, R. P., Little, D. M. & Wright, J. T. (1985). Inhibition of platelet
aggregation and thromboxane production by pinacidil. Prostaglandins Leukotrines
andMedicine, 19, 115-122.
Goto, K. Y., Kasuya, Y., Matsuki, N., Takuwa, Y., Kurihara, H., Ishikawa, T.,
Kimura, S., Yanagisawa, M. & Masaki, T. (1989). Endothelin activates the
dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth
muscle. Proc. Natl. Acad. Sci., 86, 3915-3918.
Grant, J. & Scrutton, M. (1979). Novel alpha2-adrenoceptors primarily responsible
for human platelet aggregation. Nature, 277, 659-661.
Greutter, C., Barry, B., McNamara, D., Greutter, D., Kadowitz, P. & Ignarro, L.
(1979). Relaxation of bovine coronary artery and activation of coronary arterial
guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J
Cyclic Nucleotide Res, 5, 211-224.
Griendling, K. K., Tsuda, T. & Alexander, R. W. (1989). Endothelin stimulates
diacylglycerol accumulation and activates protein kinase C in cultured vascular
smooth muscle cells. J Biol Chem, 264, 8237-8240.
Grover, G. J., Dzwonczyk, S. & Parham, C. S. (1993). The endothelin-1 receptor
antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and
reperfusion. Cardiovasc Res, 27, 1613-1618.
207
Gu, X.-H., Liu, J. J., Dillon, J. S. & Nayler, W. G. (1989). The failure of endothelin
to displace bound, radioactively labelled, calcium antagonists (PN 200/110, D888
and diltiazem). Br. J. Pharmacol., 96, 262-264.
Halim, A., Kanayama, N., El Maradny, E„ Machara, K., Hirano, M., Kobayashi, T.
& Terao, T. (1995). Endothelin-1 evoked an increase and oscillations in cytosolic
calcium concentration in adherent single human platelets and increased GMP-140
(p-selectin) in platelet suspension. Thromb Res, 80, 105-112.
Haller, H., Oeney, T., Hauck, U., Distler, A. & Philipp, T. (1989). Increased
intracellular free calcium and sensitivity to angiotensin II in platelets of preeclamptic
women. Am J Hypertens, 2, 238-243.
Hamroun, D., Mathieu, M.-N., Clain, E., Germani, E., Laliberte, M.-F., Laliberte, F.
& Chevillard, C. (1995). Expression of endothelin and ETg receptors in the
megakaryoblastic MEG-01 cell line. J Cardiovasc Phannacol, 26, S156-S158.
Hashimoto, Y., Togo, M., Tsukamoto, M. T. K., Horie, Y., Watanabe, T. &
Kurokawa, K. (1994). Protein kinase C-dependent and -independent mechanisms of
dense granule exocytosis by human platelets. Biochimica et Biophysica Acta, 1222,
55-62.
Haslam, R. J. & Taylor, A. (1971). Effects of catecholamines on the formation of
adenosine 3':5'-cyclic monophosphate in human platelets. Biochem J, 125, 377-379.
Haynes, W. G., Clarke, J. G., Cockcroft, J. R. & Webb, D. J. (1991). Pharmacology
of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol, 17, S284-S286.
Haynes, W. G., Hand, M. F., Johnstone, H., Padfield, P. L. & Webb, D. J. (1994).
Direct and sympathetically mediated venoconstriction in essential hypertension. J
Clin Invest, 94, 1359-1364.
Haynes, W. G., Noon, J. P., Walker, B. R. & Webb, D. J. (1993). Inhibition of nitric
oxide synthesis increases blood pressure in healthy humans. J Hypertens; 11, 1375-
1380.
208
Haynes, W. G„ Strachan, F. E. & Webb, D. J. (1995). Endothelin ETA and ETg
receptors cause vasoconstriction of human resistance and capacitance vessels in
vivo. Circulation, 92, 357-363.
Haynes, W. G. & Webb, D. J. (1993a). The endothelin family of peptides: local
hormones with diverse roles in health and disease? Clin Sci, 84, 485-500.
Haynes, W. G. & Webb, D. J. (1993b). Endothelium-dependent modulation of
responses to endothelin-1 in human veins. Clin Sci, 84, 427-433.
Haynes, W. G. & Webb, D. J. (1993c). Venoconstriction to endothelin-1 in humans:
role of calcium and potassium channels. Am J Physiol, 265, H1676-H1681.
Haynes, W. G. & Webb, D. J. (1994). Contribution of endogenous generation of
endothelin-1 to basal vascular tone. Lancet, 344, 852-854.
Heintz, B., Schmidt, P., Maurin, N., Kirsten, R., Nelson, K., Wieland, D. & Sieberth,
H.-G. (1994). Endothelin-1 potentiates ADP-induced platelet aggregation in chronic
renal failure. Renal Failure, 16, 481-489.
Herman, F., Magyar, K., Chabrier, P.-E., Braquet, P. & Filep, J. (1989). Prostacyclin
mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized
dogs. Br J Pharmacol, 98, 38-40.
Herman, F., Yano, M. & Filep, J. G. (1993). The in vivo antiaggregatory action of
endothelin-1 is not mediated through the endothelin ETA receptor. Eur J Pharmacol,
263, 143-146.
Heslet, E., Slidnes, T., Seljelid, R. & Konopski, Z. S. (1993). Endothelin-1
stimulates human monocytes in vitro to release TNF-alpha, IL-1 beta and IL-6.
Mediators of Inflammation, 2, 417-422.
Hickey, K., Rubanyi, G., Paul, R. & Highsmith, R. (1985). Characterization of a
coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol, 17,
550-556.
209
Hilal-Dandan, R., Merck, D. T., Lujan, J. P. & Brunton, L. L. (1994). Coupling of
type A endothelin receptor to multiple responses in adult rat cardiac myocytes. Mol
Pharmacol, 45, 1183-1190.
Huang, E. M. & Detwiler, T. C. (1987). Thrombin-induced phophoinositide
hydrolysis in platelets. Receptor occupancy and desensitization. Biochem J, 242, 11-
18.
Ignarro, L. & Kadowitz, P. (1985). The pharmacological and physiological role of
cyclic GMP in vascular smooth muscle relaxation. Ann Rev Pharmacol Toxicol, 25,
171-191.
Ihara, M., Noguchi, K., Saeki, T., Fukuroda, T., Tsuchida, S., Kimura, S., Fukami,
T., Ishikawa,-K., Nishikibe, M. & Yano, M. (1992). Biological profiles of highly
potent novel endothelin antagonists selective for the ETA receptor. Life Sci., 50,
247-255.
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. &
Masaki, T. (1989a). The human endothelin family: three structurally and
pharmacologically distinct isopeptides predicted by three different genes. Proc Natl
Acad Sci USA, 86, 2863-2867.
Inoue, A., Yanagisawa, M., Takuwa, Y., Mitsui, Y., Kobayashi, M. & Masaki, T.
(1989b). The human preproendothelin-1 gene. Complete nucleotide sequence and
regulation of expression. J Biol Chem, 264, 14954-14959.
Ishii, K., Warner, T. D., Sheng, H. & Murad, F. (1991). Endothelin increases cyclic
GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an
endothelium-derived relaxing factor-like substance. J Pharmacol Exp Ther, 259,
1102-1108.
Ishikawa, K., Ihara, M., Noguchi, K., Mase, T., Mino, N., Saeki, T., Fukuroda, T.,
Fukami, T., Ozaki, S., Nagase, T., Nishikibe, M. & Yano, M. (1994). Biochemical
and pharmacological profile of a potent and selective endothelin B-receptor
antagonitst, BQ-788. Proc. Natl. Acad. Sci. USA, 91, 4892-4896.
210
Islim, I., Beevers, D. & Bareford, D. (1992). The effect of antihypertensive drugs on
in vivo platelet activity in essential hypertension. J Hypertens; 10, 379-383.
Jappa, J. (1943). A study of the morphology and developement of the
megakaryocytes. British Journal ofExperimental Pathology, 25, 73-90.
Johansson, J. & Haynes, D. (1992). Cyclic GMP increases the rate of of the calcium
extrusion pump in intact human platelets but has no direct effect on the dense tubular
calcium accumulation system. Biochimica et Biophysica Acta, 1105, 40-50.
Johansson, J., Nied, L. & Haynes, D. (1992). Cyclic AMP stimulates Ca2+-ATPase-
9 _i_
mediated Ca extrusion from human platelets. Biochimica et Biophysica Acta,
1105,19-28.
Joseph, R., Scicli, A. G., Han, E., Grunfeld, S., Carretero, O. A. & Welch, K. M. A.
(1991). Endothelin-1 and human platelet activity. Thromb Res, 61, 529-536.
Karaki, H., Sudjarwo, S. A. & Hori, M. (1994). Novel antagonist for endothelin
ETB1 and ETB2 receptors BQ 788: effects on blood vessel and small intestine.
Biochem Biophys Res Commun, 205, 168-173.
Karne, S., Jayawickreme, C. K. & Lerner, M. R. (1993). Cloning and
characterisation of an endothelin-3 specific receptor (ETC receptor) from Xenopus
laevis dermal melanophores. J Biol Chem, 268, 19126-19133.
Kaufman, R. M., Airo, R., Pollack, S., Crosby, W. H. & Doberneck, R. (1965).
Origin of pulmonary megakaryocytes. Blood, 25, 767-775.
Kloog, Y. & Sokolovsky, M. (1989). Similarities in mode and sites of actions of
sarafotoxins and endothelins. Trends Pharmacol Sci, 10, 212-215.
Knofler, R., Urano, T., Malyszko, J., Takada, Y. & Takada, A. (1995). In vitro effect
of endothelin-1 on collagen and ADP-induced aggregation in human whole blood
and platelet rich plasma. Thromb Res, 77, 69-78.
Kon, H. (1968). Paramagnetic resonance study of nitric oxide hemoglobin. J Biol
Chem, 243, 4350-4357.
211
Kristensen, S. D. & Martin, J. F. (1991). Platelet heterogeneity and coronary artery
stenosis. Platelets, 2, 11-17.
Kroll, M. H., Heliums, J. D., Guo, Z., Durante, W., Razdan, K., Hirbolich, J. K. &
Schaefer, A. I. (1993). Protein kinase C is activated in platelets subjected to
pathological shear stress. J Biol Chem, 268, 3520-3529.
Kurihara, H., Yamaoki, K., Nagai, R., Yoshizumi, M., Takaku, F., Satoh, H., Inui, J.
& Yazaki, Y. (1989). Endothelin: a potent vasoconstrictor associated with
vasospasm. Life Sci, 44, 1937-1944.
Lam, H. C., Takahashi, K., Ghatei, M. A., Warrens, A. N., Rees, A. J. & Bloom, S.
R. (1991). Immunoreactive endothelin in human plasma, urine, milk and saliva. J
Cardiovasc Pharmacol, 17, S390-S393.
Le Quan Sang, K. H. & Devynck, M. A. (1986). Increased platele cytosolic free
calcium concentration in essential hypertension. J Hypertens, 4, 567-574.
Lechi, C., Arosio, E., Minuz, P., Guzzo, P., Paulani, F., Sinigalia, D. & Lechi, A.
(1989). Increased platelet aggregation and intracellular calcium in hypertensive
patients: effects of cyclo-oxygenase blockade. J Hypertens, 7, S160-S161.
Lee, T. S., Chao, T., Hu, K. Q. & King, G. L. (1989). Endothelin stimulates a
sustained 1,2 diacylglycerol increase and protein kinase C activation in bovine aortic
smooth muscle cells. Biochem Biophys Res Commun., 162, 381-386.
Lidbury, P. S., Thiemermann, C., Thomas, R. G. & Vane, J. R. (1989). Endothelin-3
selectivity as an anti-aggregatory peptide in vivo. Eur J Pharmacol, 166, 335-338.
Linder, L., Kiowski, W., Biihler, F. R. & Liischer, T. F. (1990). Indirect evidence for
release of endothelium-derived relaxing factor in human forearm circulation in vivo.
Circulation, 81, 1762-7.
Liu, J., Chen, R., Casley, D. J. & Nayler, W. G. (1990). Ischaemia and reperfusion
increase 125I-labelled endothelin-1 binding in rat cardiac membranes. Am J Physiol,
258, 829-835.
212
Lonchampt, M. O., Pinelis, S., Goulin, J., Charbrier, P. E. & Braquet, P. (1991).
Proliferation and Na+/H+ exchange activation by endothelin in vascular smooth
mucle cells. Am J Hypertens, 4, 776-779.
Lopez-Farre, A., Gomez-Garre, D., Bernabeu, F. & Lopez-Nova, J. M. (1991). A
role for endothelin in the maintenance of post-ischaemic renal failure in the rat. J
Physiol, 444, 513-522.
Ludmer, P. L., Selwyn, A. P., Shook, T. L., Wayne, R. R., Mudge, G. H., Alexander,
R. W. & Ganz, P. (1986). Paradoxical venoconstriction induced by acetycholine in
atherosclerotic coronary arteries. N Engl JMed, 315, 1046-1051.
MacKinnon, A. C., Kilpatrick, A. T., Kenny, B. A., Spedding, M. & Brown, C. M.
(1992). 3[H]-RS-15385-197, a selective and high affinity radioligand for a2-
adrenoceptors: implications for recptor classification. Br. J. Pharmacol, 106, 1011-
1018.
MahautSmith, M., Sage, S. & Rink, T. (1990). Receptor-activated single channels in
intact human platelets. J Biol Chem, 265, 10479-10483.
Malinski, T., Radomski, M. W., Taha, Z. & Moncada, S. (1993). Direct
electrochemical measurement of nitric oxide released from human platelets. Biochem
Biophys Res Commun, 194, 960-965.
12S
Mann, J. F. E., Sis, J. & Ritz, E. (1985). I-angiotensin II binding to human blood
cells. J Hypertension, 3, 131-137.
Markewitz, B. A., Kohan, D. E. & Michael, J. R. (1995). Endothelin-1 synthesis,
receptors and signal transduction in alveolar epithelium: Evidence for an autocrine
role. Am J Physiol, 268, L192-L200.
Martin, J. F., Trowbridge, E. A., Salmon, G. & Plumb, J. (1983). The biological
significance of platelet volume: its relationship to bleeding time, platelet
thromboxane B2 production and megakaryocyte DNA concentration. Thromb Res,
32, 443-460.
213
Martin, W., Villani, G., Jothianadran, A. & Furchgott, R. (1985). Selective blockade
of endothelium-dependent and glyceryl-trinitrate-induced relaxation by
haemoglobin and methylene blue in the rabbit aorta. J Pharmacol Exp Ther, 232,
708-716.
Masaoka, H., Suzuki, R., Hirata, Y., Emori, T., Marumo, F. & Hirakawa, K. (1989).
Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet, 2,
1402.
Matsumoto, Y., Ozaki, Y., Kariya, T. & Kume, S. (1990). Potentiating effects of
endothelin on platelet activation induced by epinephrine and ADP. Biochem
Pharmacol, 40, 909-911.
Matsumura, Y., Ikegawa, R., Suzuki, Y., Takaota, M., Uchida, T., Kido, H.,
Shinyama, H., Hayashi, K., Watanabe, M. & Morimoto, S. (1991). Phosphoramidon
prevents cerebral vasospasm following subarachnoid haemorrhage in dogs: the
relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci, 49, 841-848.
McMahon, E., Palomo, M., Moore, M., McDonald, J. & Stern, M. (1991).
Phosphoramidon blocks the pressor activity of porcine big endothelin-1-( 1-39) in
vivo and the conversion of big endothelin-1-( 1-39) to endothelin-1(1-21) in vitro.
Proc NatiAcadSci USA, 88, 703-707.
McMurdo, L., Lidbury, P. S., Corder, R., Thiemermann, C. & Vane, J. R. (1993a).
Heterogeneous receptors mediate endothelin -1 induced changes in blood pressure,
hematocrit and platelet aggregation. J Cardiovasc Pharmacol, 22, S185-S188.
McMurdo, L., Lidbury, P. S., Thiemermann, C. & Vane, J. R. (1993b). Mediation of
endothelin-1 induced inhibition of platelet aggregation via the ETB receptor. Br J
Pharmacol, 109, 530-534.
Mehta, J. & Mehta, P. (1981). Platelet function in hypertension and effect of therapy.
Am J Cardiol, 47, 331-334.
Michel, M. C., Brodde, O.-E. & Insel, P. (1990). Peripheral adrenergic receptors in
hypertension. Hypertension, 16, 107-120.
214
Miura, K., Yukimura, T., Yashamita, Y., Shimen, T., Okumura, M., Yamanaka, S.,
Imanishi, M. & Yamamoto, K. (1991). Renal and femoral vascular responses to
endothelin-1 in dogs: role of prostaglandins. J Pharmacol Exp Ther, 256, 11-17.
Miyauchi, T., Yanagisawa, M., Tomizawa, T., Sugishita, Y., Suzuki, N., Fujino, M.,
Ajisaka, R., Goto, K. & Masaki, T. (1989). Increased plasma concentrations of
endothelin-1 and big endothelin-1 in acute myocardial infarct size. Lancet, ii, 53-54.
Mollace, V., Salvemini, D. & Vane, J. (1991). Studies on the importance of the
proposed release of nitric oxide from platelets. Thromb Res, 64, 533-542.
Moncada, S., Gryglewski, R., Bunting, S. & Vane, J. R. (1976). An enzyme isolated
from arteries transforms prostaglandin endoperoxides to an unstable substance that
inhibits platelet aggregation. Nature, 263, 663-665.
Moncada, S. & Higgs, A. (1993). The L-arginine-nitric oxide pathway. New
England Journal ofMedicine, 329, 2002-2012.
Moore, T. & Williams, G. (1982). Angiotensin II receptors on human platelets. Circ
Res, 51, 314-320.
Mtigge, A., Fostermann, U. & Lichtlen, P. R. (1991). Platelets, endothelium-
dependent responses and atherosclerosis. Annals ofMedicine, 23, 545-550.
Munson, P. & Rodbard, D. (1980). A versatile computerised approach for
characterisation of ligand binding systems. Anal Biochem, 107, 220-239.
Murthy, M., Rao, G. H., Robinson, P. & Reddy, S. (1995). Influx of extracellular
calcium and agonist-coupling appear essential for the activation of thromboxane A2-
dependent phospholipase A2 in human platelets. Prostaglandins Leukotrienes and
Essential Fatty Acids, 53, 31-39.
Mustard, J. F., Perry, D. W., Kinlough-Rathbone, R. L. & Packham, M. A. (1975).
Factors reponsible for ADP-induced release reaction of human platelets. Am J
Physiol, 228, 1757-1765.
Nakamaru, M., Jackson, E. K. & Inagami, T. (1986). Beta-adrenoceptor-mediated
release of angiotensin II from mesenteric arteries. Am J Physiol, 250, H144-H148.
215
Nieuwland, R., Van Willigen, G. & Akkerman, J.-W. N. (1993). 4,4V-Di-
isothiocyanatostilbene-2,2v-disulphonic acid ('DIDS') activates protein kinase C and
Na+/ H+ exchange in human platelets via a2A-adrenergic receptors. Biochem. J, 293,
523-530.
Nubile, G., D'Alonzo, L., Gregorio, M. & Izzi, L. (1989). Platelet subpopulations in
adult and geriatric males. Am. J. Clin. Pathol., 91, 196-198.
O'Donnell, S. R., Wanstall, J. C. & Zeng, X. P. (1990). Pinacidil antagonism of
endothelin-induced contractions of smooth muscle in the lung: differences between
tracheal and pulmonary artery preparations. J Pharmacol Exp Ther, 252, 1318-1323.
Ohlstein, E. H., Horohonich, S. & Hay, D. W. P. (1989). Cellular mechanisms of
endothelin in rabbit aorta. J Pharmacol Exp Ther, 250, 548-555.
Ohlstein, E. H., Storer, B., Nambi, P., Given, M. & Lippton, H. (1990). Endothelin
and platelet function. Thromb Res, 57, 961-91A.
Ohlstein, E. H., Storer, B. L., Butcher, J. A., Debouck, C. & Feuerstein, G. (1991).
Platelets stimulate expression of endothelin mRNA and endothelin biosynthesis in
cultured endothelial cells. Circ Res, 69, 832-841.
Omlamd, T., Lie, R. T., Aakvaag, A., Aarsland, T. & Dickstein, K. (1994). Plasma
endothelin determination as a prognostic indicator of 1-year mortality after acute
myocardial infarction. Circulation, 89, 1573-1579.
Palmer, R., Ashton, D. & Moncada, S. (1988). Vascular endothelial cells synthesize
nitric oxide from L-arginine. Nature, 333, 664-666.
Palmer, R., Ferridge, A. & Moncada, S. (1987). Nitric oxide release accounts for the
biological activity of endothelium derived relaxing factor. Nature, 327, 524-526.
Panza, J. L., Quyyumi, A. A., Brush Jnr, J. E. & Epstein, S. E. (1990). Abnormal
endothelium-dependent vascular relaxation in patients with essential hypertension. N
Engl JMed, 323, 22-7.
Patel, A., Fairbanks, L., Gordge, M. P. & Neild, G. H. (1989). Failure of endothelin
to influence in vitro platelet responses. Thromb Res, 56, 769-770.
216
Patelunas Hoffman, D. M., Carmint, W. J., Colatsky, T. J. & Fenichel, R. L. (1994).
Analysis of the potassium channel openers celikalim, pinacidil and cromakalim in
platelet models of thrombosis. Thromb Res, 74, 441-452.
Pietraszek, M. H., Takada, Y. & Takada, A. (1992). Endothelins inhibit serotonin-
induced platelet aggregation via a mechanism involving protein kinase C. Eur J
Pharmacol, 219, 289-293.
Plumpton, C., Haynes, W. G., Webb, D. J. & Davenport, A. P. (1995).
Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to
endothelin-1 in the human forearm. Br J Pharmacol, 116, 1821-8.
Pollock, W. K., Sage, S. O. & Rink, T. J. (1987). Stimulation of Ca2+ efflux from
fura-2-loaded platelets activated by thombin or phorbol myristate acetate. FEBS Eett,
210, 132-136.
Poston, L. & Taylor, P. D. (1995). Endothelium-mediated vascular function in
insulin-dependent diabetes mellitus. Clin Sci, 88, 245-255.
Powling, M. J. & Hardisty, R. M. (1987). Potentiation by adrenaline of Ca2+ influx
and mobilization in stimulated human platelets: dissociation from thromboxane
generation and aggregation. Thrombosis and Haemostasis, 272, 212-215.
Pussard, G., Gascard, J. P., Gorenne, I., Labat, C., Norel, X., Dulmet, E. & Brink, C.
(1995). Endothelin-1 modulates cyclic GMP production and relaxation in human
pulmonary vessels. J Pharmacol Exp Ther, 274, 696-675.
Radomski, M., Palmer, R. & Moncada, S. (1987). Comparative pharmacology of
endothelium derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J.
Pharmacol., 92, 181-187.
Radomski, M. W., Palmer, R. M. J. & Moncada, S. (1990). Characterization of the
L-arginine : nitric oxide pathway in human platelets. Br. J. Pharmacol, 101, 325-
328.
217
Reuter, H. D. & Deter, K. (1979). Comparative investigations on the quantitative
determination of ADP and adrenaline induced aggregation by means of a microscope
test and an electronic platelet counting method. Thromb Res, 15, 711-719.
Reynolds, E. E., Hwang, O., Flynn, M. A., Welsh, K. M., Cody, W. L., Steinbaugh,
B., He, J. X., Chung, F. Z. & Doherty, A. M. (1995). Pharmacological differences
between rat and human endothelin B receptors. Biochem Biophys Res Commun, 209,
506-512.
Richards, N. T., Poston, L., Goldsmith, D. J. A., Cragoe, E. J. & Hilton, P. J. (1989).
Endothelin-induced contraction of human peripheral resistance vessels is partly
dependent on stimulation of sodium hydrogen exchange. J Hypertens, 7, 777-780.
Rink, T. & Sage, S. (1990). Calcium signalling in human platelets. Ann Rev Physiol,
52, 431-449.
Roberts, J. & Redman, C. (1993). Pre-eclampsia: more than pregnancy induced
hypertension. Lancet, 341, 1447-1451.
Robertson, R., Robertson, D. & Friesinger, G. (1980). Platelet aggregation in
peripheral and coronary-sinus blood in patients with spontaneous coronary-artery
spasm. Lancet, 62, 829-831.
Robinson, B. (1984). Altered calcium handling as a cause of primary hypertension. J
Hypertension, 2, 453-460.
Roos, J., Ferracin, F. & Pletscher, A. (1986). Interaction of vasopressin with human
<21
blood platelets: dependency on Mg . Thromb. Haemostasis, 56, 260-262.
Roth, G. J., Hickey, M. J., Chung, D. W. & Hickstein, D. D. (1989). Circulating
human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem
Biophys Res Commun, 160, 705-710.
Rubanyi, G. M. & Polokoff, M. A. (1994). Endothelins: molecular biology,
biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Revs, 46,
325-415.
218
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. &
Masaki, T. (1990). Cloning of a cDNA encoding a non isopeptide selective subtype
of the endothelin receptor. Nature, 348, 732-735.
Sargeant, F., Clarkson, W., Sage, S. & Heemskerk, J. (1992). Calcium influx evoked
by Ca2+ store depletion in human platelets is more susceptible to cytochrome P-450
inhibitors than receptor-mediated calcium increase. Cell Calcium, 13, 553-564.
Sawamura, T., Kasuya, Y., Matsushita, Y., Suzuki, N., Shinmi, O., Kishi, N., Sugita,
Y., Yanagisawa, M., Goto, K., Masaki, T. & Kimura, S. (1991). Phosphoramidon
inhibits the intracellular conversion of big endothelin-1 to endothelin-1 in cultured
endothelial cells. Biochem Biophys Res Commun, 174, 779-784.
Schulz, R. & Triggle, C. (1994). Role of NO in vascular smooth muscle and cardiac
muscle function. TiPS, 15, 255-259.
Seiffert, V., Loffler, B. M., Zimmermann, M., Roux, S. & Stolke, D. (1995).
Endothelin concentrations in patients with aneurysmal subarachnoid haemorrhage.
Journal ofNeurosurgery, 82, 55-62.
Shen, Y. & Hong, C. (1995). The effect of trilinolein on cyclic nucleotide formation
in human platelets: relationship with its antiplatelet effect and nitric oxide synthesis.
Br. J. Pharmacol., 116, 1644-1648.
Shepherd, J. & Katusic, Z. (1991). Endothelium-derived vasoactive factors: I
endothelium-dependent relaxation. Hypertension, 18, III-76-III-85.
Shibata, H., Suzuki, H., Murakami, M., Sato, A. & Saruta, T. (1994). Angiotensin II
type 1 receptor messenger RNA levels in human blood cells of patients with primary
and secondary hypertension: reference to renin profile. J Hypertension, 12, 1275-
1284.
Shraga-Levine, Z., Galron, R. & Sokolovsky, M. (1994). Cyclic GMP formation in
rat cerebellar slices is stimulated by endothelins via nitric oxide formation and by
sarafotoxins via formation of carbon monoxide. Biochem, 33, 14656-14659.
219
Shyamala, V., Moulthrop, T. H. M., Stratton Thomas, J. & Tekamp Olson, P. (1994).
Two distinct human endothelin B receptors generated by alternative splicing from a
single gene. Cellular and Molecular Biology Research, 40, 285-296.
Siess, W. (1989). Molecular mechanisms of platelet activation. Physiol Rev, 69, 58-
173.
Siess, W., Roth, P. & Weber, P. C. (1981). Stimulated platelet aggregation,
thromboxane B2 formation and platelet sensitivity to prostacyclin. A critical
evaluation. Thrombosis and Haemostasis, 45, 204-207.
Siess, W., Siegel, F. & Lapetina, E. (1983). Arachidonic acid stimulates the
formation of 1, 2-diacylglycerol and phosphatidic acid in human platelets. Degree of
phospholipase C activity correlates with protein phosphorylation, platelet shape
change, serotonin release and aggregation. J Biol Chem, 258, 11236-1242.
Sigmon, D. H. & Beierwaltes, W. H. (1995). Endothelium-derived constricting
factor in renovascular hypertension. Hypertension, 25 (part 2), 803-8.
Sixma, J. J., Nievelstein, P. F., Zwaginga, J. J. & de Groot, P. G. (1987). Adhesion
of blood platelets to the extracellular matrix of cultured human endothelial cells. Ann
NYAcad Sci, 516, 39-51.
Sokolovsky, M., Galron, R., Kloog, Y., Bdohlah, A., Indig, F. E., Blumberg, S. &
Fleminger, G. (1990). Endothelins are more sensitive than sarafotoxins to neutral
endopeptidase: possible physiological significance. Proceedings of the National
Academy ofSciences of the USA, 87, 4702-4706.
Steen, V. M., Holmsen, H. & Aarbakke, G. (1993). The platelet-stimulating effect of
adrenaline through a2-adrenergic receptors requires simultaneous activationby a true
stimulatory platelet agonist. Thrombosis and Haemostasis, 70, 506-513.
Stewart, D. J., Kubac, G., Costello, K. B. & Cernacek, P. (1991). Increased plasma
endothelin 1 in the early hours of acute myocardial infarction. J Am Coll Cardiol.
18, 38-43.
220
Takada, A. & Takada, Y. (1992). Inhibition of serotonin-induced platelet
aggregation by endothelins. Jpn J Clin Med, 50, 315-318.
Thaulow, E., Erikssen, J., Sandvik, L., Stormorken, H. & Cohn, P. (1991). Blood
platelet count and function are related to total and cardiovascular death in apparently
healthy men. Circulation, 84, 613-617.
Thiemermann, C., Lidbury, P. S., Thomas, G. R. & R., V. J. (1989). Endothelin-1
releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized
rabbit. J Cardiovasc Pharmacol, 13, S138-S141.
Thiemermann, C., May, G. R., Page, C. P. & Vane, J. R. (1990). Endothelin-1
inhibits platelet aggregation in vivo: a study with 11 'indium-labelled platelets. Br J
Pharmacol, 99, 303-308.
Touyz, R. M. & Schiffrin, E. L. (1993a). The effect of angiotensin II on platelet
intracellular free magnesium and calcium ionic concentrations in essential
hypertension. J Hypertension, 11, 551-558.
Touyz, R. M. & Schiffrin, E. L. (1993b). Effects of angiotensin II and endothelin-1
on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential
hypertension. Hypertension, 22, 853-862.
Touyz, R. M. & Schiffrin, E. L. (1995). Role of protein kinase C in the anti¬
aggregatory effects of endothelin-1 on human platelets. Clin Sci, 88, 277-283.
Trip, M., Manger Cats, V., Van Capelle, F. & Vreeken, J. (1990). Platelet
hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med,
322, 1549-1554.
Trovati, M., Massucco, P., Mattiello, L., Mularoni, E., Cavalot, F. & Anfossi, G.
(1994). Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets.
Diabetes, 43, 1015-1019.
Tsunoda, Y., Matsuno, K. & Tashiro, Y. (1988). Spatial distribution and temporal
change of cytoplasmic free calcium in human platelets. Biochem Biophys Res
Commun, 156, 1152-1159.
221
Vallance, P. (1989). The interplay between platelet and vessel-wall mediators in
coronary artery occlusion. Biomed. & Pharmacother., 43, 113-119.
Vanhoutte, P. (1991). Platelet derived serotonin, the endothelium, and cardiovascular
disease. J Cardiovasc Pharmacol, 17, S6-S12.
Vittet, D., Mathieu, M.-N., Cantau, B. & Chevillard, C. (1988). Vasopressin
inhibition of human platelet adenylate cyclase: variable responsiveness between
donors and involvement of a G-protein different from Gj. Eur J Pharmacol, 150,
367-372.
Vlachakis, N. D. & Aledort, L. (1980). Hypertension and propranolol therapy: effect
on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol,
45, 321-325.
Vu, T., Hung, D., Wheaton, V. & Coughlin, S. (1991). Molecular cloning of a
functional thrombin receptor reveals a novel proteolytic mechanism of receptor
activation. Cell, 1991, 6.
Waldmann, R. & Walter, U. (1989). Cyclic nucleotide elevating vasodilators inhibit
platelet aggregation at an early step of the activation cascade. Eur J Pharmacol, 159,
317-320.
Walker, T. R. & Watson, S. P. (1993). Synergy between Ca2+ and protein kinase C is
the major factor in determining the level of secretion from human platelets. Biochem.
J., 289, 277-282.
Wang, F., Naik, U. P., Ehrlich, Y. H., Freyberg, Z., Osada, S. I., Ohno, S., Kuroki,
T., Suzuki, K. & Kornecki, E. (1993). A new protein kinase C, nPKCeta', and
nPKCtheta in signal transduction stimulated by PAF. Biochemical and Biophysical
Research Communication, 191, 240-246.
Warner, T. D., Allcock, G. H., Mickley, E. J., Corder, R. & Vane, J. R. (1993).
Comparative studies with the endothelin receptor antagonists BQ-123 and PD
142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol, 22,
SI 17-S120.
222
Watanabe, T., Suzuki, N., Shimamoto, N., Fujino, M. & Imada, A. (1991).
Contribution of endogenous endothelin to the extension of myocardial infarct size in
rats. Circ Res, 69, 370-377.
Watson, S. P., Blake, R. A., Lane, T. & Walker, T. R. (1993). The use of inhibitors
of protein kinases and protein phosphatases to investigate the role of protein
phosphorylation in platelet activation. Advances in Experimental Medical Biology,
344, 105-118.
Watson, S. P. & Lapetina, E. G. (1985). 1,2-Diacylglycerol and phorbol ester inhibit
agonist-induced formation of inositol phosphates in human platelets: Possible
implications for negative feedback regulation of inositol phospholipid hydrolysis.
Proc. Natl. Acad. Sci., 82, 2632-2626.
Watt, G. C., Harrap, S. B., Foy, C. J., Holton, D.W., Edwards, H. V., Davidson,
H.R., Connor, J.M., Lever, A.F. & Fraser, R. Abnormalities of glucocorticoid
metabolism and the renin-angiotensin system: a four corner approach to the
identification of genetic determinants of blood pressure./ Hypertens.,10, 473-482
Waugh, C. J., Dockrell, M. E. C., Haynes, W. G., Olverman, H. J., Williams, B. C.
& Webb, D. J. (1992). Inhibition of 125I endothelin-1 binding to rat cardiac
membranes by the potassium channel opener lemakalim. Biochem Biophys Res
Commun, 185, 630-635.
Webb, D. J. (1995). The pharmacology of human blood vessels in vivo. J Vase Res,
32, 2-15.
White, J., Rao, G. & Estensen, R. (1974). Investigation of the release reaction in
platelets exposed to phorbol myristate acetate. Am J Pathol, 75, 135-150.
Willerson, J., Golino, P., Eidt, J., Campbell, W. & Buja, L. (1989). Specific platelet
mediators and unstable coronary artery lesions. Circulation, 80, 198-205.
Williams, D. L., Jones, K. L., Petibone, D. J., Lis, E. V. & Clineschmidt, B. V.
(1991). Sarafotoxin S6c: an agonist which distinguishes between endothelin
receptor subtypes. Biochem Biophys Res Commun, 175, 556-561.
223
Wu, C.-C., Ko, F.-N., Kuo, S.-C., Lee, F.-Y. & Teng, C.-M. (1995). YC-1 inhibited
human platelet aggregation through NO-independent activation of soluble guanylate
cyclase. Br J Pharmacol, 116, 1973-1978.
Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D. & Yanagisawa, M.
(1994). ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic
activation of big endothelin-1. Cell, 78, 473-485.
Yamaura, I., Tani, E., Maeda, Y., Minami, N. & Shindo, H. (1992). Endothelin-1 of
canine basilar artery in vasospasm. J Neurosurg, 76, 99-105.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y.,
Yazaki, Y., Goto, K. & Masaki, T. (1988). A novel potent vasoconstrictor peptide
produced by vascular endothelial cells. Nature, 332, 411-415.
Yang, M. C. M„ Tu, M. S„ Chou, C. K„ Hong, C. Y. & Kuo, J. S. (1991). cAMP
and vascular action of endothelin. Pharmacology, 42, 252-256.
Yang, Z., Richard, V., Von Segesser, L., Bauer, E., Stulz, P., Turina, M. & Luscher,
T. F. (1990). Threshold concentrations of endothelin-1 potentiate contractions to
norepinephrine and serotonin in human arteries: a new mechanism for vasospasm?
Circulation, 82, 188-195.
Yasuda, M., Kohno, M., Tahara, A., Itagane, H., Toda, I., Akioka, K., Teragaki, M.,
Oku, H., Takeuchi, K. & Takeda, T. (1990). Circulating immunoreactive endothelin
in ischemic heart disease. American Heart Journal, 119, 801-806.
Zemel, M., Zemel, P., Berry, S., Norman, G., Kowalczyk, C., Sokol, R., Standley,
P., Walsh, M. & Sowers, J. (1990). Altered platelet calcium metabolism as an early
predictor of increased peripheral vascular resistance and preeclampsia in urban black
women. N Engl JMed, 323, 434-438.
224
Journal of Cardiovascular Pharmacology "*
22(Suppl. 8):S204-S206 © 1993 Raven Press, Ltd., New York
Endothelin-1 and Aggregation of Human Platelets In Vitro
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Summary: Endothelin-1 (ET-1) is a potent vasoconstrictor
peptide produced by endothelial cells. We investigated
whether ET-1, like other potent endothelium-derived va¬
soactive agents, interacts directly with human platelets in
vitro. Platelet-rich plasma was obtained from healthy male
volunteers and incubated with ET-1 (1 \i.M) or vehicle
(sodium chloride 154 mM) for 10 min at 37°C. Platelet
aggregation was measured by the Born method, using light
transmittance through the plasma sample as an index of
activation. Although a significant increase in light trans¬
mittance was observed when plasma was incubated with
ET-1 compared with vehicle, (3.8 ± 0.4% versus 2.7 ±
0.2%; n = 24; p = 0.038), this effect was small and is
unlikely to be of biologic significance. To investigate the
possibility that ET-1 -stimulated platelet nitric oxide (NO)
synthesis might be masking a direct aggregatory effect of
ET-1, in a second study in six subjects N°-monomethyl-
l-arginine (l-NMMA, 10 and 100 |xM), an inhibitor ofNO
synthase, was preincubated with the plasma before the
addition of ET-1 (1 nM and 1 piM). No significant differ¬
ence was observed whether samples were incubated with
l-NMMA alone or with l-NMMA and ET-1. The results
of this study suggest that ET-1 does not have a major
direct effect as a platelet aggregating agent. Key Words:
Human—Platelets—Endothelin-1—Nitric oxide.
Endothelin-1 (ET-1) is a potent 21-amino acid va¬
soconstrictor peptide produced by endothelial cells
(1). Bolus administration of ET-1 causes transient
vasodilation (2) followed by prolonged vasocon¬
striction (1). Whereas the prolonged vasoconstrictor
effects of ET-1 are paracrine and are believed to be
mediated by an ETA receptor subtype situated on
vascular smooth muscle (3), the brief vasodilator ef¬
fects appear to be autocrine and mediated by an ETB
receptor situated on endothelial cells (4). Vasodila¬
tion can be caused by production of either nitric
oxide (NO), prostacyclin (PGI2), or a combination
of the two, depending on the species and the vascu¬
lar bed studied (5,6).
Previous studies have shown that ET-1 inhibits
platelet aggregation in vivo and ex vivo (7,8). As
this is associated with a rise in platelet cAMP, it
has been attributed to endothelial PGI2 production,
although the effect is only partially attenuated by
indomethacin (7). We examined the direct effects of
ET-1 on human platelets in vitro in the absence of
the influence of other endothelial factors, using
Born aggregometry. To investigate whether platelet
aggregation induced by ET-1 is masked by stimula¬
tion of platelet NO synthase, we also performed ex¬
periments in the presence and absence of the NO
synthase inhibitor NG-rnonomethyl-l-arginine (l-'
NMMA).
METHODS
Subjects were healthy men aged 21 to 44 years (n =
24). None of the participants had taken vasoactive drugs
or drugs known to alter platelet activity, including nonste¬
roidal anti-inflammatory drugs, in the preceding 10 days.
All subjects had abstained from tobacco and alcohol for
a minimum of 2 h, and rested supine for 30 min before
venesection.
The aggregation protocol was based on that described
by Gow et al. (9). Venous blood (54 ml) was drawn
through a 19 SWG steel needle into a polypropylene sy¬
ringe and immediately transferred into six 10-ml tubes,
each containing 1 ml acid citrate dextrose (8 mg/ml citric
acid, 22 mg/ml sodium citrate, 20'mg/ml glucose). Blood
was centrifuged at 110 g for 10 min at room temperature
to obtain platelet-rich plasma (PRP). PRP was removed
and the residue was spun for a further 20 min at 3,000 g
to obtain platelet-poor plasma (PPP). PRP was stored
under 5% C02:95% 02 in sealed polypropylene tubes at
room temperature until required. Aggregation was as¬
sessed at 37°C on a six-channel aggregometer (Malin)
linked to a Macintosh computer through a MacLab digital
analogue converter.
Experiments were performed according to the method
Address correspondence and reprint requests to Dr. D. J. Webb at University of Edinburgh, Department of Medicine, Western
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of Born (10). Briefly, the extent of aggregation was calcu¬
lated by the change in light transmittance, where light
transmittance through PRP was taken as 0% aggregation
and that through PPP as 100% aggregation. Aggregometer
recordings were examined for the three classical signs of
platelet activation and aggregation: shape change, pri¬
mary aggregation, and secondary irreversible aggregation.
In the first study in 24 subjects, 900 |xl of sample was
incubated for 3 min before the addition of 50 g.1 vehicle
(sodium chloride 154 mAf), followed 1 min later by 50 |xl
ET-1 (final concentration 1 \±M) or vehicle. In the second
study in six subjects, 900 pd of sample was incubated for
3 min before the addition of 50 p.1 l-NMMA, (final concen¬
trations 10 and 100 \cM) or vehicle, followed 1 min later
by the addition of 50 pi ET-1 (final concentrations 1 nM
and 1 puW) or vehicle. Responses were followed for 10
min after the addition of ET-1. Both l-NMMA (Sigma
Chemical Co. Ltd, Poole, U.K.) and ET-1 (NovaBio-
chem, Nottingham, U.K.) were dissolved in sodium chlo¬
ride 154 mM. Results are expressed as means ± SEM.
Statistical analysis was by analysis of variance followed
by Student's paired t test where applicable, with a value
of p < 0.05 accepted as significant.
RESULTS
Aggregation was slightly but significantly greater
in the 10-min period after the addition of ET-I than
after saline (3.8 ± 0.4% and 2.7 ± 0.2%, respec¬
tively; n = 24; p = 0.038). There were no significant
differences in the responses to l-NMMA whether
or not ET-1 was present, showing that l-NMMA did
not unmask aggregation to ET-1 (Table 1). No shape
change or secondary aggregation was observed in
any of these studies.
DISCUSSION
A slight but significant difference in aggregation,
as observed by light transmittance, was noted be¬
tween the control sample and the sample incubated
with ET-1 (1 jxA/) in the first study. Such a differ¬
ence is unlikely to be of biological significance and
may not be related to platelet aggregation. It is un¬
likely that a substantial aggregatory effect would
emerge with higher ET-1 concentrations because the
concentration employed was substantially higher
than the Kd for either the ETA or ETB receptor (3,4),
which is in the nanomolar range, and higher than
concentrations associated with biologic activity (5).
TABLE 1. Aggregation, as measured by change in
light transmittance, from coincubation of l-NMMA
with ET-1 or vehicle (n = 6)
Vehicle ET-1 (1 nM) ET-1 (1 \cM)
Vehicle 2.3 ± 0.29%
t.-NMMA 10 p.M 3.2 ± 0.42% 3.0 ± 0.85% 2.8 ± 0.79%
l-NMMA 100 \cM 3.3 ± 0.31% 3.8 ± 0.53% 2.8 ± 0.77%
From these data it can be concluded that ET-1 has,
at most, very limited aggregating properties and is
unlikely to act directly as an aggregating agent at
physiologic concentrations.
Light transmittance after incubation of platelets
with l-NMMA at concentrations of 10 and 100 pM
was not significantly different in the presence or ab¬
sence of ET-1 at either 1 nM or 1 p,Af. This result
excludes the possibility that ETB-mediated stimula¬
tion of NO generation masks a direct aggregatory
effect of ET-1.
Although ET-1 may not stimulate platelet aggre¬
gation directly, there is evidence that it modulates
platelet aggregation initiated by other agonists. ET-
1 can modify epinephrine- (11,12) and thrombin-in-
duced aggregation (13). Dequeker et al. (13) also
demonstrated that endothelin-3 produces a small but
significant decrease in Ca2+ mobilization when
coincubated with thrombin. Stimulation of the ETA
receptor might be expected to mediate phosphati-
dylinositol hydrolysis, resulting in platelet aggrega¬
tion and a concomitant rise in intracellular calcium
[Ca2 + ]i. By activating NO synthase, stimulation of
the ETb receptor might reduce [Ca2 + ]i and inhibit
platelet aggregation. ET-1 may act like other potent
vasoactive agents, angiotensin II (14) and epineph¬
rine (15), via specific membrane-bound receptors to
modify the actions of other aggregating agents with¬
out directly initiating platelet aggregation. This re¬
quires further investigation.
From our results, we conclude that ET-1 causes
significant but not physiologically relevant platelet
aggregation and that aggregatory effects are not
masked by ETB-mediated NO production.
Acknowledgment: This work was supported by a grant
from the Scottish Home and Health Department.
REFERENCES
1. Yanagisawa M, Kurihawa H, Kimura S, et al. A novel potent
vasoconstrictor peptide produced by vascular endothelial
cells. Nature 1988;332:41 1-5.
2. de Nucci G, Thomas GR, D'Orleans-Juste P, et al. Pressor
effects of circulating endothelin are limited by its removal in
the pulmonary circulation and by release of prostacyclin and
endothelium-derived relaxing factor. Proc Natl Acad Sci
USA 1988;85:9797-800.
3. Arai H, Hori S, Aramori I, Okhubo H, Kakanishi S. Cloning
of a cDNA encoding an endothelin receptor. Nature 1990;
348:730-2.
4. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a
cDNA encoding a non-isopeptide-selective subtype of the
endothelin receptor. Nature 1990;348:732-5.
5. Masaki T, Kimura S, Yanagisawa M, Goto K. Focus on mo¬
lecular biology: molecular and cellular mechanism of endo¬
thelin regulation: implications for vascular function. Circula¬
tion 1991;84:1457-68.
6. Haynes WG, Webb DJ. The endothelin family: local hor¬
mones with diverse roles in health and disease? Clin Sci 1993;
84:485-500.
7. Thiemermann C, May GR, Page CP, Vane JR. Endothelin-
I inhibits platelet aggregation in vivo: a study with "'indium-
labelled platelets. Br J Pharmacol 1990;99:303-8.
J Curtliuvaxc t'imrnuu . Vat. 22 (Slippl. X). IVV.i
S206 M. E. C. DOCKRELL ET AL.
8. Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Endo¬
thelial releases prostacyclin and inhibits ex vivo platelet
aggregation in the anesthetized rabbit. J Cardiovasc Pharma¬
col 1989;13(suppl 5):S138-41.
9. Gow IF, Dockrell M, Edwards CRW, et al. The sensitivity
of human blood platelets to the aggregating agent ADP during
different dietary sodium intakes in healthy men. Eur J Clin
Pharmacol 1992;43:635-8.
10. Born GVR. Aggregation of blood platelets by adenosine di¬
phosphate and its reversal. Nature 1962;194:927-9.
11. Matsumoto Y, Ozaki Y, Kariya T, Kume S. Potentiating ef¬
fects of endothelin on platelet activation induced by epineph¬
rine and ADP. Biochem Pharmacol 1990;40:909-11.
12. Dockrell MEG, Waugh CJ, Haynes WG, Webb DJ, Williams
BC. Effect of endolhelin-l on adrenaline stimulated aggrega¬
tion of human platelets: evidence in support of a biphasic
effect [Abstract], J Vase Res 1992;29:104.
13. Astastaire-Dequeker C, Iouzalen L, David-Dufilho M,
Devynck M-A. In vitro inhibition by endothelins of thrombin-
induced aggregation and Ca+ mobilization in human plate¬
lets. Br J Pharmacol 1992;106:966-71.
14. Ding YA, Macintyre DE, Kenyon CJ, Semple PF. Potentia¬
tion of adrenaline-induced platelet aggregation by angioten¬
sin II. Thromb Haemost 1985;54:717-20.
15. Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave
JP. Epinephrine potentiates human platelet activation but is
not an aggregating agent. Am J Physiol 1988;255(6 pt 2):
H1276-88.
5
J Cardiovasc Pharmacol", Vol. 22 (Suppl. 8). 1993
